

## Contents

### Company information

Breakdown of capital	1
----------------------	---

### Individual financial statements

Balance sheet - Assets	2
------------------------	---

Balance sheet – Liabilities	3
-----------------------------	---

Statement of income	5
---------------------	---

Statement of comprehensive income	7
-----------------------------------	---

Statement of cash flows (Indirect method)	8
---	---

#### Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) - 01/01/2025–06/30/2025	9
---	---

Statement of changes in shareholders' equity (DMPL) - 01/01/2024–06/30/2024	10
---	----

Statement of added value	11
--------------------------	----

### Consolidated financial statements

Balance sheet - Assets	12
------------------------	----

Balance sheet – Liabilities	13
-----------------------------	----

Statement of income	15
---------------------	----

Statement of comprehensive income	17
-----------------------------------	----

Statement of cash flows (Indirect method)	18
---	----

#### Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) - 01/01/2025–06/30/2025	19
---	----

Statement of changes in shareholders' equity (DMPL) - 01/01/2024–06/30/2024	20
---	----

Statement of added value	21
--------------------------	----

Performance comment	22
---------------------	----

Notes to the financial statements	49
-----------------------------------	----

Other information the Company deems to be relevant	79
--	----

### Opinions and Statements

Special review report - Unqualified	82
-------------------------------------	----

Statement of the Executive Officers on the Financial Statements	83
---	----

Statement of the Directors on Independent Auditor's Report	84
--	----

Company information / Breakdown of capital

Quantity of shares (Unit)	Current quarter 06/30/2025
Paid-in capital	
Common	545,825,286
Preferred	0
Total	545,825,286
Treasury	
Common	732100
Preferred	0
Total	732100

**Individual financial statements / Balance sheet – Assets****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 06/30/2025</b>	<b>Prior year 12/31/2024</b>
1	Total assets	2,071,052	2,067,888
1.01	Current assets	427,804	409,557
1.01.01	Cash and cash equivalents	21,888	15,783
1.01.02	Interest earning bank deposits	325,284	327,637
1.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	325,284	192,982
1.01.02.01.04	Free investments	325,284	192,982
1.01.02.03	Interest earning bank deposits measured at amortized cost	0	134,655
1.01.02.03.01	Investments that guarantee technical reserves	0	37,251
1.01.02.03.02	Free investments	0	97,404
1.01.03	Accounts receivable	46,465	51,202
1.01.03.01	Clients	26,533	25,501
1.01.03.01.06	Assets of insurance and reinsurance contracts	26,533	25,501
1.01.03.02	Other accounts receivable	19,932	25,701
1.01.06	Recoverable taxes	23,868	7,364
1.01.06.01	Current taxes recoverable	23,868	7,364
1.01.06.01.01	Tax and social security credits	23,868	7,364
1.01.07	Prepaid expenses	10,299	7,571
1.01.07.20	Other	10,299	7,571
1.02	Non-current assets	1,643,248	1,658,331
1.02.01	Non-current receivables	632,688	644,932
1.02.01.03	Interest earning bank deposits measured at amortized cost	548,761	539,081
1.02.01.03.01	Investments that guarantee technical reserves	140,764	139,379
1.02.01.03.03	Free investments	407,997	399,702
1.02.01.07	Deferred taxes	0	25,879
1.02.01.07.01	Deferred income tax and social contribution	0	25,879
1.02.01.08	Prepaid expenses	37	0
1.02.01.10	Other non-current assets	83,890	79,972
1.02.01.10.03	Judicial and tax deposits	34,291	32,104
1.02.01.10.04	Other credits receivable	13,697	13,697
1.02.01.10.06	Tax and social security credits (recoverable taxes)	35,902	34,171
1.02.02	Investments	82,440	86,656
1.02.02.01	Equity interest	82,440	86,656
1.02.02.01.02	Interest in subsidiaries	78,016	82,309
1.02.02.01.03	Interest in jointly-controlled subsidiaries	4,423	4,346
1.02.02.01.04	Other investments	1	1
1.02.03	Property, plant and equipment	25,678	29,345
1.02.03.01	Construction in progress	15,601	18,313
1.02.03.02	Right-of-use in lease	10,077	11,032
1.02.04	Intangible assets	902,442	897,398
1.02.04.01	Intangible assets	902,442	897,398

**Individual financial statements - Balance sheet - Liabilities****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 06/30/2025</b>	<b>Prior year 12/31/2024</b>
2	Total liabilities	2,071,052	2,067,888
2.01	Current liabilities	658,943	725,553
2.01.01	Social and labor obligations	43,550	57,620
2.01.01.02	Labor obligations	43,550	57,620
2.01.01.02.01	Salaries, vacation and fees	43,550	57,620
2.01.02	Suppliers	43,638	31,413
2.01.02.01	Domestic suppliers	43,638	31,413
2.01.02.01.01	Trading on operations	25,687	11,675
2.01.02.01.02	Suppliers of goods and services	11,641	11,495
2.01.02.01.03	Other debits from health care operations	933	1,071
2.01.02.01.04	Consideration/premiums to be repaid	185	45
2.01.02.01.07	Anticipated revenue from consideration/premiums	5,192	7,127
2.01.03	Tax liabilities	40,744	39,986
2.01.03.01	Federal tax liabilities	37,930	37,273
2.01.03.01.01	Income tax and social contribution payable	18,254	15,952
2.01.03.01.02	Other federal tax liabilities	19,676	21,321
2.01.03.03	Municipal tax liabilities	2,814	2,713
2.01.05	Other liabilities	531,011	596,534
2.01.05.02	Other	531,011	596,534
2.01.05.02.01	Dividends and interest on own capital payable	260,509	261,213
2.01.05.02.05	Other accounts payable	21,523	36,076
2.01.05.02.12	Liabilities from insurance and reinsurance contracts	246,971	297,287
2.01.05.02.13	Lease liabilities	2,008	1,958
2.02	Non-current liabilities	120,412	114,566
2.02.02	Other liabilities	39,052	47,339
2.02.02.02	Other	39,052	47,339
2.02.02.02.03	Other liabilities	15,045	14,767
2.02.02.02.04	Fees payable	275	0
2.02.02.02.07	Lease liabilities	10,450	11,460
2.02.02.02.12	Other accounts payable	13,282	21,112
2.02.03	Deferred taxes	4,400	0
2.02.03.01	Deferred income tax and social contribution	4,400	0
2.02.04	Provision	76,960	67,227
2.02.04.01	Tax, social security, labor and civil provisions	76,960	67,227
2.02.04.01.01	Tax provision	30,653	28,882
2.02.04.01.02	Social security and labor provisions	428	1,304
2.02.04.01.04	Civil provision	45,879	37,041
2.03	Shareholders' equity	1,291,697	1,227,769
2.03.01	Realized capital	851,017	851,017
2.03.02	Capital reserves	-35,610	-35,610
2.03.02.10	Goodwill/negative goodwill in capital transaction	-35,610	-35,610
2.03.04	Profit reserves	326,830	420,718
2.03.04.01	Legal reserve	127,428	127,428
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	0	81,000

**Individual financial statements - Balance sheet - Liabilities****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 06/30/2025</b>	<b>Prior year 12/31/2024</b>
2.03.04.09	Treasury shares	-7,832	-71,572
2.03.04.10	Statutory Reserve of Regulatory Capital	100,000	100,000
2.03.04.11	Investment and expansion reserve	107,105	183,733
2.03.05	Retained earnings/losses	148,786	0
2.03.06	Equity valuation adjustments	-799	-795
2.03.07	Accumulated translation adjustments	2,496	2,755
2.03.08	Other comprehensive income	-1,023	-10,316

**Individual financial statements / Statement of income****(In thousands of reais)**

Code of account	Account description	Current quarter	Accumulated of the	Same quarter of the prior	Accumulated of the prior
		04/01/2025–06/30/2025	current year 01/01/2025–06/30/2025	year 04/01/2024–06/30/2024	year 01/01/2024–06/30/2024
3.01	Revenue from sales of goods and/or services	584,037	1,156,838	551,359	1,082,465
3.01.07	Insurance revenue (PAA)	450,219	893,687	418,446	828,179
3.01.08	Insurance revenue (BBA)	133,818	263,151	132,913	254,286
3.02	Cost of goods and/or services sold	-381,400	-716,428	-375,776	-722,783
3.02.08	Insurance costs	-381,400	-716,428	-375,776	-722,783
3.03	Gross income (loss)	202,637	440,410	175,583	359,682
3.04	Operating expenses/revenue	-3,556	-11,132	-7,533	-6,918
3.04.02	General and administrative expenses	-15,365	-29,316	-11,408	-23,818
3.04.02.01	Administrative expenses	-14,132	-27,030	-11,166	-23,297
3.04.02.05	Income (loss) from disposal or write-off of non-current asset items and other	-1,233	-2,286	-242	-521
3.04.04	Other operating revenues	13,559	22,533	10,188	22,735
3.04.04.01	Other operating revenues from health care plans	13,437	22,283	10,071	22,499
3.04.04.02	Health care revenues not related to the Operator's health plans	122	250	117	236
3.04.05	Other operating expenses	-4,967	-9,393	-10,517	-15,887
3.04.05.02	Provision for credit losses	-986	-263	-152	-11
3.04.05.03	Profit sharing	-3,981	-9,130	-10,365	-15,876
3.04.06	Equity in net income of subsidiaries	3,217	5,044	4,204	10,052
3.05	Income (loss) before financial income and taxes	199,081	429,278	168,050	352,764
3.06	Financial income (loss)	9,817	24,818	14,817	38,311
3.06.01	Financial revenues	25,142	56,282	27,223	62,601
3.06.02	Financial expenses	-15,325	-31,464	-12,406	-24,290
3.07	Income (loss) before income tax	208,898	454,096	182,867	391,075
3.08	Income tax and social contribution	-61,070	-136,544	-52,732	-114,203
3.08.01	Current	-52,950	-110,983	-41,920	-110,154
3.08.02	Deferred	-8,120	-25,561	-10,812	-4,049
3.09	Net income (loss) from continued operations	147,828	317,552	130,135	276,872
3.11	Income/loss for the period	147,828	317,552	130,135	276,872

Individual financial statements / Statement of income

(In thousands of reais)

Code of account	Account description	Current quarter 04/01/2025–06/30/2025	Accumulated of the current year 01/01/2025–06/30/2025	Same quarter of the prior year 04/01/2024–06/30/2024	Accumulated of the prior year 01/01/2024–06/30/2024
3.99	Earnings per share - (Reais R\$ / Shares)				
3.99.01	Basic earnings per share				
3.99.01.01	COMMON SHARES	0.2712	0.58206	0.23743	0.5026
3.99.02	Diluted earnings per share				
3.99.02.01	COMMON SHARES	0.2712	0.58206	0.23743	0.5026

**Individual financial statements / Statement of comprehensive income****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 04/01/2025–06/30/2025</b>	<b>Accumulated of the current year 01/01/2025–06/30/2025</b>	<b>Same quarter of the prior year 04/01/2024–06/30/2024</b>	<b>Accumulated of the prior year 01/01/2024–06/30/2024</b>
4.01	Net income for the period	147,828	317,552	130,135	276,872
4.02	Other comprehensive income	9,446	9,030	-5,257	-9,383
4.02.01	Accumulated translation adjustment	458	-259	148	719
4.02.03	Other comprehensive income of investees recognized under the equity method	91	132	-66	-134
4.02.04	Other comprehensive income	8,895	9,161	-5,341	-9,977
4.02.05	Equity valuation adjustments of investees recognized under the equity method.	2	-4	2	9
4.03	Comprehensive income for the period	157,274	326,582	124,878	267,489



**Individual financial statements / Statement of cash flows (Indirect method)****(In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2025–06/30/2025	01/01/2024–06/30/2024
6.01	Net cash from operating activities	165,729	153,404
6.01.01	Cash generated in operations	481,825	402,413
6.01.01.01	Net income (loss) for the period	317,552	276,872
6.01.01.02	Depreciation and amortization	26,687	22,749
6.01.01.03	Net inflation adjustments	1,961	-2,254
6.01.01.05	Provision for lawsuits	1,576	363
6.01.01.06	Disposal of non-current assets and other	2,286	521
6.01.01.07	Equity in net income of subsidiaries	-5,044	-10,052
6.01.01.08	Provision for credit losses	263	11
6.01.01.11	Income tax and social contribution	136,544	114,203
6.01.02	Changes in assets and liabilities	-316,096	-249,009
6.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	-132,302	-191,352
6.01.02.03	Other accounts receivable, recoverable taxes and prepaid expenses	-13,498	54,483
6.01.02.05	Long-term assets (Non-current)	-39	2,170
6.01.02.06	Assets and liabilities of insurance and reinsurance contracts	-37,580	2,783
6.01.02.09	Tax obligations (taxes payable)	-1,022	-3,345
6.01.02.10	Labor obligations, suppliers, and other accounts payable	-30,472	-7,239
6.01.02.11	Long-term liabilities (Non-current liabilities)	-5,972	-5,461
6.01.02.13	Income tax and social contribution paid	-108,681	-102,483
6.01.02.15	Trading on operations	14,012	1,545
6.01.02.16	Interest and fines paid	-542	-110
6.02	Net cash used in investment activities	103,600	-75,287
6.02.01	Acquisition of property, plant and equipment	-315	-4,204
6.02.02	Acquisition of intangible assets	-30,035	-28,942
6.02.07	Dividends received from Subsidiaries and jointly-controlled subsidiaries	8,975	6,625
6.02.11	Interest earning bank deposits measured at amortized cost	124,975	-48,766
6.03	Net cash from financing activities	-263,224	-81,371
6.03.01	Dividends and interest on own capital paid	-248,939	-19,580
6.03.02	Acquisition of own shares - Treasury	-12,888	-59,669
6.03.05	Payment of Lease	-1,397	-2,122
6.05	Increase (decrease) in cash and cash equivalents	6,105	-3,254
6.05.01	Opening balance of cash and cash equivalents	15,783	13,615
6.05.02	Closing balance of cash and cash equivalents	21,888	10,361

**Individual financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2025–06/30/2025****(In thousands of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity
5.01	Opening balances	851,017	-107,182	492,290	0	-8,356	1,227,769
5.02	Prior-year adjustments	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-107,182	492,290	0	-8,356	1,227,769
5.04	Capital transactions with partners	0	63,740	-157,628	-168,766	0	-262,654
5.04.04	Treasury shares acquired	0	-12,888	0	0	0	-12,888
5.04.06	Dividends	0	0	0	-118,000	0	-118,000
5.04.07	Interest on own capital	0	0	0	-50,766	0	-50,766
5.04.18	Additional dividend proposed	0	0	-81,000	0	0	-81,000
5.04.20	Cancellation of treasury shares	0	76,628	-76,628	0	0	0
5.05	Total comprehensive income	0	0	0	317,552	9,030	326,582
5.05.01	Net income for the period	0	0	0	317,552	0	317,552
5.05.02	Other comprehensive income	0	0	0	0	9,030	9,030
5.05.02.04	Translation adjustments in the period	0	0	0	0	-259	-259
5.05.02.06	Equity valuation adjustments of investees recognized under the equity method.	0	0	0	0	-4	-4
5.05.02.08	Other comprehensive income	0	0	0	0	9,161	9,161
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	132	132
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0
5.07	Closing balances	851,017	-43,442	334,662	148,786	674	1,291,697

**Individual financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2024–06/30/2024****(In thousands of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity
5.01	Opening balances	851,017	-35,610	561,679	0	9,908	1,386,994
5.02	Prior-year adjustments	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-35,610	561,679	0	9,908	1,386,994
5.04	Capital transactions with partners	0	-59,669	-242,492	-117,421	0	-419,582
5.04.04	Treasury shares acquired	0	-59,669	0	0	0	-59,669
5.04.06	Dividends	0	0	0	-73,000	0	-73,000
5.04.07	Interest on own capital	0	0	0	-44,421	0	-44,421
5.04.18	Additional dividend proposed	0	0	-242,492	0	0	-242,492
5.05	Total comprehensive income	0	0	0	276,872	-9,383	267,489
5.05.01	Net income for the period	0	0	0	276,872	0	276,872
5.05.02	Other comprehensive income	0	0	0	0	-9,383	-9,383
5.05.02.04	Translation adjustments in the period	0	0	0	0	719	719
5.05.02.06	Equity valuation adjustments of investees recognized under the equity method.	0	0	0	0	9	9
5.05.02.08	Other comprehensive income	0	0	0	0	-9,977	-9,977
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	-134	-134
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0
5.07	Closing balances	851,017	-95,279	319,187	159,451	525	1,234,901

**Individual financial statements / Statement of added value****(In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2025–06/30/2025	01/01/2024–06/30/2024
7.01	Revenues	1,156,575	1,082,454
7.01.01	Sale of goods, products and services	1,156,838	1,082,465
7.01.04	Formation/reversal of allowance for doubtful accounts	-263	-11
7.02	Inputs acquired from third parties	-560,200	-570,052
7.02.01	Cost of products, goods and services sold	-467,657	-464,046
7.02.02	Materials, energy, third-party services and other	-9,166	-9,940
7.02.04	Other	-83,377	-96,066
7.02.04.01	Other operating revenues (expenses)	10,547	-9,051
7.02.04.03	Administrative expenses	-93,924	-87,015
7.03	Gross added value	596,375	512,402
7.04	Retention	-26,687	-22,749
7.04.01	Depreciation, amortization and depletion	-26,687	-22,749
7.05	Net added value produced	569,688	489,653
7.06	Added value received as transfer	61,326	72,653
7.06.01	Equity in net income of subsidiaries	5,044	10,052
7.06.02	Financial revenues	56,282	62,601
7.07	Total added value payable	631,014	562,306
7.08	Distribution of added value	631,014	562,306
7.08.01	Personnel	74,588	80,777
7.08.01.01	Direct remuneration	58,103	63,804
7.08.01.02	Benefits	12,797	13,443
7.08.01.03	SEVERANCE PAY FUND (FGTS)	3,688	3,530
7.08.02	Taxes, duties and contributions	206,634	180,396
7.08.02.01	Federal	188,662	163,507
7.08.02.02	State	3	35
7.08.02.03	Municipal	17,969	16,854
7.08.03	Third-party capital remuneration	32,240	24,261
7.08.03.02	Rentals	776	-29
7.08.03.03	Other	31,464	24,290
7.08.04	Remuneration of own capital	317,552	276,872
7.08.04.01	Interest on own capital	50,766	44,421
7.08.04.02	Dividends	118,000	73,000
7.08.04.03	Retained earnings / Loss for the period	148,786	159,451

**Consolidated financial statements / Balance sheet – Assets****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 06/30/2025</b>	<b>Prior year 12/31/2024</b>
1	Total assets	2,118,058	2,122,069
1.01	Current assets	503,735	490,076
1.01.01	Cash and cash equivalents	31,530	16,531
1.01.02	Interest earning bank deposits	342,372	357,791
1.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	342,372	223,136
1.01.02.01.04	Free investments	342,372	223,136
1.01.02.03	Interest earning bank deposits measured at amortized cost	0	134,655
1.01.02.03.01	Investments that guarantee technical reserves	0	37,251
1.01.02.03.02	Free investments	0	97,404
1.01.03	Accounts receivable	79,291	85,065
1.01.03.01	Clients	34,241	33,316
1.01.03.01.07	Assets of insurance and reinsurance contracts	34,241	33,316
1.01.03.02	Other accounts receivable	45,050	51,749
1.01.04	Inventories	6	56
1.01.06	Recoverable taxes	33,091	15,853
1.01.06.01	Current taxes recoverable	33,091	15,853
1.01.06.01.01	Tax and social security credits	33,091	15,853
1.01.07	Prepaid expenses	10,711	8,690
1.01.07.20	Other	10,711	8,690
1.01.08	Other current assets	6,734	6,090
1.01.08.03	Other	6,734	6,090
1.01.08.03.02	Assets held for sale	6,734	6,090
1.02	Non-current assets	1,614,323	1,631,993
1.02.01	Non-current receivables	636,315	653,691
1.02.01.03	Interest earning bank deposits measured at amortized cost	548,761	539,081
1.02.01.03.01	Investments that guarantee technical reserves	140,764	139,379
1.02.01.03.02	Free investments	407,997	399,702
1.02.01.07	Deferred taxes	1,528	32,346
1.02.01.07.01	Deferred income tax and social contribution	1,528	32,346
1.02.01.08	Prepaid expenses	37	0
1.02.01.10	Other non-current assets	85,989	82,264
1.02.01.10.03	Judicial and tax deposits	35,541	33,435
1.02.01.10.04	Other credits receivable	14,138	14,268
1.02.01.10.06	Tax and social security credits (recoverable taxes)	36,310	34,561
1.02.02	Investments	6,199	6,121
1.02.02.01	Equity interest	6,199	6,121
1.02.02.01.01	Interest in associated companies	1,720	1,719
1.02.02.01.04	Interest in jointly-controlled subsidiaries	4,423	4,346
1.02.02.01.05	Other investments	56	56
1.02.03	Property, plant and equipment	47,117	52,154
1.02.03.01	Construction in progress	27,285	30,438
1.02.03.02	Right-of-use in lease	19,832	21,716
1.02.04	Intangible assets	924,692	920,027
1.02.04.01	Intangible assets	924,692	920,027

**Consolidated financial statements / Balance sheet - Liabilities****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 06/30/2025</b>	<b>Prior year 12/31/2024</b>
2	Total liabilities	2,118,058	2,122,069
2.01	Current liabilities	698,224	764,626
2.01.01	Social and labor obligations	55,640	69,765
2.01.01.02	Labor obligations	55,640	69,765
2.01.01.02.01	Salaries, vacation and fees	55,640	69,765
2.01.02	Suppliers	49,740	36,361
2.01.02.01	Domestic suppliers	49,740	36,361
2.01.02.01.01	Trading on operations	25,754	11,732
2.01.02.01.02	Suppliers of goods and services	17,676	16,386
2.01.02.01.03	Other debits from health care operations	933	1,071
2.01.02.01.04	Consideration/premiums to be repaid	185	45
2.01.02.01.07	Anticipated revenue from consideration/premiums	5,192	7,127
2.01.03	Tax liabilities	47,646	47,600
2.01.03.01	Federal tax liabilities	44,187	44,262
2.01.03.01.01	Income tax and social contribution payable	18,817	16,735
2.01.03.01.02	Other federal tax liabilities	25,370	27,527
2.01.03.03	Municipal tax liabilities	3,459	3,338
2.01.05	Other liabilities	545,198	610,900
2.01.05.02	Other	545,198	610,900
2.01.05.02.01	Dividends and interest on own capital payable	260,509	261,213
2.01.05.02.05	Other accounts payable	29,516	43,514
2.01.05.02.12	Liabilities from insurance and reinsurance contracts	248,205	299,398
2.01.05.02.13	Lease liabilities	6,968	6,775
2.02	Non-current liabilities	127,859	129,210
2.02.02	Other liabilities	47,833	57,925
2.02.02.02	Other	47,833	57,925
2.02.02.02.03	Other liabilities	15,498	15,351
2.02.02.02.04	Fees payable	275	0
2.02.02.02.07	Lease liabilities	16,893	19,010
2.02.02.02.11	Taxes and charges payable	286	303
2.02.02.02.12	Other accounts payable	14,881	23,261
2.02.04	Provision	80,026	71,285
2.02.04.01	Tax, social security, labor and civil provisions	80,026	71,285
2.02.04.01.01	Tax provision	31,956	30,185
2.02.04.01.02	Social security and labor provisions	2,185	4,045
2.02.04.01.04	Civil provision	45,885	37,055
2.03	Consolidated shareholders' equity	1,291,975	1,228,233
2.03.01	Realized capital	851,017	851,017
2.03.02	Capital reserves	-35,610	-35,610
2.03.02.10	Goodwill/negative goodwill in capital transaction	-35,610	-35,610
2.03.04	Profit reserves	326,830	420,718
2.03.04.01	Legal reserve	127,428	127,428
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	0	81,000
2.03.04.09	Treasury shares	-7,832	-71,572

**Consolidated financial statements / Balance sheet - Liabilities****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 06/30/2025</b>	<b>Prior year 12/31/2024</b>
2.03.04.10	Statutory Reserve of Regulatory Capital	100,000	100,000
2.03.04.11	Investment and expansion reserve	107,105	183,733
2.03.05	Retained earnings/losses	148,786	0
2.03.06	Equity valuation adjustments	-799	-795
2.03.07	Accumulated translation adjustments	2,496	2,755
2.03.08	Other comprehensive income	-1,023	-10,316
2.03.09	Non-controlling interest	278	464

**Consolidated financial statements / Statement of income****(In thousands of reais)**

Code of account	Account description	Current quarter 04/01/2025–06/30/2025	Accumulated of the current year 01/01/2025–06/30/2025	Same quarter of the prior year 04/01/2024–06/30/2024	Accumulated of the prior year 01/01/2024–06/30/2024
3.01	Revenue from sales of goods and/or services	603,695	1,191,495	570,294	1,124,795
3.01.02	Sales of goods and services	12,516	26,253	12,772	26,643
3.01.05	Taxes on sales of goods and services	-3,283	-6,532	-3,583	-7,206
3.01.07	Insurance revenue (PAA)	460,644	908,623	428,192	851,072
3.01.08	Insurance revenue (BBA)	133,818	263,151	132,913	254,286
3.02	Cost of goods and/or services sold	-379,026	-712,153	-374,911	-722,029
3.02.08	Insurance costs	-379,026	-712,153	-374,911	-722,029
3.03	Gross income (loss)	224,669	479,342	195,383	402,766
3.04	Operating expenses/revenue	-24,117	-47,147	-25,990	-46,125
3.04.01	Sales expenses	-302	-706	-310	-634
3.04.01.01	Sales expenses	-302	-706	-310	-634
3.04.02	General and administrative expenses	-33,580	-63,712	-26,068	-53,320
3.04.02.01	Administrative expenses	-32,355	-61,434	-25,814	-52,741
3.04.02.05	Income (loss) from disposal or write-off of non-current asset items and other	-1,225	-2,278	-254	-579
3.04.04	Other operating revenues	14,135	23,790	11,264	24,556
3.04.04.01	Other operating revenues from health care plans	14,036	23,591	11,146	24,319
3.04.04.02	Health care revenues not related to the Operator's health plans	99	199	118	237
3.04.05	Other operating expenses	-6,013	-9,940	-12,619	-19,526
3.04.05.02	Provision for credit losses	-833	1,917	-391	-279
3.04.05.03	Profit sharing	-4,742	-10,962	-11,925	-18,545
3.04.05.04	Long-term incentive program (ILP)	-438	-895	-303	-702
3.04.06	Equity in net income of subsidiaries	1,643	3,421	1,743	2,799
3.05	Income (loss) before financial income and taxes	200,552	432,195	169,393	356,641
3.06	Financial income (loss)	9,552	24,722	16,056	39,681
3.06.01	Financial revenues	26,198	58,449	29,279	65,525
3.06.02	Financial expenses	-16,646	-33,727	-13,223	-25,844
3.07	Income (loss) before income tax	210,104	456,917	185,449	396,322



**Consolidated financial statements / Statement of income****(In thousands of reais)**

Code of account	Account description	Current quarter 04/01/2025–06/30/2025	Accumulated of the current year 01/01/2025–06/30/2025	Same quarter of the prior year 04/01/2024–06/30/2024	Accumulated of the prior year 01/01/2024–06/30/2024
3.08	Income tax and social contribution	-62,307	-139,551	-55,439	-119,623
3.08.01	Current	-52,858	-113,541	-43,218	-114,374
3.08.02	Deferred	-9,449	-26,010	-12,221	-5,249
3.09	Net income (loss) from continued operations	147,797	317,366	130,010	276,699
3.11	Income/loss for the period	147,797	317,366	130,010	276,699
3.11.01	Attributed to the Parent company's partners	147,828	317,552	130,135	276,872
3.11.02	Attributed to non-controlling partners	-31	-186	-125	-173
3.99	Earnings per share - (Reais R\$ / Shares)				
3.99.01	Basic earnings per share				
3.99.01.01	COMMON SHARES	0.2712	0.58206	0.23743	0.5026
3.99.02	Diluted earnings per share				
3.99.02.01	COMMON SHARES	0.2712	0.58206	0.23743	0.5026

**Consolidated financial statements / Statement of comprehensive income****(In thousands of reais)**

<b>Code of account</b>	<b>Account description</b>	<b>Current quarter 04/01/2025–06/30/2025</b>	<b>Accumulated of the current year 01/01/2025–06/30/2025</b>	<b>Same quarter of the prior year 04/01/2024–06/30/2024</b>	<b>Accumulated of the prior year 01/01/2024–06/30/2024</b>
4.01	Consolidated net income for the period	147,797	317,366	130,010	276,699
4.02	Other comprehensive income	9,446	9,030	-5,257	-9,383
4.02.01	Accumulated translation adjustment	460	-263	150	728
4.02.03	Other comprehensive income of investees recognized under the equity method	91	132	-66	-134
4.02.04	Other comprehensive income	8,895	9,161	-5,341	-9,977
4.03	Consolidated comprehensive income for the period	157,243	326,396	124,753	267,316
4.03.01	Attributed to the Parent company's partners	157,274	326,582	124,878	267,489
4.03.02	Attributed to non-controlling partners	-31	-186	-125	-173

**Consolidated financial statements / Statement of cash flows (Indirect method)****(In thousands of reais)**

Code of account	Account description	Accumulated of the	Accumulated of the prior
		current year 01/01/2025–06/30/2025	year 01/01/2024–06/30/2024
6.01	Net cash from operating activities	184,120	162,157
6.01.01	Cash generated in operations	487,783	419,542
6.01.01.01	Net income (loss) for the period	317,366	276,699
6.01.01.02	Depreciation and amortization	30,815	27,235
6.01.01.03	Net inflation adjustments	1,992	-2,530
6.01.01.05	Provision for lawsuits	1,119	456
6.01.01.06	Disposal of non-current assets and other	2,278	579
6.01.01.07	Equity in net income of subsidiaries	-3,421	-2,799
6.01.01.08	Provision for credit losses	-1,917	279
6.01.01.11	Income tax and social contribution	139,551	119,623
6.01.02	Changes in assets and liabilities	-303,663	-257,385
6.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	-119,236	-192,992
6.01.02.03	Other accounts receivable, recoverable taxes and prepaid expenses and other current assets	-13,216	53,139
6.01.02.04	Inventories	50	1,398
6.01.02.05	Long-term assets (Non-current)	389	2,823
6.01.02.06	Assets and liabilities of insurance and reinsurance contracts	-36,323	-3,438
6.01.02.09	Tax obligations (taxes payable)	-1,492	-2,556
6.01.02.10	Labor obligations, suppliers, and other accounts payable	-26,116	-1,834
6.01.02.11	Long-term liabilities (Non-current liabilities)	-9,772	-8,520
6.01.02.13	Income tax and social contribution paid	-111,362	-106,788
6.01.02.15	Trading on operations	14,022	1,543
6.01.02.17	Interest and fines paid	-607	-160
6.02	Net cash used in investment activities	96,958	-79,580
6.02.01	Acquisition of property, plant and equipment	-1,405	-5,276
6.02.02	Acquisition of intangible assets	-30,087	-29,163
6.02.07	Dividends received from Subsidiaries and jointly-controlled subsidiaries	3,475	3,625
6.02.11	Interest earning bank deposits measured at amortized cost	124,975	-48,766
6.03	Net cash from financing activities	-266,079	-84,865
6.03.01	Dividends and interest on own capital paid	-248,939	-19,726
6.03.02	Acquisition of own shares - Treasury	-12,888	-59,669
6.03.05	Payment of Lease	-4,252	-5,470
6.05	Increase (decrease) in cash and cash equivalents	14,999	-2,288
6.05.01	Opening balance of cash and cash equivalents	16,531	14,391
6.05.02	Closing balance of cash and cash equivalents	31,530	12,103

**Consolidated financial statements / Statement of changes in shareholders' equity / DMPL - 01/01/2025–06/30/2025****(In thousands of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity	Non-controlling interest	Consolidated shareholders' equity
5.01	Opening balances	851,017	-107,182	492,290	0	-8,356	1,227,769	464	1,228,233
5.02	Prior-year adjustments	0	0	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-107,182	492,290	0	-8,356	1,227,769	464	1,228,233
5.04	Capital transactions with partners	0	63,740	-157,628	-168,766	0	-262,654	0	-262,654
5.04.04	Treasury shares acquired	0	-12,888	0	0	0	-12,888	0	-12,888
5.04.06	Dividends	0	0	0	-118,000	0	-118,000	0	-118,000
5.04.07	Interest on own capital	0	0	0	-50,766	0	-50,766	0	-50,766
5.04.18	Additional dividend proposed	0	0	-81,000	0	0	-81,000	0	-81,000
5.04.20	Cancellation of treasury shares	0	76,628	-76,628	0	0	0	0	0
5.05	Total comprehensive income	0	0	0	317,552	9,030	326,582	-186	326,396
5.05.01	Net income for the period	0	0	0	317,552	0	317,552	-186	317,366
5.05.02	Other comprehensive income	0	0	0	0	9,030	9,030	0	9,030
5.05.02.04	Translation adjustments in the period	0	0	0	0	-263	-263	0	-263
5.05.02.08	Other comprehensive income	0	0	0	0	9,161	9,161	0	9,161
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	132	132	0	132
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0	0	0
5.07	Closing balances	851,017	-43,442	334,662	148,786	674	1,291,697	278	1,291,975

**Consolidated financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2024–06/30/2024****(In thousands of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity	Non-controlling interest	Consolidated shareholders' equity
5.01	Opening balances	851,017	-35,610	561,679	0	9,908	1,386,994	680	1,387,674
5.02	Prior-year adjustments	0	0	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-35,610	561,679	0	9,908	1,386,994	680	1,387,674
5.04	Capital transactions with partners	0	-59,669	-242,492	-117,421	0	-419,582	0	-419,582
5.04.04	Treasury shares acquired	0	-59,669	0	0	0	-59,669	0	-59,669
5.04.06	Dividends	0	0	0	-73,000	0	-73,000	0	-73,000
5.04.07	Interest on own capital	0	0	0	-44,421	0	-44,421	0	-44,421
5.04.18	Additional dividend proposed	0	0	-242,492	0	0	-242,492	0	-242,492
5.05	Total comprehensive income	0	0	0	276,872	-9,383	267,489	-278	267,211
5.05.01	Net income for the period	0	0	0	276,872	0	276,872	-173	276,699
5.05.02	Other comprehensive income	0	0	0	0	-9,383	-9,383	-105	-9,488
5.05.02.04	Translation adjustments in the period	0	0	0	0	719	719	0	719
5.05.02.07	Gain and losses from changes in equity interest	0	0	0	0	9	9	0	9
5.05.02.08	Other comprehensive income	0	0	0	0	-9,977	-9,977	-105	-10,082
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	-134	-134	0	-134
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0	0	0
5.07	Closing balances	851,017	-95,279	319,187	159,451	525	1,234,901	402	1,235,303

**Consolidated financial statements / Statement of added value****(In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2025–06/30/2025	01/01/2024–06/30/2024
7.01	Revenues	1,199,944	1,131,722
7.01.01	Sale of goods, products and services	1,171,774	1,105,358
7.01.02	Other revenues	26,253	26,643
7.01.02.02	Sale of goods and services	26,253	26,643
7.01.04	Formation/reversal of allowance for doubtful accounts	1,917	-279
7.02	Inputs acquired from third parties	-543,418	-553,880
7.02.01	Cost of products, goods and services sold	-461,807	-461,107
7.02.02	Materials, energy, third-party services and other	-8,504	-10,820
7.02.04	Other	-73,107	-81,953
7.02.04.01	Other operating revenues (expenses)	12,928	-10,101
7.02.04.02	Sales expenses	-706	-634
7.02.04.03	Administrative expenses	-85,329	-71,218
7.03	Gross added value	656,526	577,842
7.04	Retention	-30,815	-27,235
7.04.01	Depreciation, amortization and depletion	-30,815	-27,235
7.05	Net added value produced	625,711	550,607
7.06	Added value received as transfer	61,870	68,324
7.06.01	Equity in net income of subsidiaries	3,421	2,799
7.06.02	Financial revenues	58,449	65,525
7.07	Total added value payable	687,581	618,931
7.08	Distribution of added value	687,581	618,931
7.08.01	Personnel	111,976	118,038
7.08.01.01	Direct remuneration	86,518	92,175
7.08.01.02	Benefits	19,883	20,348
7.08.01.03	SEVERANCE PAY FUND (FGTS)	5,575	5,515
7.08.02	Taxes, duties and contributions	222,817	198,219
7.08.02.01	Federal	202,300	178,427
7.08.02.02	State	210	250
7.08.02.03	Municipal	20,307	19,542
7.08.03	Third-party capital remuneration	35,422	25,975
7.08.03.02	Rentals	1,695	131
7.08.03.03	Other	33,727	25,844
7.08.04	Remuneration of own capital	317,366	276,699
7.08.04.01	Interest on own capital	50,766	44,421
7.08.04.02	Dividends	118,000	73,000
7.08.04.03	Retained earnings / Loss for the period	148,786	159,451
7.08.04.04	Non-controlling interest in retained earnings	-186	-173

## Performance comment

---



São Paulo, August 05<sup>th</sup>, 2025

Odontoprev (B3: ODPV3 BZ), Brazil's largest dental plan operator, announces today its consolidated results for the second quarter of 2025 (2Q25).

The information contained in the Quarterly Report (ITR), released to CVM/B3, include the IFRS 17, CPC 50 – Insurance Contracts and IFRS 9/CPC 48 – Financial Instruments were also applied.

The **performance comments** maintain the comparability of data from historical series, since 2006, and are based on standards approved by the National Supplementary Health Agency – ANS.

Below are the conciliation tables from the financial statements (Balance Sheet, Income Statement and Cash Flow) for IFRS 17 and calculating solvency.

## Performance comment



### Balance sheet

(in thousand reais)

	Consolidated		
	Balance at June 30, 2025 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Balance at June 30, 2025 (CPC 50/IFRS 17)
<b>ASSETS</b>			
<b>Current assets</b>	<b>607,601</b>	<b>(103,866)</b>	<b>503,735</b>
Cash and cash equivalents	31,530	-	31,530
Interest earning bank deposits	342,372	-	342,372
Accounts receivable	142,087	(62,796)	79,291
Cash considerations/ Premiums receivable	92,960	(92,960)	-
Provision for credit losses	(23,160)	23,160	-
Participation of beneficiaries in indemnifying events/claims	2,209	(2,209)	-
Healthcare plan operators	8,845	(8,845)	-
Other receivables from operations with healthcare plans	25,626	(25,626)	-
Assets of insurance and reinsurance contracts	-	34,241	34,241
Other accounts receivable	35,607	9,443	45,050
Inventory	6	-	6
Recoverable taxes	33,091	-	33,091
Prepaid expenses	10,711	-	10,711
Other current assets	47,804	(41,070)	6,734
<b>Non-current assets</b>	<b>1,612,308</b>	<b>2,015</b>	<b>1,614,323</b>
Interest earning bank deposits valued at amortized cost	548,761	-	548,761
Deferred income tax and social contribution	-	1,528	1,528
Prepaid expenses	37	-	37
Other non-current assets	85,989	-	85,989
Investments (ownership interest under the equity method)	5,712	487	6,199
Property, plant and equipment	47,117	-	47,117
Intangible assets	924,692	-	924,692
<b>TOTAL ASSETS</b>	<b>2,219,909</b>	<b>(101,851)</b>	<b>2,118,058</b>
	Consolidated		
	Balance at June 30, 2025 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Balance at June 30, 2025 (CPC 50/IFRS 17)
<b>LIABILITIES</b>			
<b>Current assets</b>	<b>734,998</b>	<b>(36,774)</b>	<b>698,224</b>
Technical reserves for health care operations	286,881	(286,881)	-
Liabilities of insurance and reinsurance contracts	-	248,205	248,205
Debits from health care operations	28,487	(1,615)	26,872
Taxes and charges payable	47,646	-	47,646
Sundry debits	371,984	3,517	375,501
<b>Non-current assets</b>	<b>149,201</b>	<b>(21,342)</b>	<b>127,859</b>
Technical reserves for health care operations	156	(156)	-
Provision for lawsuits (Contingencies)	80,026	-	80,026
Taxes and social security charges payable	21,472	(21,186)	286
Sundry debits	47,547	-	47,547
<b>Shareholders' equity</b>	<b>1,335,710</b>	<b>(43,735)</b>	<b>1,291,975</b>
Realized capital	851,017	-	851,017
Capital reserves	(35,610)	-	(35,610)
Legal reserve	127,428	-	127,428
Tax incentive reserve	129	-	129
Treasury shares	(7,832)	-	(7,832)
Investment and expansion statutory reserve	254,977	(47,872)	207,105
Retained earnings and losses	144,062	4,724	148,786
Equity valuation adjustments	(799)	-	(799)
Accumulated translation adjustments	2,060	436	2,496
Other comprehensive income	-	(1,023)	(1,023)
Non-controlling interest	278	-	278
<b>TOTAL LIABILITIES</b>	<b>2,219,909</b>	<b>(101,851)</b>	<b>2,118,058</b>



## Performance comment



### Statement of income

(in thousands of reais)

	Consolidated		
	Balance at June 30, 2025 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Balance at June 30, 2025 (CPC 50/IFRS 17)
Net considerations/Retained premiums	1,171,502	(1,171,502)	-
Insurance	17,040	(17,040)	-
Insurance revenue (PAA)	-	908,623	908,623
Insurance revenue (BBA)	-	263,151	263,151
<b>INSURANCE AND REINSURANCE REVENUES</b>	<b>1,188,542</b>	<b>(16,768)</b>	<b>1,171,774</b>
Net indemnifiable events/retained claims	(337,155)	337,155	-
Changes in provision for events/claims incurred but Not Reported (IBNR)	4,361	(4,361)	-
Claims	(5,374)	5,374	-
Claims technical Reserves	563	(563)	-
Sales expenses	(129,181)	128,475	(706)
Direct taxes from operations with health care plans for the operator	(56,106)	56,106	-
Dental materials	(7,938)	7,938	-
Other operating costs	(41,740)	41,740	-
Insurance expenses	-	(712,153)	(712,153)
<b>INSURANCE AND REINSURANCE EXPENSES</b>	<b>(572,570)</b>	<b>(140,289)</b>	<b>(712,859)</b>
<b>INCOME (LOSS) FROM INSURANCE AND REINSURANCE OPERATIONS</b>	<b>615,972</b>	<b>(157,057)</b>	<b>458,915</b>
Sales of goods and services	26,253	-	26,253
Taxes on sales of goods and services	(6,532)	-	(6,532)
Provision for credit losses	(16,533)	18,450	1,917
Other operating revenues (expenses)	3,705	20,085	23,790
<b>GROSS INCOME</b>	<b>622,865</b>	<b>(118,522)</b>	<b>504,343</b>
Administrative expenses	(202,730)	139,018	(63,712)
Long-term incentive program (ILP)	(8,422)	7,527	(895)
Profit sharing	(10,962)	-	(10,962)
Net financial income (loss)	45,649	(20,927)	24,722
Financial revenues	58,449	-	58,449
Financial expenses	(12,800)	(20,927)	(33,727)
Financial expenses	(12,800)	(20,927)	(33,727)
Equity in net income of subsidiaries	3,246	175	3,421
<b>INCOME (LOSS) BEFORE INCOME TAXES</b>	<b>449,646</b>	<b>7,271</b>	<b>456,917</b>
Income tax and social contribution	(137,004)	(2,547)	(139,551)
<b>NET INCOME FOR THE YEAR</b>	<b>312,642</b>	<b>4,724</b>	<b>317,366</b>
Attributable to:			
Company's shareholders	312,828	4,724	317,552
Non-controlling interest	(186)	-	(186)
<b>NET INCOME FOR THE YEAR</b>	<b>312,642</b>	<b>4,724</b>	<b>317,366</b>

## Performance comment



### Statement of cash flow

(in thousands of reais)

	Balance at June 30, 2025 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Consolidated Balance at June 30, 2025 (CPC 50/IFRS 17)
<b>Net cash from operating activities</b>	<b>184,120</b>	-	<b>184,120</b>
<b>Cash generated in operations</b>	<b>488,414</b>	<b>(631)</b>	<b>487,783</b>
Net income (loss) for the period	312,642	4,724	317,366
Depreciation and amortization	30,815	-	30,815
Net inflation adjustments	1,992	-	1,992
Provision for lawsuits	1,119	-	1,119
Disposal of non-current assets and other	2,278	-	2,278
Equity in net income of subsidiaries	(3,246)	(175)	(3,421)
Provision for credit losses	16,533	(18,450)	(1,917)
Changes in provision for events/claims incurred but Not Reported (PEONA)	(4,361)	4,361	-
Income tax and social contribution	137,004	2,547	139,551
Provision for unearned premiums (UP)/considerations	(5,799)	5,799	-
Changes in technical claims reserves	(563)	563	-
<b>Changes in assets and liabilities</b>	<b>(304,294)</b>	<b>631</b>	<b>(303,663)</b>
Interest earning bank deposits (Financial assets at fair value through profit or loss)	(119,236)	-	(119,236)
Receivables from operations with healthcare plans (clients)	(15,042)	15,042	-
Other accounts receivable, recoverable taxes and prepaid expenses and other current assets	(30,768)	17,552	(13,216)
Inventories	50	-	50
Long-term assets (Non-current)	389	-	389
Provision for Unsettled claims (UC)	(6,158)	6,158	-
Assets and liabilities of insurance and reinsurance contracts	-	(36,323)	(36,323)
Tax obligations (taxes payable)	(1,492)	-	(1,492)
Labor obligations, Suppliers, Advance from clients and Other accounts payable (Sundry debits)	(25,892)	(224)	(26,116)
Non-current liabilities	(9,772)	-	(9,772)
Income tax and social contribution paid	(111,362)	-	(111,362)
Trading on operations	14,527	(505)	14,022
Other technical reserves (OTHER)	1,069	(1,069)	-
Interest and fines paid	(607)	-	(607)
<b>Net cash from investment activities</b>	<b>96,958</b>	-	<b>96,958</b>
Acquisition of Fixed assets	(1,405)	-	(1,405)
Acquisition of Intangibles assets	(30,087)	-	(30,087)
Dividends received from Subsidiaries and jointly-controlled subsidiaries	3,475	-	3,475
Interest earning bank deposits (Financial assets valued at amortized cost)	124,975	-	124,975
<b>Net cash from financing activities</b>	<b>(266,079)</b>	-	<b>(266,079)</b>
Dividends and Interest on capital paid	(248,939)	-	(248,939)
Acquisition of Treasury shares	(12,888)	-	(12,888)
Rent payments	(4,252)	-	(4,252)
<b>Increase (decrease) in cash and cash equivalents</b>	<b>14,999</b>	-	<b>14,999</b>
Opening balance of cash and cash equivalents	16,531	-	16,531
Closing balance of cash and cash equivalents	31,530	-	31,530

## Performance comment

---



**ANS establishes the rules for recognizing technical provisions and criteria for maintaining minimum shareholders' equity in accordance with RN 569/2022. As of 2023, the regulatory capital assessment must consider the highest of the following values: (i) base capital; and (ii) risk-based capital.**

The risk-based regulatory capital model considers five risk categories, namely:

(a) **Underwriting risk** is the uncertainty measure related to an adverse economic position that goes against the operator's expectations at the time of preparing its underwriting policy regarding the uncertainties existing in the estimation of technical provisions and those related to pricing.

(b) **Credit risk** is the measure of uncertainty related to the probability of the counterparty to a transaction, or a debt issuer, not honoring, total or partially, its financial commitments, or having its credit risk classification changed.

(c) **Operational risk** is the measure of uncertainty that understands the risks related to internal procedures (loss resulting from inadequacies or failures in internal processes, people and systems).

(d) **Legal risk** is the measure of uncertainty related to the lack of a complete legal foundation; is the risk of non-compliance with applicable laws, rules, regulations, agreements, current practices or ethical standards, including the risk that the nature of the product/service provided may make the operator particularly vulnerable to litigation.

(e) **Market risk** is the measure of uncertainty related to exposure to losses arising from the volatility of asset prices, such as share prices, interest rates, exchange rates, commodity prices and property prices.

## Performance comment



The required sufficiency went from R\$151 million on March 31 to R\$50 million on June 30. In 2Q25, it was approved the distribution of R\$81 million in dividends for 4Q24, R\$118 million in dividends for 1Q25 and R\$26 million in Interest on Capital for 2Q25, added to the share buyback of R\$5 million.

Description:	June 30, 2025	March 31, 2025	December 31, 2024
Reference capital	11,702	11,702	11,702
(x) K factor <sup>1</sup>	3.23%	3.23%	3.23%
<b>Adjusted minimum shareholders' equity (PMA)</b>	<b>378</b>	<b>378</b>	<b>378</b>
Shareholders' equity	1,335,432	1,418,929	1,285,651
Ownership interest in regulated entities	(3,936)	(4,225)	(4,166)
Deferred acquisition costs	(41,070)	(38,321)	(22,604)
Prepaid expenses	(10,336)	(5,254)	(7,571)
Intangible assets	(902,442)	(899,598)	(897,398)
Goodwill from indirect interests	(14,532)	(14,532)	(14,532)
<b>Adjusted shareholders' equity (PLA)</b>	<b>363,116</b>	<b>456,999</b>	<b>339,380</b>
<b>Risk-based capital (CBR)<sup>2</sup></b>	<b>313,244</b>	<b>306,392</b>	<b>296,780</b>
<b>Required sufficiency</b>	<b>49,872</b>	<b>150,607</b>	<b>42,600</b>

<sup>1</sup> Factor K corresponds to the classification: group dentistry, tertiary segment and region 1 as per appendix RN 569/2022;

<sup>2</sup> The CBR value takes into account the use of the reduced factors, as defined in article 6 of NR 569/2022.

## Performance comment



## Key metrics

(R\$000, except otherwise specified)	2Q25	2Q24	Δ%	6M25	6M24	Δ%	JUL24-JUN25	JUL23-JUN24	Δ%
Net operating revenue (NOR)	601,846	558,059	7.8	1,192,312	1,108,754	7.5	2,353,344	2,199,966	7.0
Average ticket (R\$/member/month)	22.74	21.65	5.0	22.55	21.46	5.1	22.41	21.51	4.2
Number of members	8,981,160	8,771,718	2.4	8,981,160	8,771,718	2.4	8,981,160	8,771,718	2.4
Organic net additions (members)	80,648	137,593	(41.4)	56,891	153,825	(63.0)	209,442	351,199	(40.4)
Cost of services	220,835	228,059	(3.2)	432,099	420,120	2.9	883,414	872,744	1.2
Average Cost of services (R\$/member/month)	8.23	8.73	(5.7)	8.04	8.05	(0.1)	8.29	8.46	(2.0)
Gross Profit (ex-IBNR)	381,010	330,000	15.5	760,213	688,634	10.4	1,469,930	1,327,223	10.8
Dental care ratio (%)	36.7	40.9	(4.2 p.p.)	36.2	37.9	(1.7 p.p.)	37.5	39.7	(2.2 p.p.)
Selling expenses (%)	11.7	11.0	0.7 p.p.	10.8	11.0	(0.2 p.p.)	11.4	10.6	0.8 p.p.
G&A (%)	15.3	14.8	0.5 p.p.	14.4	14.3	0.1 p.p.	15.3	15.6	(0.3 p.p.)
SG&A (%)	27.0	25.8	1.2 p.p.	25.2	25.3	(0.1 p.p.)	26.7	26.3	0.4 p.p.
Combined ratio (%)	63.7	66.6	(2.9 p.p.)	61.5	63.1	(1.6 p.p.)	64.3	65.9	(1.6 p.p.)
Bad debt (%)	1.2	1.9	(0.7 p.p.)	1.2	1.9	(0.7 p.p.)	2.0	2.0	-
Adjusted EBITDA	205,086	162,072	26.5	431,153	364,536	18.3	761,011	662,402	14.9
Adjusted EBITDA margin (%)	34.1	29.0	5.1 p.p.	36.2	32.9	3.3 p.p.	32.3	30.1	2.2 p.p.
Net financial income	19,726	25,221	(21.8)	45,649	54,446	(16.2)	101,012	92,224	9.5
Net income	146,196	122,354	19.5	312,828	277,739	12.6	568,669	527,420	7.8
(-) Non-recurring events	-	-	-	-	4,572	-	-	46,089	-
Recurring Net income	146,196	122,354	19.5	312,828	273,167	14.5	568,669	481,331	18.1
Total Capital (thousand)	545,825	552,496	(1.2)	545,825	552,496	(1.2)	545,825	552,496	(1.2)
Number of Treasury shares (thousand)	732	5,069	(85.6)	732	5,069	(85.6)	732	5,069	(85.6)
Outstanding shares	545,093	547,427	(0.4)	545,093	547,427	(0.4)	545,093	547,427	(0.4)
Recurring EPS (R\$/ share)	0.268	0.224	20.0	0.574	0.499	15.0	1.043	0.879	18.7
Dividends	115,155	85,478	34.7	233,155	158,478	47.1	437,582	585,732 *	(25.3)
IOC	26,016	21,642	20.2	50,765	44,421	14.3	90,581	84,545	7.1
Share buyback	5,025	15,234	(67.0)	12,888	59,669	(78.4)	24,791	59,669	(58.5)
Total Shareholder Remuneration	146,196	122,354	19.5	296,809	262,568	13.0	552,954	729,946 *	(24.2)
Payout (%)	100.0	100.0	-	94.9	94.5	0.4 p.p.	97.2	138.4	(41.2 p.p.)
Capex	16,870	21,410	(21.2)	31,487	35,152	(10.4)	88,884	82,973	7.1
Net cash	922,664	1,231,620	(25.1)	922,664	1,231,620	(25.1)	922,664	1,231,620	(25.1)
Required sufficiency	49,872	75,594	(34.0)	49,872	75,594	(34.0)	49,872	75,594	(34.0)
ROE	-	-	-	-	-	-	43.3	39.1	4.2 p.p.

\* Includes R\$427 million in 2023 dividends approved at the AGM in April 2024.

## Performance comment



## Key Metrics per segment

Key metrics	Corporate								
	2Q25	2Q24	Δ%	6M25	6M24	Δ%	JUL24-JUN25	JUL23-JUN24	Δ%
Net operating revenue (NOR)	333,792	310,718	7.4	662,423	611,645	8.3	1,310,436	1,208,896	8.4
Average ticket	18.33	17.40	5.3	18.13	17.13	5.8	18.03	17.08	5.6
Number of members (000)	6,333	6,273	1.0	6,333	6,273	1.0	6,333	6,273	1.0
Net additions (000)	33	169	-	(26)	165	-	60	299	-
Cost of services	157,797	161,920	(2.5)	309,225	295,544	4.6	632,101	614,502	2.9
Dental care ratio (%)	47.3	52.1	(4.8 p.p.)	46.7	48.3	(1.6 p.p.)	48.2	50.8	(2.6 p.p.)
Cost of services / member / month	8.33	8.72	(4.5)	8.12	7.96	2.1	8.36	8.36	(0.1)
Gross profit	175,994	148,798	18.3	353,198	316,100	11.7	678,335	594,394	14.1
Gross margin (%)	52.7	47.9	4.8 p.p.	53.3	51.7	1.6 p.p.	51.8	49.2	2.6 p.p.
Selling expenses	23,566	21,480	9.7	44,342	43,105	2.9	93,948	84,410	11.3
Selling expenses (%)	7.1	6.9	0.2 p.p.	6.7	7.0	(0.3 p.p.)	7.2	7.0	0.2 p.p.
Contribution Margin	152,429	127,317	19.7	308,858	272,995	13.1	584,389	509,983	14.6
Contribution Margin (% NOR)	45.7	41.0	4.7 p.p.	46.6	44.6	2.0 p.p.	44.6	42.2	2.4 p.p.

Key metrics	SME								
	2Q25	2Q24	Δ%	6M25	6M24	Δ%	JUL24-JUN25	JUL23-JUN24	Δ%
Net operating revenue (NOR)	124,666	113,317	10.0	247,266	226,141	9.3	489,619	447,511	9.4
Average ticket	26.07	25.73	1.3	26.19	25.76	1.7	26.48	26.38	0.4
Number of members (000)	1,710	1,538	11.1	1,710	1,538	11.1	1,710	1,538	11.1
Net additions (000)	64	(26)	-	101	(13)	-	171	96	-
Cost of services	32,113	32,797	(2.1)	61,240	59,933	2.2	122,989	124,820	(1.5)
Dental care ratio (%)	25.8	28.9	(3.1 p.p.)	24.8	26.5	(1.7 p.p.)	25.1	27.9	(2.8 p.p.)
Cost of services / member / month	6.38	7.05	(9.5)	6.15	6.47	(4.9)	6.31	6.98	(9.6)
Gross profit	92,553	80,520	14.9	186,026	166,208	11.9	366,630	322,691	13.6
Gross margin (%)	74.2	71.1	3.1 p.p.	75.2	73.5	1.7 p.p.	74.9	72.1	2.8 p.p.
Selling expenses	23,532	14,981	57.1	38,309	28,575	34.1	71,193	54,494	30.6
Selling expenses (%)	18.9	13.2	5.7 p.p.	15.5	12.6	2.9 p.p.	14.5	12.2	2.3 p.p.
Contribution Margin	69,021	65,538	5.3	147,717	137,633	7.3	295,437	268,197	10.2
Contribution Margin (% NOR)	55.4	57.8	(2.4 p.p.)	59.7	60.9	(1.2 p.p.)	60.3	59.9	0.4 p.p.

Key metrics	Individual plans								
	2Q25	2Q24	Δ%	6M25	6M24	Δ%	JUL24-JUN25	JUL23-JUN24	Δ%
Net operating revenue (NOR)	123,960	115,114	7.7	245,472	230,261	6.6	478,473	463,088	3.3
Average ticket	46.30	42.41	9.2	45.79	42.50	7.7	44.48	41.71	6.7
Number of members (000)	938	960	(2.3)	938	960	(2.3)	938	960	(2.3)
Net additions (000)	(16)	(5)	-	(19)	1	-	(22)	(44)	-
Cost of services	20,455	25,854	(20.9)	42,370	48,133	(12.0)	90,817	102,214	(11.2)
Dental care ratio (%)	16.5	22.5	(6.0 p.p.)	17.3	20.9	(3.6 p.p.)	19.0	22.1	(3.1 p.p.)
Cost of services / member / month	7.21	8.95	(19.5)	7.45	8.36	(10.9)	7.97	8.67	(8.1)
Gross profit	103,505	89,260	16.0	203,102	182,129	11.5	387,656	360,874	7.4
Gross margin (%)	83.5	77.5	6.0 p.p.	82.7	79.1	3.6 p.p.	81.0	77.9	3.1 p.p.
Selling expenses	22,054	23,678	(6.9)	44,554	47,332	(5.9)	98,997	91,115	8.7
Selling expenses (%)	17.8	20.6	(2.8 p.p.)	18.2	20.6	(2.4 p.p.)	20.7	19.7	1.0 p.p.
Contribution Margin	81,449	65,582	24.2	158,547	134,797	17.6	288,658	269,759	7.0
Contribution Margin (% NOR)	65.7	57.0	8.7 p.p.	64.6	58.5	6.1 p.p.	60.3	58.3	2.0 p.p.

\*Excludes the free choice plans provisions/ reversal between 2020 and 2023.

## Performance comment



## ESG Metrics



In July, Odontoprev was the first dental only operator certificated with the Accredited Operator seal by ANS, achieving Level I – Gold. This regulatory recognition reinforces our commitment to corporate governance and high-quality services.

Environmental key indicators	2Q24	6M24	2Q25	6M25
Total consumption of electricity (kWh) [GRI-302]	678,857	952,674	376,410	953,764
Total consumption of water (m³) [GRI-303]	622	1,234	630	1,263
Greenhouse gas emissions per scope (tCO2e) [GRI 305]	149	247	140	257
Scope 1 - direct emissions (tCO2e)	1	1	1	2
Scope 2 - indirect emissions related to purchase of energy (tCO2e)	14	27	11	37
Scope 3 - indirect emissions from the value chain (tCO2e)	134	219	128	217
Waste Management[GRI 306]	44	101	129	247
Paper disposal (Kg)	40	91	116	223
Plastic disposal (Kg)	3	7	9	17
Aluminium disposal (Kg)	1	2	3	5
Glass disposal (Kg)	1	1	1	2
Personnel key indicators	2Q24	6M24	2Q25	6M25
Total employees (a)	1,959	1,959	1,952	1,952
Board of Directors & Fiscal Council Members (b)	11	11	11	11
Total employees ex Board members (a) - (b)	1,948	1,948	1,941	1,941
Call Center employees	134	134	185	185
Total turnover	6.2%	13.0%	8.8%	15.2%
Turnover without Call Center	6.0%	12.2%	7.2%	12.8%
Call Center turnover	12.1%	25.3%	23.8%	37.8%
[GRI G4-LA12]				
Gender distribution				
% Men	27.2%	27.2%	27.2%	27.2%
% Women	72.8%	72.8%	72.8%	72.8%
% Women at Strategic Management	45.1%	45.1%	45.6%	45.6%
[GRI G4-LA12]				
Functional distribution				
Statutory	0.4%	0.4%	0.4%	0.4%
Management/Superintendence	4.5%	4.5%	4.5%	4.5%
Supervisory	4.9%	4.9%	5.4%	5.4%
Administrative	32.2%	32.2%	33.3%	33.3%
Operational	53.9%	53.9%	52.2%	52.2%
Apprentice/Interns	4.1%	4.1%	4.1%	4.1%
[GRI G4-LA12]				
Age distribution				
< 21 years	4.5%	4.5%	4.6%	4.6%
21 - 29 years	23.6%	23.6%	23.4%	23.4%
30 - 39 years	35.7%	35.7%	34.1%	34.1%
40 - 49 years	24.2%	24.2%	25.1%	25.1%
> 50 years	12.0%	12.0%	12.8%	12.8%

## Performance comment



## Operational and financial performance


## Net operating revenue (NOR)

Net operating revenue (NOR)															
	2Q25		2Q24		Δ%	6M25		6M24		Δ%	JUL24-JUN25		JUL23-JUN24		Δ%
	R\$ 000	% NOR	R\$ 000	% NOR		R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% NOR	R\$ 000	% NOR	
(+) Payments, net	609,966	101.3	565,378	101.3	7.9	1,211,269	101.6	1,119,802	101.0	8.2	2,386,713	101.4	2,218,336	100.8	7.6
(+) Sales of services and products	12,517	2.1	12,772	2.3	(2.0)	26,253	2.2	26,643	2.4	(1.5)	52,276	2.2	54,622	2.5	(4.3)
(+) Odontored (México)	10,194	1.7	9,721	1.7	4.9	17,428	1.5	21,270	1.9	(18.1)	36,343	1.5	41,437	1.9	(12.3)
Gross operating revenue (GOR)	632,677	105.1	587,871	105.3	7.6	1,254,950	105.3	1,167,715	105.3	7.5	2,475,332	105.2	2,314,395	105.2	7.0
(-) Direct taxes on dental care operations	27,549	4.6	26,230	4.7	5.0	56,107	4.7	51,754	4.7	8.4	108,183	4.6	98,843	4.5	9.4
(-) Taxes on sales of services and products	3,283	0.5	3,583	0.6	(8.4)	6,532	0.5	7,206	0.6	(9.4)	13,804	0.6	15,586	0.7	(11.4)
Net operating revenue (NOR)	601,846	100.0	558,059	100.0	7.8	1,192,312	100.0	1,108,754	100.0	7.5	2,353,344	100.0	2,199,966	100.0	7.0

The consolidated net revenue (NOR) reached **R\$601,846 in 2Q25, up 7.8% YoY**, with a higher average ticket in all segments. Over the last twelve months, NOR was R\$2,353,344, up 7.0% Y/Y.

## Net revenue

R\$ million



## Consolidated Average Ticket

The consolidated average ticket in 2Q25 was R\$22.74, **5.0% higher** than the R\$21.65 registered in 2Q24.

	2Q25	2Q24	Δ%	6M25	6M24	Δ%	JUL24-JUN25	JUL23-JUN24	Δ%
Payments, net R\$000 (A)	609,966	565,378	7.9	1,211,269	1,119,802	8.2	2,386,713	2,218,336	7.6
Average number of members (B)	8,940,836	8,702,922	2.7	8,952,715	8,694,806	3.0	8,876,439	8,596,119	3.3
<b>Average ticket (R\$/member/month) (A/B)/# of months</b>	<b>22.74</b>	<b>21.65</b>	<b>5.0</b>	<b>22.55</b>	<b>21.46</b>	<b>5.1</b>	<b>22.41</b>	<b>21.51</b>	<b>4.2</b>




## Performance comment



### Net revenue and Average ticket annual performance

% and R\$/member/month



## Total number of members

Odontoprev registered 8,981,160 members in 2Q25, with a net addition of 81 thousand beneficiaries in the quarter and 209 thousand in the last twelve months.


The corporate segment presented a net addition of 33 thousand lives in the quarter and 60 thousand new clients in the last twelve months.

**SME plans reached a record net addition of 64 thousand new customers in 2Q25, and 171 thousand in twelve months, with the Bradesco Dental brand standing out.**

Individual plans showed a net loss of 16 thousand lives in 2Q25 and 22 thousand in the last twelve months.

### Bradesco Dental: SME net additions in first quarters

Thousand lives




## Performance comment



Bradesco Dental, the best-selling brand in recent years, currently accounts for 52% of the consolidated portfolio. We highlight the SME segment, which reached a record net additions in both 2Q25 (+37% YoY), 6M25 (+62% YoY) and in the last twelve months (+42% YoY). These results reinforce the Company's strategic positioning.

## Bradesco Dental: SME record net additions in 2Q, 6M and 12M



	Portfolio	% segment	Net additions			Portfolio	% segment	Net additions		
			2Q25	6M25	JUL24-JUN25			2Q24	6M24	JUL23-JUN24
<b>Total</b>	<b>8,981,160</b>	<b>100.0%</b>	<b>80,648</b>	<b>56,891</b>	<b>209,442</b>	<b>8,771,718</b>	<b>100.0%</b>	<b>137,593</b>	<b>153,825</b>	<b>351,199</b>
bradesco dental	4,648,553	51.8%	87,654	78,255	311,335	4,337,218	49.4%	76,366	50,812	201,846
Others <sup>1</sup>	4,332,607	48.2%	(7,006)	(21,364)	(101,893)	4,434,500	50.6%	61,227	103,013	149,353
<b>Corporate</b>	<b>6,332,920</b>	<b>100.0%</b>	<b>33,027</b>	<b>(25,700)</b>	<b>59,887</b>	<b>6,273,033</b>	<b>100.0%</b>	<b>168,537</b>	<b>165,189</b>	<b>299,324</b>
bradesco dental	2,840,045	44.8%	34,739	(12,586)	151,566	2,688,479	42.9%	40,896	(10,813)	87,708
Others <sup>1</sup>	3,492,875	55.2%	(1,712)	(13,114)	(91,679)	3,584,554	57.1%	127,641	176,002	211,616
<b>SME</b>	<b>1,709,921</b>	<b>100.0%</b>	<b>63,588</b>	<b>101,417</b>	<b>171,427</b>	<b>1,538,494</b>	<b>100.0%</b>	<b>(25,668)</b>	<b>(12,772)</b>	<b>95,679</b>
bradesco dental	1,380,521	80.7%	55,476	89,959	171,733	1,208,788	78.6%	40,422	55,481	120,908
Others <sup>1</sup>	329,400	19.3%	8,112	11,458	(306)	329,706	21.4%	(66,090)	(68,253)	(25,229)
<b>Individual Plans</b>	<b>938,319</b>	<b>100.0%</b>	<b>(15,967)</b>	<b>(18,826)</b>	<b>(21,872)</b>	<b>960,191</b>	<b>100.0%</b>	<b>(5,276)</b>	<b>1,408</b>	<b>(43,804)</b>
bradesco dental	427,987	45.6%	(2,561)	882	(11,964)	439,951	45.8%	(4,952)	6,144	(6,770)
Others <sup>1</sup>	510,332	54.4%	(13,406)	(19,708)	(9,908)	520,240	54.2%	(324)	(4,736)	(37,034)

<sup>1</sup>On Corporate and SME, includes Odontoprev, Odonto System, Mogidonto and Brasilidental. On Individual Plans, also includes retail channels.

## Performance comment



## Cost of services and dental care ratio

Cost of services (ex IBNR) and dental loss ratio (% NOR)															
	2Q25		2Q24		Δ% p.p. NOR	6M25		6M24		Δ% p.p. Sales	JUL24-JUN25		JUL23-JUN24		Δ% p.p. NOR
	R\$ 000	% NOR	R\$ 000	% NOR		R\$ 000	% Sales	R\$ 000	% Sales		R\$mil	% NOR	R\$ 000	% NOR	
Cost of services (ex IBNR)	220,835	36.7	228,059	40.9	(4.2)	432,099	36.2	420,120	37.9	(1.7)	883,414	37.5	872,744	39.7	(2.2)
Indemnifiable claims, net	192,719	32.0	203,215	36.4	(4.4)	376,922	31.6	369,848	33.4	(1.8)	765,181	32.5	775,420	35.2	(2.7)
Dental materials	4,533	0.8	3,994	0.7	0.1	8,649	0.7	8,813	0.8	(0.1)	26,109	1.1	20,014	0.9	0.2
Odontored (México)	3,034	0.5	2,718	0.5	0.0	5,374	0.5	5,311	0.5	-	10,968	0.5	9,760	0.4	0.1
Other operational costs and Provisions/reversals	20,549	3.4	18,132	3.2	0.2	41,153	3.5	36,148	3.3	0.2	81,156	3.4	67,550	3.1	0.3

For comparison purposes, the IBNR Provision (incurred but not reported) and technical reserves (Odontored), were excluded from the Cost of Services.


In 2Q25, the dental care ratio was 36.7%, with an improvement of 4.2 p.p. YoY, including a reversal of R\$10,963 in technical provisions. Excluding this reversal, the dental care ratio for the quarter would have been 38.5%, down 2.4 p.p. YoY. In the last twelve months, the cost of services represented 37.5% of NOR (38.0% excluding the reversal), a more efficient level in all segments.

We demonstrated below the dental care ratio per segment, with and without the reversal of provisions:

Segment	Cost of service (ex IBNR) (R\$000)			Dental care ratio (%)	
	2Q25	Technical provision	2Q25 Ex reversal	2Q25	2Q25 Ex reversal
Corporate	157,797	7,424	165,221	47.3%	49.5%
SME	32,113	1,080	33,193	25.8%	26.6%
Individual	20,455	2,458	22,913	16.5%	18.5%
Consolidated	220,835	10,963	231,798	36.7%	38.5%

## Cost of Services

R\$ million and % NOR



\*Includes reversal of R\$10,963 in technical provision.


## Performance comment



The three business segments have a similar average cost of services. On the other hand, the pricing of non-corporate products, in particular Individual plans, assumes conservative parameters related to adverse selection, contract cancellation and bad debt.

### Quarterly Average ticket, Average cost of services and Dental care ratio by segment

R\$/member/month



\*Excludes technical provision reversals

Performance comment




Selling expenses

	2Q25	2Q24	Δ%	6M25	6M24	Δ%	JUL24-JUN25	JUL23-JUN24	Δ%
Selling expenses (R\$ 000)	70,422	61,392	14.7	129,181	121,926	6.0	268,597	233,458	15.1
Selling expenses (% NOR)	11.7	11.0	0.7 p.p.	10.8	11.0	(0.2 p.p.)	11.4	10.6	0.8 p.p.

The selling expenses were 11.7% in 2Q25, 0.7 p.p. higher YoY, given the sales mix with a growing share of non-corporate products, of a higher acquisition cost.

Selling expenses

R\$ million and % NOR



## Performance comment




## Administrative expenses (G&amp;A)

	2Q25		2Q24		Δ%	Δ% p.p. NOR	6M25		6M24		Δ%	Δ% p.p. Sales	JUL24-JUN25		JUL23-JUN24		Δ%	Δ% p.p. NOR
	R\$ 000	% NOR	R\$ 000	% NOR			R\$ 000	% Sales	R\$ 000	% Sales			R\$mil	% ROL	R\$ 000	% NOR		
Personnel	47,739	7.9	45,413	8.1	5.1	(0.2)	93,543	7.8	89,424	8.1	4.6	(0.3)	191,697	8.1	188,045	8.5	1.9	(0.4)
Third parties services	24,059	4.0	20,878	3.7	15.2	0.3	40,587	3.4	39,379	3.6	3.1	(0.2)	81,154	3.4	80,089	3.6	1.3	(0.2)
Rentals and post services	9,886	1.6	7,225	1.3	36.8	0.3	19,413	1.6	14,277	1.3	36.0	0.3	48,726	2.1	40,541	1.8	20.2	0.3
Publicity and advertising	6,633	1.1	5,685	1.0	16.7	0.1	10,584	0.9	9,252	0.8	14.4	0.1	26,848	1.1	22,217	1.0	20.8	0.1
Taxes and fees	1,092	0.2	1,282	0.2	(14.8)	-	3,059	0.3	2,204	0.2	38.8	0.1	5,051	0.2	5,209	0.2	(3.0)	-
Others	2,553	0.4	1,898	0.3	34.5	0.1	4,607	0.4	3,541	0.3	30.1	0.1	6,921	0.3	8,105	0.4	(14.6)	(0.1)
<b>G&amp;A (adjusted at EBITDA base)</b>	<b>91,963</b>	<b>15.3</b>	<b>82,381</b>	<b>14.8</b>	<b>11.6</b>	<b>0.5</b>	<b>171,793</b>	<b>14.4</b>	<b>158,077</b>	<b>14.3</b>	<b>8.7</b>	<b>0.1</b>	<b>360,398</b>	<b>15.3</b>	<b>344,205</b>	<b>15.6</b>	<b>4.7</b>	<b>(0.3)</b>
Depreciation and amortization	14,288	2.4	11,255	2.0	26.9	0.4	27,671	2.3	23,933	2.2	15.6	0.1	53,531	2.3	50,985	2.3	5.0	-
Amortization of utilization rights	1,595	0.3	1,635	0.3	(2.4)	-	3,144	0.3	3,302	0.3	(4.8)	-	6,200	0.3	8,008	0.4	(22.6)	(0.1)
<b>G&amp;A (not adjusted at EBITDA base)</b>	<b>15,883</b>	<b>2.6</b>	<b>12,890</b>	<b>2.3</b>	<b>23.2</b>	<b>0.3</b>	<b>30,815</b>	<b>2.6</b>	<b>27,235</b>	<b>2.5</b>	<b>13.1</b>	<b>0.1</b>	<b>59,731</b>	<b>2.5</b>	<b>58,993</b>	<b>2.7</b>	<b>1.3</b>	<b>(0.2)</b>
<b>Total administrative expenses (G&amp;A)</b>	<b>107,846</b>	<b>17.9</b>	<b>95,271</b>	<b>17.1</b>	<b>13.2</b>	<b>0.8</b>	<b>202,608</b>	<b>17.0</b>	<b>185,312</b>	<b>16.7</b>	<b>9.3</b>	<b>0.3</b>	<b>420,129</b>	<b>17.9</b>	<b>403,200</b>	<b>18.3</b>	<b>4.2</b>	<b>(0.4)</b>

The administrative expenses (G&A at Adjusted EBITDA basis) were 15.3% of NOR in 2Q25, up 0.5 p.p. YoY, remaining stable in relation to NOR both in the semester and in 12 months.

## G&amp;A

R\$ million and % NOR



Performance comment



Allowance for doubtful receivables


	2Q25	2Q24	Δ%	6M25	6M24	Δ%	JUL24- JUN25	JUL23- JUN24	Δ%
Allowance for doubtful receivables (R\$ 000)	7,501	10,433	(28.1)	14,657	20,736	(29.3)	45,961	44,092	4.2
Allowance for doubtful receivables (% NOR)	1.2	1.9	(0.7 p.p.)	1.2	1.9	(0.7 p.p.)	2.0	2.0	0.0 p.p.

The allowance for doubtful receivables is calculated considering overdue invoices (60 days for Individual plans and 90 days for corporate plans), plus an average percentage of historical losses.

In 2Q25, the allowance for doubtful receivables was 1.2% of NOR, -0.7 p.p. Y/Y. In the last twelve months, the allowance for doubtful receivables was 2.0% of NOR.

Allowance for doubtful receivables

R\$ million and % NOR



## Performance comment



## EBITDA and Adjusted EBITDA


	2Q25		2Q24		Y/Y %	Δ% p.p. NOR	6M25		6M24		Y/Y %	Δ% p.p. NOR	JUL24-JUN25		JUL23-JUN24		Y/Y %	Δ% p.p. NOR
	R\$ 000	% NOR	R\$ 000	% NOR			R\$ 000	% NOR	R\$ 000	% NOR			R\$ 000	% NOR	R\$ 000	% NOR		
Net Income	146,196	24.3	122,354	21.9	19.5	2.4	312,828	26.2	277,739	25.0	12.6	1.2	568,669	24.2	527,420	24.0	7.8	0.2
(+) Current income and social contribution tax	52,858	8.8	43,218	7.7	22.3	1.1	113,541	9.5	113,488	10.2	-	(0.7)	230,368	9.8	191,540	8.7	20.3	1.1
(+) Deferred income and social contribution tax	8,578	1.4	8,267	1.5	3.8	(0.1)	23,463	2.0	5,715	0.5	310.5	1.5	8,282	0.4	8,842	0.4	(6.3)	-
(-) Financial income	26,198	4.4	29,279	5.2	(10.5)	(0.8)	58,449	4.9	62,673	5.7	(6.7)	(0.8)	126,213	5.4	117,150	5.3	7.7	0.1
(+) Financial expenses	6,472	1.1	4,058	0.7	59.5	0.4	12,799	1.1	8,227	0.7	55.6	0.4	25,201	1.1	24,926	1.1	1.1	-
(-) Participation of minority shareholders	31	-	125	-	(75.1)	-	186	-	173	-	7.5	-	124	-	39	-	214.3	-
(+) Depreciation and amortization	14,288	2.4	11,255	2.0	26.9	0.4	27,671	2.3	23,933	2.2	15.6	0.1	53,531	2.3	50,985	2.3	5.0	-
(+) Amortization of utilization rights	1,595	0.3	1,635	0.3	(2.4)	-	3,144	0.3	3,302	0.3	(4.8)	-	6,200	0.3	8,008	0.4	(22.6)	(0.1)
(-) Equity in subsidiaries	1,596	0.3	1,681	0.3	(5.1)	-	3,246	0.3	2,957	0.3	9.8	-	6,286	0.3	3,007	0.1	109.0	0.2
<b>EBITDA</b>	<b>202,162</b>	<b>33.6</b>	<b>159,702</b>	<b>28.6</b>	<b>26.6</b>	<b>5.0</b>	<b>431,564</b>	<b>36.2</b>	<b>366,600</b>	<b>33.1</b>	<b>17.7</b>	<b>3.1</b>	<b>759,630</b>	<b>32.3</b>	<b>691,524</b>	<b>31.4</b>	<b>9.8</b>	<b>0.9</b>
(+) Incurred But Not Reported Provision - IBNR	1,040	0.2	20	-	5,087.3	0.2	(4,361)	(0.4)	(1,260)	(0.1)	246.0	(0.3)	(7,801)	(0.3)	8,532	0.4	(191.4)	(0.7)
(+) Odontored - Technical reserves	(334)	(0.1)	(115)	-	191.1	(0.1)	(563)	-	(340)	-	65.7	-	275	-	528	-	(48.0)	-
(+) Brásilental EBITDA Pro Forma	2,218	0.4	2,466	0.4	(10.1)	-	4,513	0.4	4,109	0.4	9.8	-	8,907	0.4	7,911	0.4	12.6	-
(-) ISS reversal	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(4,794)	(0.2)	(100.0)	0.2
(-) Reversal TSS/ ANS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(41,296)	(1.9)	(100.0)	1.9
<b>Adjusted EBITDA</b>	<b>205,086</b>	<b>34.1</b>	<b>162,072</b>	<b>29.0</b>	<b>26.5</b>	<b>5.1</b>	<b>431,153</b>	<b>36.2</b>	<b>364,536</b>	<b>32.9</b>	<b>18.3</b>	<b>3.3</b>	<b>761,011</b>	<b>32.3</b>	<b>662,403</b>	<b>30.1</b>	<b>14.9</b>	<b>2.2</b>

Adjusted EBITDA reached R\$205,086 in 2Q25, 26.5% higher than 2Q24, with a margin of 34.1%, up 5.1 p.p. Y/Y. In the last twelve months, adjusted EBITDA was a **record R\$761,011, with a margin expansion from 30.1% to 32.3%**.

Since 2022, adjusted EBITDA has shown a CAGR of 11.8%.

## Adjusted EBITDA

R\$ million and % NOR





## Performance comment



## Financial income


	2Q25		2Q24		Δ%	6M25		6M24		Δ%	JUL24-JUN25		JUL23-JUN24		Δ%
	R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales	R\$ 000	% Sales		R\$mil	% Sales	R\$ 000	% Sales	
Net financial income	19,726	3.3	25,221	4.5	(21.8)	45,649	3.8	54,446	4.9	(16.2)	101,012	4.3	92,224	4.2	9.5
(+) Financial income	26,198	4.4	29,279	5.2	(10.5)	58,449	4.9	62,673	5.7	(6.7)	126,213	5.4	117,150	5.3	7.7
(-) Financial expenses	6,472	1.1	4,058	0.7	59.5	12,799	1.1	8,227	0.7	55.6	25,201	1.1	24,926	1.1	1.1

The financial income was R\$26,198, lower than the R\$29,279 in 2Q24, mainly due to the lower cash balance after shareholder remuneration of R\$232,321 in April. As of 2025, financial expenses increased due to the monetary adjustment of legal contingencies, which will now be adjusted by the Interest rate (Selic)/ CPI (IPCA), instead of the National Consumer Price Index (INPC).

During 2021, the Company's financial portfolio was partially migrated from Current Assets to long-term Treasury bonds, currently representing 59% of total portfolio, of which post-fixed (72%) and pre-fixed (28%), with the same credit risk profile. The new instruments are booked at their yield curve, minimizing the volatility of the consolidated portfolio, and will be held to maturity. The Company does not make use of derivatives.

## Financial income recent evolution

R\$ million



## Performance comment



### Income and social contribution taxes

	2Q25		2Q24		Δ%	6M25		6M24		Δ%	JUL24-JUN25		JUL23-JUN24		Δ%
	R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales	R\$ 000	% Sales		R\$ 000	% Sales	R\$ 000	% Sales	
<b>Taxes<sup>1</sup></b>	<b>61,436</b>	<b>10.6</b>	<b>51,485</b>	<b>9.5</b>	<b>19.3</b>	<b>137,003</b>	<b>11.9</b>	<b>120,089</b>	<b>11.1</b>	<b>14.1</b>	<b>238,650</b>	<b>10.5</b>	<b>212,949</b>	<b>10.0</b>	<b>12.1</b>
(-) Current income and social contribution taxes	52,858	9.1	43,218	8.0	22.3	113,541	9.9	114,374	10.6	(0.7)	230,368	10.1	204,107	9.6	12.9
(-) Deferred income and social contribution taxes	8,578	1.5	8,267	1.5	-	23,463	2.0	5,715	0.5	-	8,282	0.4	8,842	0.4	(6.3)

<sup>1</sup> Considers income tax and social contribution relating to Odontoprev's accounting result.

### Effective tax rates

Effective tax rates						
(R\$000, except otherwise specified)	2Q25	2Q24	6M25	6M24	JUL24-JUN25	JUL23-JUN24
<b>Income before taxes and profit sharing</b>	<b>207,601</b>	<b>173,714</b>	<b>449,645</b>	<b>397,655</b>	<b>807,195</b>	<b>740,330</b>
<b>Taxes</b>						
(-) Current income and social contribution taxes	52,858	43,218	113,541	114,374	230,368	204,107
(-) Deferred income and social contribution taxes	8,578	8,267	23,463	5,715	8,282	8,842
<b>Total taxes</b>	<b>61,436</b>	<b>51,485</b>	<b>137,003</b>	<b>120,089</b>	<b>238,650</b>	<b>212,949</b>
<b>Total effective tax rate (%)<sup>1</sup></b>	<b>29.6%</b>	<b>29.6%</b>	<b>30.5%</b>	<b>30.2%</b>	<b>29.6%</b>	<b>28.8%</b>

<sup>1</sup> Considers to calculate the Total effective tax rate the Odontoprev's accounting result.

### Goodwill

Goodwill balance for future profitability resulting from the acquisition and subsequent incorporation of the company's Mogidonto (R\$4,362) and Rede Dental (R\$1,236) to be excluded from the calculation of taxable income at the rate of 1/60th for each month of the calculation period.

Goodwill amortization schedule from 2025*	
Period	Total amortization R\$000
2025	2,690
2026	2,908
<b>Total</b>	<b>5,599</b>

\*Includes the difference between all amounts paid and the fair value of assets and liabilities of investments acquired and evaluated through a Purchase Price Allocation (PPA) assessment.

## Performance comment



## Net income

	2Q25	2Q24	Δ%	6M25	6M24	Δ%	JUL24- JUN25	JUL23- JUN24	Δ%
Net income (R\$ 000)	146,196	122,354	19.5	312,828	277,739	12.6	568,669	527,420	7.8
(-) Non-recurring events	-	-	-	-	4,572	-	-	46,089	-
<b>Recurring Net income</b>	<b>146,196</b>	<b>122,354</b>	<b>19.5</b>	<b>312,828</b>	<b>273,167</b>	<b>14.5</b>	<b>568,669</b>	<b>481,331</b>	<b>18.1</b>
Outstanding shares	545,093	547,427	(0.4)	545,093.2	547,426.6	(0.4)	545,093	547,427	(0.4)
<b>Recurring EPS (R\$/share)</b>	<b>0.268</b>	<b>0.224</b>	<b>20.0</b>	<b>0.574</b>	<b>0.499</b>	<b>15.0</b>	<b>1.043</b>	<b>0.879</b>	<b>18.7</b>


The net income reached R\$146,196 in 2Q25, 19.5% higher than 2Q24. In the last twelve months, net income was R\$568,669, 18.1% higher than recurring income for the previous period.

EPS came up 20.0% in 2Q25 YoY, and 18.7% in the last twelve months.

Since 2022, recurring net income has shown a CAGR of 9.6%.

## Net Income: recurring and non-recurring

R\$ million and % NOR



## Performance comment




## Cash flow

(R\$000)	2Q25	2Q24	6M25	6M24
<b>CASH FLOW FROM OPERATIONAL ACTIVITIES</b>				
Net income for the period	146,165	122,229	312,642	277,566
Reconciliation of net income with the cash generated by operations	80,605	73,640	175,772	168,190
<b>NET CASH FROM OPERATIONAL ACTIVITIES</b>	<b>226,770</b>	<b>195,869</b>	<b>488,414</b>	<b>445,756</b>
Decrease (increase) in operational assets	(19,925)	(7,127)	(45,371)	12,591
Increase (decrease) in operational liabilities	(71,437)	(54,593)	(139,687)	(103,198)
<b>NET CASH PROVIDED BY (USED IN) OPERATIONAL ACTIVITIES</b>	<b>135,408</b>	<b>134,149</b>	<b>303,356</b>	<b>355,149</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>				
Acquisition of property and equipment	(961)	(4,879)	(1,405)	(5,276)
System development, software licenses and other	(15,909)	(15,819)	(30,087)	(29,163)
Deferred selling expenses	1,900	2,000	3,475	3,625
<b>NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</b>	<b>(14,970)</b>	<b>(18,698)</b>	<b>(28,017)</b>	<b>(30,814)</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>				
Dividends paid	(208,905)	-	(208,905)	(146)
Interest on capital paid	(18,392)	-	(40,034)	(19,580)
Share repurchased	(5,024)	(59,669)	(12,888)	(59,669)
<b>NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</b>	<b>(234,436)</b>	<b>(63,759)</b>	<b>(266,079)</b>	<b>(84,865)</b>
<b>INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</b>	<b>(113,997)</b>	<b>51,693</b>	<b>9,261</b>	<b>239,471</b>
Cash, Cash Equivalents and short-term investments				
Balance at the beginning of period	1,036,661	1,179,927	913,403	992,149
Balance at the end of period	922,664	1,231,620	922,664	1,231,620
<b>INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</b>	<b>(113,997)</b>	<b>51,693</b>	<b>9,261</b>	<b>239,471</b>


## Net cash, zero debt

R\$ million



## Cash flow

R\$ million



\*Includes Dividends, IOC and Buyback.

Performance comment



CAPEX


The IT development has historically been Odontoprev's largest investment item.

(R\$thousand)	2Q25	2Q24	JUL24-JUN25	JUL23-JUN24
IT platform, acquisition/license of software	15,908	16,040	82,909	72,250
Computer equipment	84	4,145	2,833	8,389
Dental plan equipment, furniture and utensils	192	445	1,027	842
Installations	439	219	2,228	739
Others	246	559	1,090	752
Total Capex	16,870	21,410	90,088	82,973

The annual CAPEX level reflects investments in the company's digital initiatives. In the last twelve months, investments in technology reached R\$86 million, lower than the level registered in recent years.

CAPEX: Technology represents the main investment

R\$ million and % NOR



<sup>1</sup> IT platform. acquisition/licence of software and computer equipment

## Performance comment



## Shareholder remuneration

In the first half of the year, total Dividend and Interest on Capital payments reached R\$248,939.

For the second half of the year, total Dividend and Interest on Capital payments, scheduled for December 10th, will be of R\$386,344, bringing the 2025 total cash dividends to R\$635,283.

Dividends (DIV), interest on capital (IOC) and capital reduction (CR) - R\$ thousand												
Payment	Approval	Shareholder position	Type	Period	Gross amount R\$	Net amount R\$	Net value per share R\$			Annual total gross amount R\$	Net Income	Payout
							DIV	IOC	Total			
Total paid in 2019:					250,712	241,097	0.351910051	0.095206558	0.447116609	199,334	284,762	70%
Total paid in 2020:					270,219	262,006	0.406237632	0.087765775	0.494003407	333,213	361,128	92%
Total paid in 2021:					261,159	251,455	0.372061480	0.104762084	0.476823564	188,506	380,357	96%
Total paid in 2022:					169,778	159,389	0.179075757	0.108277182	0.287352939	249,258	452,171	91% <sup>4</sup>
07/12/2023	04/05/2023	04/20/2023	DIV	4Q22	120,000	120,000	0.217196275	-	0.217196275	509,728	536,554	95%
12/19/2023	03/14/2023	03/17/2023	IOC	1Q23	21,239	18,053	-	0.032675339	0.032675339			
12/19/2023	06/26/2023	06/29/2023	IOC	2Q23	21,111	17,944	-	0.032478425	0.032478425			
12/19/2023	09/19/2023	09/22/2023	IOC	3Q23	20,544	17,462	-	0.031606078	0.031606078			
Total paid in 2023:					182,894	173,460	0.217196275	0.096759842	0.313956117	509,728	536,554	95%
02/16/2024	12/13/2023	12/18/2023	IOC	4Q23	19,580	16,643	-	0.030122765	0.030122765	447,141	533,581	97%
08/21/2024	04/03/2024	04/12/2024	DIV	4Q23	200,000	200,000	0.364065058	-	0.364065058			
12/18/2024	04/03/2024	04/12/2024	DIV	4Q23	227,254	227,254	0.413675305	-	0.413675305			
08/21/2024	03/27/2024	04/01/2024	IOC	1Q24	22,779	19,362	-	0.035162942	0.035162942			
12/18/2024	05/07/2024	05/15/2024	DIV	1Q24	73,000	73,000	0.133326134	-	0.133326134	447,141	533,581	97%
Total paid in 2024:					542,613	536,259	0.911066497	0.065285707	0.976352204			
01/29/2025	06/17/2024	06/24/2024	IOC	2Q24	21,642	18,396	-	0.033603739	0.033603739			
04/03/2025	08/06/2024	08/23/2024	DIV	2Q24	85,478	85,478	0.156145973	-	0.156145973			
04/03/2025	09/26/2024	10/01/2024	IOC	3Q24	18,392	15,633	-	0.028557637	0.028557637	447,141	533,581	97%
04/03/2025	11/05/2024	11/08/2024	DIV	3Q24	123,427	123,427	0.225673086	-	0.225673086			
Total paid in 2025:					248,939	242,934	0.381819059	0.062161376	0.443980435			
12/10/2025	12/17/2024	12/20/2024	IOC	4Q24	21,423	18,210	-	0.033307343	0.033307343			
12/10/2025	04/01/2025	04/11/2025	DIV	4Q24	81,000	81,000	0.148598445	-	0.148598445	447,141	533,581	97%
12/10/2025	03/19/2025	03/24/2025	IOC	1Q25	24,749	21,037	-	0.038559739	0.038559739			
12/10/2025	05/06/2025	05/09/2025	DIV	1Q25	118,000	118,000	0.216476748	-	0.216476748			
12/10/2025	06/18/2025	06/24/2025	IOC	2Q25	26,016	22,114	-	0.040568860	0.040568860			
12/10/2025	08/05/2025	08/08/2025	DIV	2Q25	115,155	115,155	0.211257146	-	0.211257146	447,141	533,581	97%
Total to be paid in 2025:					386,344	375,515	0.576332339	0.112435942	0.688768281			
Total since the IPO					4.365.761	4.237.579						

<sup>1</sup>In 2021, R\$177 million were disbursed under the Sare Buyback Program.

<sup>2</sup>In 2022, R\$163 million were disbursed under the Sare Buyback Program.

## Performance comment



## Share Buyback Program

The Company, from time to time, carries out Share Buyback Programs which, added to the regular payments of interest on equity and dividends, aim to maximize the generation of value for shareholders.

In 2Q25, the total number of shares repurchased under the current program reached 7,403,600 shares, at an average cost adjusted for earnings of R\$10.23. The program provides for the repurchase of up to 10 million shares, maturing on August 29, 2025.


On June 30<sup>th</sup>, the number of Treasury shares was 732,100.

Share Buyback Program						
	# Repurchased shares (thousand)	Canceled shares (thousand)	Treasury Shares (thousand)	Amount repurchased (R\$ thousand)	Nominal cost per share (R\$)	Adjusted cost per share (R\$)
1Q24	3,816	-	3,816	44,435	11.64	10.00
2Q24	1,253	-	5,069	15,234	12.16	11.08
4Q24	1,121	-	6,189	11,903	10.62	10.09
2024 Total	6,190	-	6,189	71,572	11.56	10.23
1Q25	742	-	6,930	7,864	10.60	10.18
2Q25	472	6,670	732	5,025	10.64	10.26
2025 Total	1,214	6,670	732	12,888	10.62	10.21
Total	7,404	6,670	732	84,460	11.41	10.23

On August 05<sup>th</sup>, 2025, the Board of Directors approved the distribution of dividends for the second quarter of 2025 of R\$115 million which, added to the IOC of R\$26 million and share repurchase of R\$5 million, totals shareholder remuneration of R\$146 million, 100% of the 2Q25 net income of R\$146 million. Shares will be traded EX-dividend from August 11<sup>th</sup>, and the payment will be made on December 10<sup>th</sup>.

## Total shareholder remuneration: Dividends + IOC + Share buybacks

R\$ million



## Performance comment




### Capital Markets

The total shareholder return was 16% in 2Q25, compared to 7% for the IBrX.


Odontoprev's average annual return to shareholders has been +15% since the IPO in 2006, versus the IBrX's average annual variation of +8%.

#### Odontoprev total shareholder return since IPO x IBrX



In 2Q25, the Company recorded higher stock liquidity, with an ADTV 116% higher QoQ, reaching R\$24 million. The number of trades per day rose from 3.9 thousand to 5.5 thousand, an increase of 41%.

#### ADTV and number of retail investors





## Performance comment



At the end of 2Q25, market capitalization reached R\$6.4 billion, with a closing price adjusted for earnings up 12% compared to the end of the first half of 2024.


The number of individual investors was 52,354, 24% higher than in 2Q24, with 527 more institutional investors from more than 30 countries.

Odontoprev in Capital Markets	2Q25	2Q24	Δ%
<b>Total number of shareholders</b>	<b>52,881</b>	<b>42,862</b>	<b>23.4</b>
Individual investors	52,354	42,344	23.6
Institutional investors	527	518	1.7
Shares (thousand)	545,825 <sup>1</sup>	552,496	(1.2)
Treasury shares (thousand)	732	5,069	(85.6)
Market Cap (R\$ billion)	6.4	6.3	1.9
Share price (R\$)	11.72	11.36	3.2
Adjusted share price by dividends and IOC (R\$)	11.72	10.49	11.7

<sup>1</sup>The annual meeting held on August 1, 2025 approved the cancellations of 6.7 million shares.

### Global shareholder structure: investors from more than 30 countries

June/25



## Notes to the financial statements

## Odontoprev S.A.



**Notes to the individual and consolidated, condensed interim financial statements**  
**June 30, 2025 and 2024 and December 31, 2024**  
(Amounts expressed in thousands of Reais, unless otherwise indicated)

**Balance sheet**

(In thousands of reais)

	Note	Company		Consolidated			Note	Company		Consolidated	
		06/30/2025	12/31/2024	06/30/2025	12/31/2024			06/30/2025	12/31/2024	06/30/2025	12/31/2024
<b>Assets</b>						<b>Liabilities</b>					
<b>Current assets</b>		<b>427,804</b>	<b>409,557</b>	<b>503,735</b>	<b>490,076</b>	<b>Current liabilities</b>		<b>658,943</b>	<b>725,553</b>	<b>698,224</b>	<b>764,626</b>
Cash and cash equivalents	3	21,888	15,783	31,530	16,531	Liabilities from insurance and reinsurance contracts	12	246,971	297,287	248,205	299,398
Interest earning bank deposits	4	325,284	327,637	342,372	357,791	Social and labor obligations		43,550	57,620	55,640	69,765
Measured at fair value through profit or loss		325,284	192,982	342,372	223,136	Suppliers of goods and services		11,641	11,495	17,676	16,386
Valued at amortized cost		-	134,655	-	134,655	Debts from health care operations		26,805	12,791	26,872	12,848
Assets of insurance and reinsurance contracts	12	26,533	25,501	34,241	33,316	Anticipated revenue from consideration/premiums		5,192	7,127	5,192	7,127
Other accounts receivable	6	19,932	25,701	45,050	51,749	Taxes and contributions payable	13	40,744	39,986	47,646	47,600
Inventories		-	-	6	56	Dividends and interest on own capital payable	17.5	260,509	261,213	260,509	261,213
Recoverable taxes	5	23,868	7,364	33,091	15,853	Lease liabilities	16	2,008	1,958	6,968	6,775
Assets held for sale		-	-	6,734	6,090	Other accounts payable	14	21,523	36,076	29,516	43,514
Prepaid expenses		10,299	7,571	10,711	8,690						
<b>Non-current assets</b>		<b>1,643,248</b>	<b>1,658,331</b>	<b>1,614,323</b>	<b>1,631,993</b>	<b>Non-current liabilities</b>		<b>120,412</b>	<b>114,566</b>	<b>127,859</b>	<b>129,210</b>
Long-term assets						Deferred income tax and social contribution	7.1	4,400	-	-	-
Interest earning bank deposits	4	548,761	539,081	548,761	539,081	Provision for lawsuits	15.1	92,280	81,994	95,799	86,636
Valued at amortized cost		548,761	539,081	548,761	539,081	Taxes and contributions payable	13	-	-	286	303
Deferred income tax and social contribution	7.1	-	25,879	1,528	32,346	Lease liabilities	16	10,450	11,460	16,893	19,010
Prepaid expenses		37	-	37	-	Other accounts payable	14	13,282	21,112	14,881	23,261
Other non-current assets		83,890	79,972	85,989	82,264						
Judicial and tax deposits	7.2	34,291	32,104	35,541	33,435	<b>Shareholders' equity</b>		<b>1,291,697</b>	<b>1,227,769</b>	<b>1,291,975</b>	<b>1,228,233</b>
Other credits receivable		13,697	13,697	14,138	14,268	Capital	17.1	851,017	851,017	851,017	851,017
Recoverable taxes	5	35,902	34,171	36,310	34,561	Capital reserves	17.2	(35,610)	(35,610)	(35,610)	(35,610)
Investments	8	82,440	86,656	6,199	6,121	Profit reserves:	17.3	334,662	492,290	334,662	492,290
Property, plant and equipment	9	25,678	29,345	47,117	52,154	Additional dividend proposed	17.5	-	81,000	-	81,000
Intangible assets	10	902,442	897,398	924,692	920,027	Profit reserves - other		334,662	411,290	334,662	411,290
						(-) Treasury shares	17.4	(7,832)	(71,572)	(7,832)	(71,572)
						Other comprehensive income		674	(8,356)	674	(8,356)
						Retained earnings		148,786	-	148,786	-
						Non-controlling interest		-	-	278	464
<b>Total assets</b>		<b>2,071,052</b>	<b>2,067,888</b>	<b>2,118,058</b>	<b>2,122,069</b>	<b>Total liabilities and shareholders' equity</b>		<b>2,071,052</b>	<b>2,067,888</b>	<b>2,118,058</b>	<b>2,122,069</b>

See the accompanying notes to the financial statements.

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**Statement of income**

(in thousands of reais, unless otherwise indicated)

Note	Company				Consolidated			
	Quarter ended		Period ended		Quarter ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024
<b>Revenue from sales of goods and/or services</b>	<b>19</b>							
Insurance revenue (PAA)	450,219	418,446	893,687	828,179	460,644	428,192	908,623	851,072
Insurance revenue (BBA)	133,818	132,913	263,151	254,286	133,818	132,913	263,151	254,286
Sales of goods and services	-	-	-	-	9,233	9,189	19,721	19,437
	584,037	551,359	1,156,838	1,082,465	603,695	570,294	1,191,495	1,124,795
<b>Cost of assets and services rendered</b>	<b>20</b>							
Insurance costs	(381,400)	(375,776)	(716,428)	(722,783)	(379,026)	(374,911)	(712,153)	(722,029)
<b>Gross income (loss)</b>	<b>202,637</b>	<b>175,583</b>	<b>440,410</b>	<b>359,682</b>	<b>224,669</b>	<b>195,383</b>	<b>479,342</b>	<b>402,766</b>
<b>Operating revenues and expenses</b>								
Sales expenses	-	-	-	-	(302)	(310)	(706)	(634)
General and administrative expenses	(15,365)	(11,408)	(29,316)	(23,818)	(33,580)	(26,068)	(63,712)	(53,320)
Equity in net income of subsidiaries	3,217	4,204	5,044	10,052	1,643	1,743	3,421	2,799
Other operating revenues (expenses)	8,592	(329)	13,140	6,848	8,122	(1,355)	13,850	5,030
	(3,556)	(7,533)	(11,132)	(6,918)	(24,117)	(25,990)	(47,147)	(46,125)
<b>Income (loss) before financial income (loss) and taxes</b>	<b>199,081</b>	<b>168,050</b>	<b>429,278</b>	<b>352,764</b>	<b>200,552</b>	<b>169,393</b>	<b>432,195</b>	<b>356,641</b>
<b>Financial income (loss)</b>	<b>21</b>							
Financial revenues	25,142	27,223	56,282	62,601	26,198	29,279	58,449	65,525
Financial expenses	(15,325)	(12,406)	(31,464)	(24,290)	(16,646)	(13,223)	(33,727)	(25,844)
	9,817	14,817	24,818	38,311	9,552	16,056	24,722	39,681
<b>Income (loss) before income tax</b>	<b>208,898</b>	<b>182,867</b>	<b>454,096</b>	<b>391,075</b>	<b>210,104</b>	<b>185,449</b>	<b>456,917</b>	<b>396,322</b>
<b>Income tax and social contribution</b>	<b>22</b>							
Current	(61,070)	(52,732)	(136,544)	(114,203)	(62,307)	(55,439)	(139,551)	(119,623)
Deferred	(52,950)	(41,920)	(110,983)	(110,154)	(52,858)	(43,218)	(113,541)	(114,374)
	(8,120)	(10,812)	(25,561)	(4,049)	(9,449)	(12,221)	(26,010)	(5,249)
<b>Net income for the period</b>	<b>147,828</b>	<b>130,135</b>	<b>317,552</b>	<b>276,872</b>	<b>147,797</b>	<b>130,010</b>	<b>317,366</b>	<b>276,699</b>
<b>Attributable to:</b>								
Company's shareholders	-	-	-	-	147,828	130,135	317,552	276,872
Non-controlling shareholders	-	-	-	-	(31)	(125)	(186)	(173)
<b>Earnings per share:</b>	<b>23</b>							
Basic	0.26984	0.24295	0.31097	0.50260	0.26984	0.24295	0.31097	0.50260
Diluted	0.26984	0.24295	0.31097	0.50260	0.26984	0.24295	0.31097	0.50260

See the accompanying notes to the financial statements.

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**Statement of income**

(in thousands of reais, unless otherwise indicated)

	Company				Consolidated			
	Quarter ended		Period ended		Quarter ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024
<b>Net income for the period</b>	<b>147,828</b>	<b>130,135</b>	<b>317,552</b>	<b>276,872</b>	<b>147,797</b>	<b>130,010</b>	<b>317,366</b>	<b>276,699</b>
<b>Other comprehensive income</b>	<b>9,446</b>	<b>(5,257)</b>	<b>9,030</b>	<b>(9,383)</b>	<b>9,446</b>	<b>(5,257)</b>	<b>9,030</b>	<b>(9,383)</b>
<b>Items that will be subsequently reclassified to the income (loss) for the period:</b>								
Accumulated translation adjustment	458	148	(259)	719	460	150	(263)	728
Other comprehensive income of investees recognized under the equity method (CPC 50 / IFRS 17)	91	(66)	132	(134)	91	(66)	132	(134)
Other comprehensive income, net (CPC 50 / IFRS 17)	8,895	(5,341)	9,161	(9,977)	8,895	(5,341)	9,161	(9,977)
Equity valuation adjustments of investees recognized under the equity method	2	2	(4)	9	-	-	-	-
<b>Comprehensive income for the period</b>	<b>157,274</b>	<b>124,878</b>	<b>326,582</b>	<b>267,489</b>	<b>157,243</b>	<b>124,753</b>	<b>326,396</b>	<b>267,316</b>
<b>Attributable to:</b>								
Company's shareholders	-	-	-	-	157,274	124,878	326,582	267,489
Non-controlling shareholders	-	-	-	-	(31)	(125)	(186)	(173)

See the accompanying notes to the financial statements.

## Notes to the financial statements

Odontoprev S.A.



### Notes to the individual and consolidated, condensed interim financial statements

June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

#### Statement of changes in shareholders' equity

(In thousands of reais)

Note	Capital	Capital reserves	Profit reserves	Retained earning	Treasury shares	Other comprehensive income	Shareholders' equity	Non-controlling interest	Shareholders' equity - Consolidated
<b>Balance at December 31, 2023</b>	<b>851,017</b>	<b>(35,610)</b>	<b>561,679</b>			<b>9,908</b>	<b>1,386,994</b>	<b>680</b>	<b>1,387,674</b>
<b>Capital transactions with partners</b>	-	-	<b>(161,492)</b>	<b>(447,141)</b>	<b>(71,572)</b>	-	<b>(680,205)</b>	<b>(105)</b>	<b>(680,310)</b>
Treasury shares acquired	17.4	-	-	-	(71,572)	-	(71,572)	-	(71,572)
Dividends	17.5	-	-	(281,905)	-	-	(281,905)	-	(281,905)
Interest on own capital	17.5	-	-	(84,236)	-	-	(84,236)	-	(84,236)
Additional dividend proposed	17.5	-	-	(161,492)	(81,000)	-	(242,492)	(105)	(242,597)
<b>Total comprehensive income</b>	-	-	<b>5,663</b>	<b>533,581</b>	-	-	<b>539,244</b>	<b>(111)</b>	<b>539,133</b>
Net income for the period	-	-	-	539,244	-	-	539,244	(111)	539,133
Adjustment to net income for the period (accounting practice difference)	-	-	5,663	(5,663)	-	-	-	-	-
<b>Other comprehensive income</b>	-	-	-	-	-	<b>(18,264)</b>	<b>(18,264)</b>	-	<b>(18,264)</b>
Translation adjustments in the period	-	-	-	-	-	751	751	-	751
Other comprehensive income (CPC 50/IFRS 17)	-	-	-	-	-	(18,773)	(18,773)	-	(18,773)
Other comprehensive income of investees recognized under the equity method (CPC 50 / IFRS 17)	-	-	-	-	-	(242)	(242)	-	(242)
<b>Internal changes in shareholders' equity</b>	-	-	<b>86,440</b>	<b>(86,440)</b>	-	-	-	-	-
Formation of reserves	17.3	-	86,440	(86,440)	-	-	-	-	-
<b>Balance at December 31, 2024</b>	<b>851,017</b>	<b>(35,610)</b>	<b>492,290</b>	-	<b>(71,572)</b>	<b>(8,356)</b>	<b>1,227,769</b>	<b>464</b>	<b>1,228,233</b>
<b>Capital transactions with partners</b>	-	-	<b>(157,628)</b>	<b>(168,766)</b>	<b>63,740</b>	-	<b>(262,654)</b>	-	<b>(262,654)</b>
Treasury shares acquired	17.4	-	-	-	(12,888)	-	(12,888)	-	(12,888)
Dividends	17.5	-	-	(118,000)	-	-	(118,000)	-	(118,000)
Interest on own capital	17.5	-	-	(50,766)	-	-	(50,766)	-	(50,766)
Additional dividend proposed	17.5	-	-	(81,000)	-	-	(81,000)	-	(81,000)
Cancellation of treasury shares	-	-	-	(76,628)	76,628	-	-	-	-
<b>Total comprehensive income</b>	-	-	-	<b>317,552</b>	-	-	<b>317,552</b>	<b>(186)</b>	<b>317,366</b>
Net income for the period	-	-	-	317,552	-	-	317,552	(186)	317,366
<b>Other comprehensive income</b>	-	-	-	-	-	<b>9,030</b>	<b>9,030</b>	-	<b>9,030</b>
Conversion adjustments	-	-	-	-	-	(263)	(263)	-	(263)
Other comprehensive income (CPC 50/IFRS 17)	-	-	-	-	-	9,161	9,161	-	9,161
Other comprehensive income of investees recognized under the equity method (CPC 50 / IFRS 17)	-	-	-	-	-	132	132	-	132
<b>Balance at June 30, 2025</b>	<b>851,017</b>	<b>(35,610)</b>	<b>334,662</b>	<b>148,786</b>	<b>(7,832)</b>	<b>674</b>	<b>1,291,697</b>	<b>278</b>	<b>1,291,975</b>

See the accompanying notes to the financial statements.

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**Statement of Cash Flows (Indirect method)**

(in thousands of reais, unless otherwise indicated)

	Company		Consolidated	
	Period ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024
<b>Flows from operating activities</b>				
Net income for the period	317,552	276,872	317,366	276,699
Depreciation and amortization	26,687	22,749	30,815	27,235
Net inflation adjustments	1,961	(2,254)	1,992	(2,530)
Provision for lawsuits	1,576	363	1,119	456
Disposal of non-current assets and other	2,286	521	2,278	579
Equity in net income of subsidiaries	(5,044)	(10,052)	(3,421)	(2,799)
Provision for credit losses	263	11	(1,917)	279
Income tax and social contribution	136,544	114,203	139,551	119,623
	481,825	402,413	487,783	419,542
<b>Changes in assets and liabilities</b>				
Interest earning bank deposits valued at fair value through profit or loss	(132,302)	(191,352)	(119,236)	(192,992)
Other accounts receivable, recoverable taxes and prepaid expenses and other current assets	(13,498)	54,483	(13,216)	53,139
Inventories			50	1,398
Long-term assets (non-current)	(39)	2,170	389	2,823
Assets and liabilities of insurance and reinsurance contracts	(37,580)	2,783	(36,323)	(3,438)
Tax obligations (taxes payable)	(1,022)	(3,345)	(1,492)	(2,556)
Labor obligations, suppliers, and other accounts payable	(16,460)	(5,694)	(12,094)	(291)
Long-term liabilities (non-current liabilities)	(5,972)	(5,461)	(9,772)	(8,520)
	274,952	255,997	296,089	269,105
Interest paid	(542)	(110)	(607)	(160)
Income tax and social contribution paid	(108,681)	(102,483)	(111,362)	(106,788)
<b>Increase in cash generated from operating activities</b>	165,729	153,404	184,120	162,157
<b>Flow from investment activities</b>				
Acquisition of property, plant and equipment	(315)	(4,204)	(1,405)	(5,276)
Acquisition of intangible assets	(30,035)	(28,942)	(30,087)	(29,163)
Dividends received from subsidiaries and jointly-controlled subsidiaries	8,975	6,625	3,475	3,625
Interest earning bank deposits measured at amortized cost	124,975	(48,766)	124,975	(48,766)
<b>Increase (decrease) in cash generated (invested) in investment activities</b>	103,600	(75,287)	96,958	(79,580)
<b>Flow from financing activities</b>				
Dividends and interest on own capital paid	(248,939)	(19,580)	(248,939)	(19,726)
Acquisition of own shares - Treasury	(12,888)	(59,669)	(12,888)	(59,669)
Payment of lease	(1,397)	(2,122)	(4,252)	(5,470)
<b>Decrease in cash used in financing activities</b>	(263,224)	(81,371)	(266,079)	(84,865)
<b>Increase (Decrease) in cash and cash equivalents</b>	6,105	(3,254)	14,999	(2,288)
<b>Cash and cash equivalents</b>				
Opening balance	15,783	13,615	16,531	14,391
Closing balance	21,888	10,361	31,530	12,103
<b>Increase (Decrease) in cash and cash equivalents</b>	6,105	(3,254)	14,999	(2,288)

See the accompanying notes to the financial statements.

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**Statement of added value**

(In thousands of reais)

	Company		Consolidated	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024
<b>Revenues</b>	<b>1,156,575</b>	<b>1,082,454</b>	<b>1,199,944</b>	<b>1,131,722</b>
Sale of goods, products and services	1,156,838	1,082,465	1,171,774	1,105,358
Sales of goods and services	-	-	26,253	26,643
Provision for credit losses	(263)	(11)	1,917	(279)
<b>Inputs acquired from third parties</b>	<b>(560,200)</b>	<b>(570,052)</b>	<b>(543,418)</b>	<b>(553,880)</b>
Costs of products, goods, and services sold	(467,657)	(464,046)	(461,807)	(461,107)
Materials, energy, outsourced services and other	(9,166)	(9,940)	(8,504)	(10,820)
<b>Other</b>	<b>(83,377)</b>	<b>(96,066)</b>	<b>(73,107)</b>	<b>(81,953)</b>
Other operating revenues (expenses)	10,547	(9,051)	12,928	(10,101)
Sales expenses	-	-	(706)	(634)
Administrative expenses	(93,924)	(87,015)	(85,329)	(71,218)
<b>Gross added value</b>	<b>596,375</b>	<b>512,402</b>	<b>656,526</b>	<b>577,842</b>
<b>Retentions</b>	<b>(26,687)</b>	<b>(22,749)</b>	<b>(30,815)</b>	<b>(27,235)</b>
Depreciation and amortization	(26,687)	(22,749)	(30,815)	(27,235)
<b>Net added value produced</b>	<b>569,688</b>	<b>489,653</b>	<b>625,711</b>	<b>550,607</b>
<b>Added value received as transfer</b>	<b>61,326</b>	<b>72,653</b>	<b>61,870</b>	<b>68,324</b>
Equity in net income of subsidiaries	5,044	10,052	3,421	2,799
Financial revenues	56,282	62,601	58,449	65,525
<b>Total added value payable</b>	<b>631,014</b>	<b>562,306</b>	<b>687,581</b>	<b>618,931</b>
<b>Distribution of added value</b>	<b>631,014</b>	<b>562,306</b>	<b>687,581</b>	<b>618,931</b>
<b>Personnel</b>	<b>74,588</b>	<b>80,777</b>	<b>111,976</b>	<b>118,038</b>
Direct remuneration	58,103	63,804	86,518	92,175
Benefits	12,797	13,443	19,883	20,348
SEVERANCE PAY FUND (FGTS)	3,688	3,530	5,575	5,515
<b>Taxes, rates and contributions</b>	<b>206,634</b>	<b>180,396</b>	<b>222,817</b>	<b>198,219</b>
Federal	188,662	163,507	202,300	178,427
State	3	35	210	250
Municipal	17,969	16,854	20,307	19,542
<b>Third-party capital remuneration</b>	<b>32,240</b>	<b>24,261</b>	<b>35,422</b>	<b>25,975</b>
Rentals	776	(29)	1,695	131
Other	31,464	24,290	33,727	25,844
<b>Remuneration of own capital</b>	<b>317,552</b>	<b>276,872</b>	<b>317,366</b>	<b>276,699</b>
Interest on own capital	50,766	44,421	50,766	44,421
Dividends	118,000	73,000	118,000	73,000
Retained earnings for the period	148,786	159,451	148,786	159,451
Non-controlling interest in retained earnings	-	-	(186)	(173)

See the accompanying notes to the financial statements.

**Notes to the financial statements****Odontoprev S.A.**
**Notes to the individual and consolidated, condensed interim financial statements**  
**June 30, 2025 and 2024 and December 31, 2024**

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**1. Operations and general information**

Odontoprev S.A. (Company or Odontoprev) is a publicly-held corporation located at Alameda Araguaia, 2104, 21º andar, Alphaville – Barueri, São Paulo – Brazil.

The Company started operating on August 28, 1987 and is engaged in providing private dental care plans, the management, sale or availability of these plans to corporations and/or individuals, as well holding interests, as partner, shareholder or unitholder in other civil or commercial companies, in commercial enterprises of any nature, in Brazil and/or overseas, and the management of its own assets and/or those of third parties.

The Company is classified as a dental operator in the tertiary sector, according to Normative Resolution (RN) 531 of May 02, 2022 of the National Agency of Supplementary Health (ANS).

The Odontoprev's shares are traded on B3 under the ticker "ODPV3" and has been listed in the corporate governance segment called Novo Mercado (New Market) since December 01, 2006.

On June 30, 2025, the Company declares that it is able to take to maturity the interest earning bank deposits classified in the "amortized cost" category.

The Company holds direct and indirect interests in the following companies:

	Interest in capital (%)						
	06/30/2025				12/31/2024		
	Subsidiaries		Indirect associated company	Joint control	Subsidiaries		Indirect associated company
	Direct	Indirect			Direct	Indirect	
<b>COMPANIES:</b>							
Odontoprev Serviços Ltda. (Odontoprev Serviços)	100.0	-	-	-	100.0	-	-
Easy Software S.A. (Easy Software)	-	51.0	-	-	-	51.0	-
Dental Partner Comércio de Produtos e Equipamentos Odontológicos Ltda. (Dental Partner)	-	100.0	-	-	-	100.0	-
SF 210 Participações Societárias S.A. (SF 210)	-	-	18.1	-	-	-	18.1
Clidec Participações S.A. (Clidec Participações) <sup>1</sup>	-	-	-	-	-	100.0	-
Machiron Desenvolvimento de Sistemas S.A. (MaChiron)	-	-	20.0	-	-	-	20.0
<b>TERTIARY SEGMENT DENTAL OPERATOR – RN 531 ANS:</b>							
Brasilidental Operadora de Planos Odontológicos S.A. (Brasilidental)	-	-	-	25.0	-	-	-
<b>NETWORK OF DENTAL AND RADIOLOGICAL CLINICS:</b>							
Clidec – Clínica Dentária Especializada Cura D'ars Ltda. (Clidec)	100.0	-	-	-	100.0	-	-
Boutique Dental Ltda. (Boutique Dental)	-	100.0	-	-	-	100.0	-
Clínicas Radiológicas Papaiz (Papaiz) <sup>1</sup>	-	100.0	-	-	-	100.0	-
Lúmax Radiologia e Tomografia Odontológica Ltda (Lúmax) <sup>i</sup>	-	-	-	-	-	100.0	-
<b>COMPANIES IN MEXICO:</b>							
Odontored CV Sociedad Anónima de Capital Variable (Odontored)	100.0	-	-	-	100.0	-	-
Oprev Administradora Sociedad Anónima de Capital Variable (Oprev)	-	100.0	-	-	-	100.0	-

<sup>1</sup>On January 2, 2025, the Extraordinary General Meeting (EGM) approved the merger of the indirect subsidiaries Clidec Participações and Lúmax, by the company Papaiz, both indirect subsidiaries of the Company.

**Approval of condensed interim financial statements**

The authorization and approval to issue these individual and consolidated, condensed interim financial statements were given by the Board of Directors (BD) in a meeting held on August 5, 2025.



**Notes to the financial statements****Odontoprev S.A.**
**Notes to the individual and consolidated, condensed interim financial statements**  
**June 30, 2025 and 2024 and December 31, 2024**

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**2. Description of material accounting policies****2.1. Preparation basis**

The Company's individual interim condensed financial statements were prepared in accordance with technical pronouncement CPC 21 (R1) - "Interim Financial Reporting", and the interim condensed financial statements were prepared in accordance with technical pronouncement CPC 21 (R1) - "Interim Financial Reporting", equivalent to IAS 34, issued by the International Accounting Standards Board (IASB), according to the going concern assumption. Moreover, all relevant information specific to the financial statements, and only such information, is being evidenced, and corresponds to the information used by the Management in Company's administration.

The individual, consolidated and condensed interim financial statements were prepared and are being presented in accordance with the requirements of the Brazilian Securities and Exchange Commission (CVM).

According to CVM/SNC/SEP Circular Letter 003/2011, this quarterly information is presented in line with the concept of selected explanatory notes without repeating certain explanatory notes previously disclosed, but with an indication of the changes that occurred in the period and, therefore, must be read together with the annual financial statements for the year ended December 31, 2024, disclosed to the CVM on February 26, 2025. The relationship of these Notes is presented below:

Note	Title	Situation	Page on DFP (*)
1	Operations and general information	(a)	46
2	Description of significant accounting policies	(a)	47
3	Estimates and accounting judgements	(b)	59
4	Risk management	(b)	59
9.3	Other credits receivable	(b)	66
13	Minimum capital	(a)	69
17.2 (a)	Social security and labor	(b)	77
17.2 (b)	Civil	(b)	77
17.2 (c)	Tax assessment notices - stock options	(b)	77
17.3	Other liabilities	(b)	79
17.4	Investments payable	(b)	79
19.3	Profit reserves	(a)	80
19.5	Allocation of profits	(c)	81

(a) Explanatory note presented with reduced content when compared to the financial statements as of December 31, 2024.

(b) Explanatory note not presented since there was no change in accounting policies and no unusual transactions, when compared with the financial statements as of December 31, 2024.

(c) Explanatory note not presented since condensed interim financial statements are not applicable.

(\*) Page where the explanatory note is located in the Standardized Financial Statements (DFP) for the year ended December 31, 2024, available on the Brazilian Securities Commission (CVM) website ([www.cvm.gov.br](http://www.cvm.gov.br)) and on the Company's website (<https://ri.odontoprev.com.br>).

**Notes to the financial statements****Odontoprev S.A.**
**Notes to the individual and consolidated, condensed interim financial statements**  
**June 30, 2025 and 2024 and December 31, 2024**

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**2.2. Standards and interpretations issued not in force****CVM Resolution 193/2023**

The CVM published on October 20, 2023, effective as of November 1, 2023, Resolution CVM 193, which allows publicly-held companies to voluntarily prepare and disclose a sustainability-related financial information report based on the international standard (IFRS S1 and S2) issued by the International Sustainability Standards Board (ISSB). The adoption of this new standard will be mandatory for publicly-held companies starting from years beginning on or after January 01, 2026. The Company is preparing for implementation to meet the requirements of the new standard, according to the regulatory term. The Company's Management has chosen not to make this early voluntary disclosure.

**IFRS 18/2024**

The International Accounting Standards Board (IASB) issued IFRS 18 - Presentation and Disclosure in Financial Statements on April 09, 2024. This standard includes requirements for all entities applying IFRS for the presentation and disclosure of information in financial statements and will replace IAS 1 - Presentation of Financial Statements, being applicable to an annual reporting period beginning on or after January 1, 2027. The Company is assessing the possible impacts of this standard.

**Complementary Law No. 214 of January 16, 2025**

On January 16, 2025, the Tax on Goods and Services (IBS) was introduced at the state/municipal level, as well as the Social Contribution on Goods and Services (CBS) and the Selective Tax (IS) at the federal level, unifying five taxes — ICMS, ISS, IPI, PIS and COFINS — into a single levy as of 2033. There will be a transition period from 2026 to 2032, in which the two tax systems – old and new – will coexist. The impacts of the Reform on the calculation of the aforementioned taxes, from the beginning of the transition period, will only be fully known when the process of regulating pending issues through a Complementary Law is finalized.

**3. Cash and cash equivalents**

	Company		Consolidated	
	06/30/2025	12/31/2024	06/30/2025	12/31/2024
Cash	6	6	73	58
Cash in transit <sup>1</sup>	18,392	9,019	18,392	9,019
Banks checking account	446	213	9,913	773
Interest earning bank deposits (remunerated checking account)	3,044	6,545	3,152	6,681
	<b>21,888</b>	<b>15,783</b>	<b>31,530</b>	<b>16,531</b>

<sup>1</sup>Receipts from clients to be transferred by financial institutions, as well as monetary amounts under confirmation.

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

#### 4. Interest earning bank deposits (financial assets at fair value through profit or loss and amortized cost)

		Investment portfolio per original maturities - Company					
	Average interest rate	Without maturity	01–180 days	> 360 days	Book value	Fair value adjustment	Restated amount
Balance at 12/31/2024		192,982	134,655	539,081	866,718	(54,155)	812,563
Quotas of investment funds							
Fixed income inv. fund	12.50% p.a.	325,284	-	-	325,284	-	325,284
Fair value through profit or loss		325,284	-	-	325,284	-	325,284
Fixed income securities - Public							
National Treasury Notes – NTN							
Series B - IPCA with half-yearly interest	9.53% p.a.	-	-	395,247	395,247	(29,946)	365,301
Series F - Fixed rate with half-yearly interest	10.13% p.a.	-	-	153,514	153,514	(12,192)	141,322
Amortized cost		-	-	548,761	548,761	(42,138)	506,623
Balance at 06/30/2025		325,284	-	548,761	874,045	(42,138)	831,907
Current assets		325,284	-	-	325,284		
Non-current assets		-	-	548,761	548,761		
		325,284	-	548,761	874,045		

		Investment portfolio per original maturities - Consolidated					
	Average interest rate	Without maturity	01–180 days	> 360 days	Book value	Fair value adjustment	Restated amount
Balance at 12/31/2024		213,489	144,302	539,081	896,872	(54,155)	842,717
Quotas of investment funds							
Fixed income inv. fund	12.50% p.a.	342,068	-	-	342,068	-	342,068
CETES	7.53% p.a.	-	304	-	304	-	304
Fair value through profit or loss		342,068	304	-	342,372	-	342,372
Fixed income securities - Public							
National Treasury Notes – NTN							
Series B - IPCA with half-yearly interest	9.53% p.a.	-	138,658	395,247	395,247	(29,946)	365,301
Series F - Fixed rate with half-yearly interest	10.13% p.a.	-	-	153,514	153,514	(12,192)	141,322
Amortized cost		-	138,658	548,761	548,761	(42,138)	506,623
Balance at 06/30/2025		342,068	304	548,761	891,133	(42,138)	848,995
Current assets		342,068	304	-	342,372		
Non-current assets		-	-	548,761	548,761		
		342,068	304	548,761	891,133		

**Investment funds (fixed income inv. fund):** investment fund quotas on Bradesco FI RF Bond and BRAM FI RF Referenced DI Coral which are measured based on the quota values disclosed by the administrator institution Bradesco Asset Management.

**Certificados de la Tesorería de la Federación (CETES):** fixed-income government bonds held by Odontored issued by the Mexican government. The fair value of the investment was obtained as disclosed by the Bank of Mexico.

**National Treasury Notes - Series B (NTN-B) - Treasury IPCA with twice-yearly interest:** federal government bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. Government bonds had

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

their fair values obtained from average rate tables, published by the ANBIMA (Brazilian Association of Financial and Capital Market Entities).

**National Treasury Notes - Series F (NTN-F) - Fixed rate Treasury with twice-yearly interest:** federal government bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. Government bonds had their fair values obtained from average rate tables, published by the ANBIMA (Brazilian Association of Financial and Capital Market Entities).

	Changes in investment portfolio - Company					
	Fair value through profit or loss	Amortized cost				Total balance
	Fixed income inv. fund	NTN-B	NTN-F	LTN	Total	
Balance at 12/31/2023	180,916	604,660	153,350	10,845	768,855	949,771
Investments	1,335,748	34,994	-	-	34,994	1,370,742
(-) Redemptions¹	(1,364,114)	(174,635)	(14,238)	(11,499)	(200,372)	(1,564,486)
Earnings	40,432	55,097	14,508	654	70,259	110,691
Balance at 12/31/2024	192,982	520,116	153,620	-	673,736	866,718
Investments	756,474	-	-	-	-	756,474
(-) Redemptions¹	(639,053)	(151,267)	(7,119)	-	(158,386)	(797,439)
Earnings	14,881	26,398	7,013	-	33,411	48,292
Balance at 06/30/2025	325,284	395,247	153,514	-	548,761	874,045

<sup>1</sup> Redemptions of securities at amortized cost refer to the maturity of the respective securities.

	Changes in investment portfolio - Consolidated							
	Fair value through profit or loss			Amortized cost				Total balance
	Fixed income inv. fund	CETES	Total	NTN-B	NTN-P	LTN	Total	
Balance at 12/31/2023	199,104	9,799	208,903	604,660	153,350	10,845	768,855	977,758
Investments	1,437,148	108,877	1,546,025	34,994	-	-	34,994	1,581,019
(-) Redemptions	(1,465,626)	(110,035)	(1,575,661)	(174,635)	(14,238)	(11,499)	(200,372)	(1,776,033)
Earnings	42,863	1,006	43,869	55,097	14,508	654	70,259	114,128
Balance at 12/31/2024	213,489	9,647	223,136	520,116	153,620	-	673,736	896,872
Investments	807,354	253,630	1,060,984	-	-	-	-	1,060,984
(-) Redemptions	(694,996)	(263,407)	(958,403)	(151,267)	(7,119)	-	(158,386)	(1,116,789)
Earnings	16,221	434	16,655	26,398	7,013	-	33,411	50,066
Balance at 06/30/2025	342,068	304	342,372	395,247	153,514	-	548,761	891,133

<sup>1</sup> Redemptions of securities at amortized cost refer to the maturity of the respective securities.

## 5. Tax and social security credits

	Company		Consolidated	
	06/30/2025	12/31/2024	06/30/2025	12/31/2024
IRPJ	40,290	27,273	45,019	30,897
CSLL	11,542	6,897	14,109	9,176
INSS	6,218	5,646	6,218	5,646
ISS	1,453	1,455	1,469	1,472
PIS and COFINS	140	137	423	1,218
IRRF	127	127	1,430	977
Other	-	-	733	1,028
	<b>59,770</b>	<b>41,535</b>	<b>69,401</b>	<b>50,414</b>
Current assets	23,868	7,364	33,091	15,853
Non-current assets	35,902	34,171	36,310	34,561
	<b>59,770</b>	<b>41,535</b>	<b>69,401</b>	<b>50,414</b>

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**Corporate income tax (IRPJ) and social contribution (CSLL):** corporate income tax (IRPJ) balance composed of advances from the current and previous years, and social contribution (CSLL) balance composed of credits from previous years, both arising from technological innovation, subject to approval by the MCTI (Ministry of Science, Technology and Innovation).

#### 6. Other accounts receivable

	Company		Consolidated	
	06/30/2025	12/31/2024	06/30/2025	12/31/2024
Advances to suppliers and other advances <sup>1</sup>	360	2,402	1,627	6,364
Advances to employees <sup>2</sup>	787	9,054	1,046	10,504
Other credits receivable <sup>3</sup>	18,785	14,245	42,377	34,881
	<b>19,932</b>	<b>25,701</b>	<b>45,050</b>	<b>51,749</b>

<sup>1</sup>The reduction refers mainly to the settlement of expenses related to medical assistance.

<sup>2</sup>The reduction refers mainly to the payment of profit sharing that occurred in April 2025.

<sup>3</sup>Credit receivables arising from the sales of assets, rendering of services, and post-payment contracts.

#### 7. Long-term assets

##### 7.1. Income tax e Social contribution Deferred assets

Timing differences	Realization estimate	Company				Consolidated			
		12/31/2024	Formation	Realization	06/30/2025	12/31/2024	Formation	Realization	06/30/2025
Provision for lawsuits (Contingencies)	>12 months	13,267	2,730	-	15,997	13,854	2,731	-	16,585
Sundry provisions <sup>1</sup>	Up to 12 months	3,717	-	(1,773)	1,944	3,765	-	(1,758)	2,007
ILP Program	≤12 months and >12 months	9,341	-	(2,591)	6,750	10,425	-	(2,813)	7,612
Profit sharing	Up to 12 months	6,238	-	(3,287)	2,951	7,385	-	(3,772)	3,613
CPC 50/IFRS 17 effect	>12 months	30,280	-	(7,884)	22,396	29,973	-	(7,257)	22,716
Other <sup>2</sup>	Up to 12 months	19,955	-	(2,595)	17,360	23,863	-	(3,070)	20,793
<b>Deferred IRPJ/CSLL (Assets)</b>		<b>82,798</b>	<b>2,730</b>	<b>(18,130)</b>	<b>67,398</b>	<b>89,265</b>	<b>2,731</b>	<b>(18,670)</b>	<b>73,326</b>
Amortization of goodwill	>12 months	(56,919)	(915)	-	(57,834)	(56,919)	(915)	-	(57,834)
Insurance contract liabilities	Up to 12 months	-	(13,964)	-	(13,964)	-	(13,964)	-	(13,964)
<b>Deferred IRPJ/CSLL (Liabilities)</b>		<b>(56,919)</b>	<b>(14,879)</b>	<b>-</b>	<b>(71,798)</b>	<b>(56,919)</b>	<b>(14,879)</b>	<b>-</b>	<b>(71,798)</b>
<b>Deferred IRPJ/CSLL</b>		<b>25,879</b>	<b>(12,149)</b>	<b>(18,130)</b>	<b>(4,400)</b>	<b>32,346</b>	<b>(12,148)</b>	<b>(18,670)</b>	<b>1,528</b>
Deferred income tax (IRPJ)		19,030	(8,944)	(13,320)	(3,234)	23,701	(8,933)	(13,562)	1,206
Deferred social contribution (CSLL)		6,849	(3,205)	(4,810)	(1,166)	8,645	(3,215)	(5,108)	322
<b>Deferred IRPJ/CSLL</b>		<b>25,879</b>	<b>(12,149)</b>	<b>(18,130)</b>	<b>(4,400)</b>	<b>32,346</b>	<b>(12,148)</b>	<b>(18,670)</b>	<b>1,528</b>

<sup>1</sup>Services rendered - administrative and operational (Note 14).

<sup>2</sup>Refers mainly to commissions and provision for credit losses.

##### 7.2. Judicial and tax deposits

	Company		Consolidated	
	06/30/2025	12/31/2024	06/30/2025	12/31/2024
<b>Tax</b>	<b>31,624</b>	<b>29,857</b>	<b>32,818</b>	<b>31,051</b>
ISS <sup>1</sup>	29,915	28,211	29,915	28,211
Other	1,709	1,646	2,903	2,840
<b>Social security and labor</b>	<b>408</b>	<b>395</b>	<b>464</b>	<b>532</b>
<b>Civil</b>	<b>2,259</b>	<b>1,852</b>	<b>2,259</b>	<b>1,852</b>
	<b>34,291</b>	<b>32,104</b>	<b>35,541</b>	<b>33,435</b>

<sup>1</sup>From the merged company Odonto System, the full amount of the Service Tax – ISS was deposited in court without deducting the events from the calculation basis (object of the lawsuit). Amount fully provisioned in non-current liabilities under “Provision for lawsuits (Note 15.1)”.

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 8. Investments

Company					
Changes in investments:	Balance at 12/31/2024	Dividends	Equity in net income of subsidiaries	Other comprehensive income	Balance at 06/30/2025
<b>Direct subsidiaries</b>					
Odontored	14,563	-	(1,379)	(412)	12,772
Clidec	46,517	(2,000)	1,599	(1)	46,115
Odontoprev Serviços	21,229	(3,500)	1,404	(4)	19,129
<b>Jointly-controlled subsidiary</b>					
Brasildental	4,346	(3,475)	3,420	132	4,423
<b>Others investments</b>					
Other	1	-	-	-	1
<b>Total</b>	<b>86,656</b>	<b>(8,975)</b>	<b>5,044</b>	<b>(285)</b>	<b>82,440</b>

Consolidated					
Changes in investments:	Balance at 12/31/2024	Dividends	Equity in net income of subsidiaries	Other comprehensive income	Balance at 06/30/2025
<b>Jointly-controlled subsidiary</b>					
Brasil dental	4,346	(3,475)	3,420	132	4,423
<b>Associated companies</b>					
MaChiron	41	-	(31)	-	10
SF 210	1,678	-	32	-	1,710
<b>Others investments</b>					
Other	56	-	-	-	56
<b>Total</b>	<b>6,121</b>	<b>(3,475)</b>	<b>3,421</b>	<b>132</b>	<b>6,199</b>

Company and Consolidated						
Position as of 06/30/2025	Subsidiaries:			Associated companies:		Joint Venture:
	Odontoprev Serviços	Clidec	Odontored	Machiron	SF210	Brasildental
Capital	9,700	31,516	6,030	595	8,859	9,500
Interest (%)	100.0	100.0	100.0	20.0	18.1	25.0
Assets	33,424	53,412	17,794	111	9,467	30,795
Liabilities	14,295	7,297	5,022	101	43	13,102
Shareholders' equity	19,129	46,115	12,772	10	9,424	17,693
Revenues	24,931	18,870	14,941	451	-	54,585
Income (loss) for the period	1,404	1,599	(1,379)	(153)	177	13,678

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

### 9. Property, plant and equipment

	Changes in property, plant and equipment - Company								
	12/31/2024	Acquisitions	Write-offs	Depreciation / Amortization	06/30/2025	Cost	Accumulated depreciation	Book balance, net	Depreciation rate (% p.a.)
IT equipment	10,917	52	-	(1,902)	9,067	21,780	(12,713)	9,067	20
Vehicles	1,247	245	(1)	(176)	1,315	2,105	(790)	1,315	20
Facilities	605	-	-	(37)	568	746	(178)	568	10
Machinery and equipment	504	8	-	(38)	474	840	(366)	474	10
Furniture and fixtures	643	10	-	(71)	582	1,797	(1,215)	582	10
Communication equipment	16	-	-	(1)	15	47	(32)	15	10
Dental equipment	64	-	-	(6)	58	168	(110)	58	10
<b>Total for own use</b>	<b>13,996</b>	<b>315</b>	<b>(1)</b>	<b>(2,231)</b>	<b>12,079</b>	<b>27,483</b>	<b>(15,404)</b>	<b>12,079</b>	
Other property, plant, and equipment (improvements)	4,317	-		(795)	3,522	10,134	(6,612)	3,522	20
<b>Total other property, plant and equipment</b>	<b>18,313</b>	<b>315</b>	<b>(1)</b>	<b>(3,026)</b>	<b>15,601</b>	<b>37,617</b>	<b>(22,016)</b>	<b>15,601</b>	
Right-of-use (CPC 06 (R2)/IFRS 16) <sup>1</sup>	11,032	2		(957)	10,077	17,455	(7,378)	10,077	
<b>Total property, plant and equipment</b>	<b>29,345</b>	<b>317</b>	<b>(1)</b>	<b>(3,983)</b>	<b>25,678</b>	<b>55,072</b>	<b>(29,394)</b>	<b>25,678</b>	

<sup>1</sup> Depreciation calculated according to the duration of the real estate and machinery and equipment lease contract.

	Changes in property, plant and equipment - Consolidated								
	12/31/2024	Acquisitions	Write-offs	Depreciation / Amortization	06/30/2025	Cost	Accumulated depreciation	Book balance, net	Depreciation rate (% p.a.)
IT equipment	11,570	285	-	(2,090)	9,765	24,797	(15,032)	9,765	20
Vehicles	1,444	245	(1)	(205)	1,483	2,387	(904)	1,483	20
Facilities	776	-	-	(48)	728	960	(232)	728	10
Machinery and equipment	6,050	98	-	(573)	5,575	13,008	(7,433)	5,575	10
Furniture and fixtures	1,466	113	-	(141)	1,438	3,547	(2,109)	1,438	10
Communication equipment	24	3	-	(1)	26	82	(56)	26	10
Dental equipment	2,031	109	-	(160)	1,980	3,817	(1,837)	1,980	10
<b>Total for own use</b>	<b>23,361</b>	<b>853</b>	<b>(1)</b>	<b>(3,218)</b>	<b>20,995</b>	<b>48,598</b>	<b>(27,603)</b>	<b>20,995</b>	
Other property, plant, and equipment (improvements)	7,077	552	(16)	(1,323)	6,290	20,168	(13,878)	6,290	20
<b>Total other property, plant and equipment</b>	<b>30,438</b>	<b>1,405</b>	<b>(17)</b>	<b>(4,541)</b>	<b>27,285</b>	<b>68,766</b>	<b>(41,481)</b>	<b>27,285</b>	
Right-of-use (CPC 06 (R2)/IFRS 16) <sup>1</sup>	21,716	1,950	(754)	(3,080)	19,832	37,419	(17,587)	19,832	-
<b>Total property, plant and equipment</b>	<b>52,154</b>	<b>3,355</b>	<b>(771)</b>	<b>(7,621)</b>	<b>47,117</b>	<b>106,185</b>	<b>(59,068)</b>	<b>47,117</b>	

<sup>1</sup> Depreciation calculated according to the duration of the real estate and machinery and equipment lease contract.

### 10. Intangible assets

	Company							
Cash generating unit (CGU)	12/31/2024	Additions	Write-offs	Amortizations	06/30/2025	Cost	Accumulated amortization*	Book balance, net
Odontoprev <sup>1</sup>	99,515	-	-	-	99,515	114,390	(14,875)	99,515
Bradesco Dental <sup>2</sup>	409,640	-	-	-	409,640	409,640	-	409,640
Odonto System <sup>3</sup>	145,793	-	-	-	145,793	145,793	-	145,793
Goodwill in investment acquisitions	654,948	-	-	-	654,948	669,823	(14,875)	654,948
Development of systems and software use licenses	220,934	30,035	(2,287)	(22,402)	226,280	419,836	(193,556)	226,280
Client portfolio	3,465	-	-	(266)	3,199	45,390	(42,191)	3,199
Trademarks and patents	17,943	-	-	-	17,943	22,260	(4,317)	17,943
Non-competition agreement	108	-	-	(36)	72	1,864	(1,792)	72
Allocated intangible assets	21,516	-	-	(302)	21,214	69,514	(48,300)	21,214
Intangible assets	897,398	30,035	(2,287)	(22,704)	902,442	1,159,173	(256,731)	902,442

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Consolidated							
	12/31/2024	Additions	Write-offs	Amortizations	06/30/2025	Cost	Accumulated amortization <sup>4</sup>	Book balance, net
Cash generating unit (CGU)								
Odontoprev <sup>1</sup>	99,515	-	-	-	99,515	114,390	(14,875)	99,515
Bradesco Dental <sup>2</sup>	409,640	-	-	-	409,640	409,640	-	409,640
Odonto System <sup>3</sup>	145,793	-	-	-	145,793	145,793	-	145,793
Various units, with non-significant goodwill <sup>5</sup>	14,521	-	-	-	14,521	14,785	(264)	14,521
Goodwill in investment acquisitions	669,469	-	-	-	669,469	684,608	(15,139)	669,469
Development of systems and software use licenses	223,532	30,087	(2,287)	(22,633)	228,699	427,630	(198,931)	228,699
Client portfolio	3,619	-	-	(279)	3,340	45,624	(42,284)	3,340
Trademarks and patents	22,154	-	-	-	22,154	26,472	(4,318)	22,154
Non-competition agreement	1,253	-	-	(223)	1,030	3,747	(2,717)	1,030
Allocated intangible assets	27,026	-	-	(502)	26,524	75,843	(49,319)	26,524
Intangible assets	920,027	30,087	(2,287)	(23,135)	924,692	1,188,081	(263,389)	924,692

<sup>1</sup>It refers to a grouping of cash-generating units from businesses acquired over time with the aim of regional expansion, products and strengthening the brand.

<sup>2</sup>Integration of the activities carried out, complementing skills and creating a differentiated operation in the market.

<sup>3</sup>Objective of regional expansion and products.

<sup>4</sup>The accumulated amortization amounts presented refer to the tax amortization of goodwill made up to December 2013, as allowed by the Transition Tax Regime (RTT), pursuant to the legislation in force at the time. As of January 01, 2014, with the revocation of the RTT by Law 12973/2014, there was no new recognition of tax amortization of goodwill.

<sup>5</sup>Acquisitions of businesses with the aim of verticalizing the operation.

The annual amortization rate for systems development and software licenses is 20%.

### 10.1. Goodwill on the acquisition of investments

The Company evaluates its recoverability through impairment tests and for goodwill from acquisitions of investments allocated to cash generating units (CGUs).

On June 30, 2025, through internal assessments, the Management concluded that there was no evidence of impairment.

The last impairment test was performed on November 30, 2024 and is carried out annually by the Company.

### 11. Minimum capital

The Company is a dental operator regulated by the Brazilian Supplementary Health Agency (ANS), which imposes regulatory limits on it with the mandatory adoption of the risk-based capital model. For this reason, the amounts and nomenclatures presented in this note follow the ANS accounting standards, i.e. disregarding the effects of CPC 50/IFRS 17, which has not been approved by this regulator.

ANS establishes the rules for recognizing technical reserves and criteria for maintaining minimum shareholders' equity in accordance with NR 569/2022.



## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Company: calculation of PMA, PLA, MS and CBR		
Description:	06/30/2025	12/31/2024
Reference capital	11,702	11,702
(x) K factor <sup>1</sup>	3.23%	3.23%
<b>Adjusted minimum shareholders' equity (PMA)</b>	<b>378</b>	<b>378</b>
Book value of shareholders' equity	1,335,432	1,285,651
Ownership interest in regulated entities	(3,936)	(4,166)
Deferred acquisition costs	(41,070)	(22,604)
Prepaid expenses	(10,336)	(7,571)
Intangible assets	(902,442)	(897,398)
Goodwill from indirect interests	(14,532)	(14,532)
<b>Adjusted shareholders' equity (ASE)</b>	<b>363,116</b>	<b>339,380</b>
<b>Risk-based capital (CBR)<sup>2</sup></b>	<b>313,244</b>	<b>296,780</b>
<b>Required sufficiency (PLA ANS - CBR)</b>	<b>49,872</b>	<b>42,600</b>

<sup>1</sup>K Factor corresponds to the classification: group dentistry, tertiary segment and region 1 according to appendix RN 569/2022.<sup>2</sup>The CBR value considers the use of the reduced factors, under the terms of what was defined in article 6 of Regulatory Resolution 569/2022.**12. Liabilities from insurance and reinsurance contracts****(a) Liabilities from insurance and reinsurance contracts**

	Company		Consolidated	
	06/30/2025	12/31/2024	06/30/2025	12/31/2024
Assets for Remaining Coverage (PAA)	(26,533)	(25,501)	(34,241)	(33,316)
Liabilities for Remaining Coverage (BBA)	91,285	125,755	91,285	125,755
Liabilities - claims incurred (PAA)	140,705	154,862	141,939	156,973
Liabilities claims incurred (BBA)	14,981	16,670	14,981	16,670
	<b>220,438</b>	<b>271,786</b>	<b>213,964</b>	<b>266,082</b>
Assets of insurance and reinsurance contracts	(26,533)	(25,501)	(34,241)	(33,316)
Liabilities from insurance and reinsurance contracts	246,971	297,287	248,205	299,398
	<b>220,438</b>	<b>271,786</b>	<b>213,964</b>	<b>266,082</b>

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## (b) Remaining coverage for general model (BBA)

	Company and Consolidated	
	Period ended	
	06/30/2025	12/31/2024
Cash flows from acquisition	3,363,773	3,228,525
Events and other directly attributable expenses	6,881,114	6,673,517
<b>Estimates of present value of future cash outflow</b>	<b>10,244,887</b>	<b>9,902,042</b>
Estimates of present value of future cash inflow	(10,853,187)	(10,412,965)
Risk adjustment for non-financial risk adjustment	14,167	12,653
Contractual service margin (CSM)	685,418	624,025
<b>Net amount included in the provision of insurance contracts</b>	<b>91,285</b>	<b>125,755</b>

## (c) Realization of contractual service margin (CSM)

	Company and Consolidated					
	≤01 year	01–02 years	02–03 years	03–04 years	04–05 years	>05 years
Direct Insurance	167,782	136,319	101,450	78,501	61,481	139,885
<b>Insurance contracts issued</b>	<b>167,782</b>	<b>136,319</b>	<b>101,450</b>	<b>78,501</b>	<b>61,481</b>	<b>139,885</b>

	Company and Consolidated					
	≤01 year	01–02 years	02–03 years	03–04 years	04–05 years	>05 years
Direct Insurance	160,172	118,698	89,823	70,422	55,488	129,422
<b>Insurance contracts issued</b>	<b>160,172</b>	<b>118,698</b>	<b>89,823</b>	<b>70,422</b>	<b>55,488</b>	<b>129,422</b>

## (d) Changes in reserves - remaining coverage

	Company					
	Liabilities for Remaining Coverage (BBA)				Premium Allocation Approach (PAA)	TOTAL
	Best outflow estimate (BEL)	Risk adjustment (RA)	Insurance coverage margin (CSM)	Subtotal		
Balance at 12/31/2023	(668,220)	15,097	764,942	111,819	(31,125)	80,694
Technical changes related to the current period (insurance revenue)	(225,764)	(6,646)	(272,317)	(504,727)	(1,695,907)	(2,200,634)
Contracts by the fair value method	(106,094)	(1,554)	(118,441)	(226,089)	-	(226,089)
Issue of contracts after transition (Other contracts)	(119,670)	(5,092)	(153,876)	(278,638)	-	(278,638)
Settlement relating to contracts premium allocation approach	-	-	-	-	(1,695,907)	(1,695,907)
Technical changes related to future periods	(67,614)	2,921	57,872	(6,821)	-	(6,821)
Changes in the CMS adjusting estimates	783,396	(26,189)	(792,479)	(35,272)	-	(35,272)
Changes in the estimates that do not adjust CSM (OCI)	29,642	(1,191)	-	28,451	-	28,451
Contracts initially recognized in the period	(880,652)	30,301	850,351	-	-	-
Insurance expenses	95,618	-	-	95,618	167,330	262,948
Costs of purchase	95,618	-	-	95,618	167,330	262,948
Total financial expenses	(40,366)	1,281	73,528	34,443	-	34,443
Insurance contract financial expenses	(40,366)	1,281	73,528	34,443	-	34,443
Cash flows	395,423	-	-	395,423	1,534,201	1,929,624
Premiums received	491,622	-	-	491,622	1,534,201	2,025,823
Cash flows from acquisition of insurance	(96,199)	-	-	(96,199)	-	(96,199)
Balance at 12/31/2024	(510,923)	12,653	624,025	125,755	(25,501)	100,254
Technical changes related to the current period (insurance revenue)	(117,455)	(3,658)	(142,038)	(263,151)	(893,687)	(1,156,838)
Contracts by the fair value method	(48,394)	(682)	(53,699)	(102,775)	-	(102,775)
Issue of contracts after transition (Other contracts)	(69,061)	(2,976)	(88,339)	(160,376)	-	(160,376)
Settlement relating to contracts premium allocation approach	-	-	-	-	(893,687)	(893,687)
Technical changes related to future periods	(216,593)	4,306	157,463	(54,824)	-	(54,824)
Changes in the CMS adjusting estimates	261,983	(11,729)	(291,207)	(40,953)	-	(40,953)
Changes in the estimates that do not adjust CSM (OCI)	(14,539)	668	-	(13,871)	-	(13,871)
Contracts initially recognized in the period	(464,037)	15,367	448,670	-	-	-
Insurance expenses	53,191	-	-	53,191	75,430	128,621
Costs of purchase	53,191	-	-	53,191	75,430	128,621
Total financial expenses	(26,823)	866	45,968	20,011	-	20,011
Insurance contract financial expenses	(26,823)	866	45,968	20,011	-	20,011
Cash flows	210,303	-	-	210,303	817,225	1,027,528
Premiums received	252,205	-	-	252,205	817,225	1,069,430
Cash flows from acquisition of insurance	(41,902)	-	-	(41,902)	-	(41,902)
Balance at 06/30/2025	(608,300)	14,167	685,418	91,285	(26,533)	64,752

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Consolidated					
	Liabilities for Remaining Coverage (BBA)				Premium Allocation Approach (PAA)	TOTAL
	Best outflow estimate (BEL)	Risk adjustment (RA)	Insurance coverage margin (CSM)	Subtotal		
Balance at 12/31/2023	(668,220)	15,097	764,942	111,819	(32,912)	78,907
Technical changes related to the current period (insurance revenue)	(225,764)	(6,646)	(272,317)	(504,727)	(1,738,279)	(2243,006)
Contracts by the fair value method	(106,094)	(1,554)	(118,441)	(226,089)	-	(226,089)
Issue of contracts after transition (Other contracts)	(119,670)	(5,092)	(153,876)	(278,638)	-	(278,638)
Settlement relating to contracts premium allocation approach	-	-	-	-	(1,738,279)	(1,738,279)
Technical changes related to future periods	(67,614)	2,921	57,872	(6,821)	-	(6,821)
Changes in the CMS adjusting estimates	783,156	(26,189)	(792,479)	(35,512)	-	(35,512)
Changes in the estimates that do not adjust CSM (OCI)	29,882	(1,191)	-	28,691	-	28,691
Contracts initially recognized in the period	(880,652)	30,301	850,351	-	-	-
Insurance expenses	95,618	-	-	95,618	172,681	268,299
Costs of purchase	95,618	-	-	95,618	172,681	268,299
Total financial expenses	(40,366)	1,281	73,528	34,443	-	34,443
Insurance contract financial expenses	(40,366)	1,281	73,528	34,443	-	34,443
Cash flows	395,423	-	-	395,423	1,565,194	1,960,617
Premiums received	491,622	-	-	491,622	1,565,194	2,056,816
Cash flows from acquisition of insurance	(96,199)	-	-	(96,199)	-	(96,199)
Balance at 12/31/2024	(510,923)	12,653	624,025	125,755	(33,316)	92,439
Technical changes related to the current period (insurance revenue)	(117,455)	(3,658)	(142,038)	(263,151)	(908,623)	(1,171,774)
Contracts by the fair value method	(48,394)	(682)	(53,699)	(102,775)	-	(102,775)
Issue of contracts after transition (Other contracts)	(69,061)	(2,976)	(88,339)	(160,376)	-	(160,376)
Settlement relating to contracts premium allocation approach	-	-	-	-	(908,623)	(908,623)
Technical changes related to future periods	(216,593)	4,306	157,463	(54,824)	-	(54,824)
Changes in the CMS adjusting estimates	261,983	(11,729)	(291,207)	(40,953)	-	(40,953)
Changes in the estimates that do not adjust CSM (OCI)	(14,539)	668	-	(13,871)	-	(13,871)
Contracts initially recognized in the period	(464,037)	15,367	448,670	-	-	-
Insurance expenses	53,191	-	-	53,191	77,365	130,556
Costs of purchase	53,191	-	-	53,191	77,365	130,556
Total financial expenses	(26,823)	866	45,968	20,011	-	20,011
Insurance contract financial expenses	(26,823)	866	45,968	20,011	-	20,011
Cash flows	210,303	-	-	210,303	830,333	1,040,636
Premiums received	252,205	-	-	252,205	830,333	1,082,538
Cash flows from acquisition of insurance	(41,902)	-	-	(41,902)	-	(41,902)
Balance at 06/30/2025	(608,300)	14,167	685,418	91,285	(34,241)	57,044

## (e) Changes in reserves – events incurred

	Company						
	Liabilities claims incurred - BBA			Liabilities - claims incurred - PAA			Total
	Best outflow estimate (BEL)	Risk adjustment (RA)	Subtotal	Best outflow estimate (BEL)	Risk adjustment (RA)	Subtotal	
Balance at 12/31/2023	19,195	1,389	20,584	135,239	8,282	143,521	164,105
Expenses from rendering of services	75,482	(76)	75,406	686,799	2,636	689,435	764,841
Events incurred and other expenses in rendering of services	228,775	10,597	239,372	1,494,424	70,961	1,565,385	1,804,757
Adjustments to incurred claims liabilities	(153,293)	(10,673)	(163,966)	(807,625)	(68,325)	(875,950)	(1,039,916)
Insurance contract financial expenses	1,843	169	2,012	-	-	-	2,012
Changes recognized in other comprehensive income	(4)	(1)	(5)	-	-	-	(5)
Cash flows	(81,327)	-	(81,327)	(678,094)	-	(678,094)	(759,421)
Events and other expenses with rendering of insurance paid	(81,327)	-	(81,327)	(678,094)	-	(678,094)	(759,421)
Balance at 12/31/2024	15,189	1,481	16,670	143,944	10,918	154,862	171,532
Expenses from rendering of services	33,844	21	33,865	322,567	1,808	324,375	358,240
Events incurred and other expenses in rendering of services	93,668	4,669	98,337	709,858	36,992	746,850	845,187
Adjustments to incurred claims liabilities	(59,824)	(4,648)	(64,472)	(387,291)	(35,184)	(422,475)	(486,947)
Insurance contract financial expenses	833	83	916	-	-	-	916
Changes recognized in other comprehensive income	(7)	(2)	(9)	-	-	-	(9)
Cash flows	(36,461)	-	(36,461)	(338,532)	-	(338,532)	(374,993)
Events and other expenses with rendering of insurance paid	(36,461)	-	(36,461)	(338,532)	-	(338,532)	(374,993)
Balance at 06/30/2025	13,398	1,583	14,981	127,979	12,726	140,705	155,686

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Consolidated					
	Liabilities claims incurred - BBA			Liabilities - claims incurred - PAA		
	Best outflow estimate (BEL)	Risk adjustment (RA)	Subtotal	Best outflow estimate (BEL)	Risk adjustment (RA)	Subtotal
Balance at 12/31/2023	19,195	1,389	20,584	136,867	8,291	145,158
Expenses from rendering of services	75,482	(76)	75,406	679,204	2,636	681,840
Events incurred and other expenses in rendering of services	228,775	10,597	239,372	1,486,829	70,961	1,557,790
Adjustments to incurred claims liabilities	(153,293)	(10,673)	(163,966)	(807,625)	(68,325)	(875,950)
Insurance contract financial expenses	1,843	169	2,012	-	-	-
Changes recognized in other comprehensive income	(4)	(1)	(5)	-	-	-
Cash flows	(81,327)	-	(81,327)	(670,025)	-	(670,025)
Events and other expenses with rendering of insurance paid	(81,327)	-	(81,327)	(670,025)	-	(670,025)
Balance at 12/31/2024	15,189	1,481	16,670	146,046	10,927	156,973
Expenses from rendering of services	33,844	21	33,865	316,036	1,808	317,844
Events incurred and other expenses in rendering of services	93,668	4,669	98,337	720,314	36,992	757,306
Adjustments to incurred claims liabilities	(59,824)	(4,648)	(64,472)	(404,278)	(35,184)	(439,462)
Insurance contract financial expenses	833	83	916	-	-	-
Changes recognized in other comprehensive income	(7)	(2)	(9)	-	-	-
Cash flows	(36,461)	-	(36,461)	(332,878)	-	(332,878)
Events and other expenses with rendering of insurance paid	(36,461)	-	(36,461)	(332,878)	-	(332,878)
Balance at 06/30/2025	13,398	1,583	14,981	129,204	12,735	141,939

## (f) Contractual service margin (CSM)

	Company and Consolidated		
	Contracts assessed through the fair value in the transition	Issue of contracts after transition (Other contracts)	Total
Balance at 12/31/2023	460,446	304,496	764,942
CSM recognized for services rendered	(118,441)	(153,876)	(272,317)
Changes regarding the current service	(118,441)	(153,876)	(272,317)
Contracts initially recognized in the period	-	850,351	850,351
Changes in the CMS adjusting estimates	(29,295)	(763,184)	(792,479)
Changes regarding the future service	(29,295)	87,167	57,872
Income (loss) from insurance service	(147,736)	(66,709)	(214,445)
Insurance contract financial expenses	36,634	36,894	73,528
Balance at 12/31/2024	349,344	274,681	624,025
CSM recognized for services rendered	(53,699)	(88,339)	(142,038)
Changes regarding the current service	(53,699)	(88,339)	(142,038)
Contracts initially recognized in the period	-	448,670	448,670
Changes in the CMS adjusting estimates	10,049	(301,256)	(291,207)
Changes regarding the future service	10,049	147,414	157,463
Income (loss) from insurance service	(43,650)	59,075	15,425
Insurance contract financial expenses	19,603	26,365	45,968
Balance at 06/30/2025	325,297	360,121	685,418

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 13. Tax obligations

	Company		Consolidated	
	06/30/2025	12/31/2024	06/30/2025	12/31/2024
<b>Income tax and social contribution payable<sup>1</sup></b>	<b>18,254</b>	<b>15,952</b>	<b>18,817</b>	<b>16,735</b>
IRPJ	13,281	10,827	13,696	11,406
CSLL	4,973	5,125	5,121	5,329
<b>Other federal tax liabilities</b>	<b>19,676</b>	<b>21,321</b>	<b>25,656</b>	<b>27,830</b>
COFINS	5,341	5,303	5,764	5,749
PIS	868	862	951	950
PIS, COFINS and CSLL (PCC)	1,257	1,898	1,329	1,978
IRRF	7,865	8,770	8,171	9,274
IVA <sup>2</sup>	-	-	2,696	2,937
Other	29	9	356	359
Charges payable (social charges)	4,316	4,479	6,389	6,583
<b>Municipal tax liabilities</b>	<b>2,814</b>	<b>2,713</b>	<b>3,459</b>	<b>3,338</b>
	<b>40,744</b>	<b>39,986</b>	<b>47,932</b>	<b>47,903</b>
Current liabilities	40,744	39,986	47,646	47,600
Non-current liabilities	-	-	286	303
	<b>40,744</b>	<b>39,986</b>	<b>47,932</b>	<b>47,903</b>

<sup>1</sup> The Company adopts the annual taxable income regime, paying the amount monthly based on the suspension and reduction balance sheets, through advance payment of taxes. This modality is directly related to the performance of the result for the period.

<sup>2</sup> Value Added Tax from subsidiary Odontored.

## 14. Other accounts payable

	Company		Consolidated	
	06/30/2025	12/31/2024	06/30/2025	12/31/2024
<b>Sundry provisions</b>	<b>5,441</b>	<b>10,930</b>	<b>5,628</b>	<b>11,074</b>
IT support and service	3,446	5,764	3,469	5,764
Services	1,301	3,416	1,465	3,560
Marketing actions	694	1,750	694	1,750
<b>Advances from clients</b>	<b>-</b>	<b>941</b>	<b>666</b>	<b>1,600</b>
<b>Investments payable</b>	<b>8,098</b>	<b>7,844</b>	<b>8,538</b>	<b>8,415</b>
<b>Repurchase of shares payable</b>	<b>-</b>	<b>2,419</b>	<b>-</b>	<b>2,419</b>
<b>Long-term incentive</b>	<b>10,907</b>	<b>18,737</b>	<b>12,274</b>	<b>20,487</b>
<b>Credits to be identified<sup>1</sup></b>	<b>8,105</b>	<b>12,649</b>	<b>10,023</b>	<b>15,184</b>
<b>Unearned revenue (CPC 47/IFRS 15)</b>	<b>-</b>	<b>-</b>	<b>3,466</b>	<b>2,777</b>
<b>Outros<sup>2</sup></b>	<b>2,254</b>	<b>3,668</b>	<b>3,802</b>	<b>4,819</b>
	<b>34,805</b>	<b>57,188</b>	<b>44,397</b>	<b>66,775</b>
Current liabilities	21,523	36,076	29,516	43,514
Non-current liabilities	13,282	21,112	14,881	23,261
	<b>34,805</b>	<b>57,188</b>	<b>44,397</b>	<b>66,775</b>

<sup>1</sup>Correspond to amounts received from clients still unidentified.

<sup>2</sup>Refers mainly to known or notified events related to post-payment contracts.

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 15. Non-current liabilities

## 15.1. Provision for lawsuits

	Company		Consolidated	
	06/30/2025	12/31/2024	06/30/2025	12/31/2024
Provision for tax, labor and civil lawsuits	76,960	67,227	80,026	71,285
Other liabilities	15,045	14,767	15,498	15,351
Fees payable	275	-	275	-
	<b>92,280</b>	<b>81,994</b>	<b>95,799</b>	<b>86,636</b>

## 15.2. Provision for tax, labor and civil lawsuits

	Company					
Changes	Tax	Civil		Social security and labor	06/30/2025	12/31/2024
		ANS1	Other			
Opening balance	28,882	29,608	7,433	1,304	67,227	59,750
Formation	976	1,855	15,451	38	18,320	34,703
Write-offs (payments/reversals)	(561)	(976)	(11,303)	(998)	(13,838)	(33,148)
Inflation adjustment	1,356	3,007	804	84	5,251	5,922
Provision	30,653	33,494	12,385	428	76,960	67,227
Number of lawsuits					1,513	1,227

<sup>1</sup> This is a Tax Assessment Notices drawn up by the ANS whose purpose is the non-payment of reimbursement for treatments performed at free choice by beneficiaries linked to certain products, mapped and monitored internally.

	Consolidated					
Changes	Tax	Civil		Social security and labor	06/30/2025	12/31/2024
		ANS1	Other			
Opening balance	30,185	29,609	7,446	4,045	71,285	62,832
Formation	975	1,854	15,705	467	19,001	36,911
Write-offs (payments/reversals)	(564)	(976)	(11,565)	(2,634)	(15,739)	(34,458)
Inflation adjustment	1,360	3,007	805	307	5,479	6,000
Provision	31,956	33,494	12,391	2,185	80,026	71,285
Number of lawsuits					1,525	1,251

<sup>1</sup> This is a Tax Assessment Notices drawn up by the ANS whose purpose is the non-payment of reimbursement for treatments performed at free choice by beneficiaries linked to certain products, mapped and monitored internally.

As of June 30, 2025, the amounts related to possible losses not provided for in the Company and its Subsidiaries totaled (i) R\$ 6,214 - 76 labor lawsuits (R\$ 2,653 - 60 lawsuits in 2024); (ii) R\$ 98,433 - 3,076 civil lawsuits (R\$ 89,152 - 3,304 in 2024); and (iii) R\$ 101,017 - 49 tax lawsuits (R\$ 73,756 - 50 in 2024).

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**16. Lease liabilities – CPC 06 (R2) IFRS 16**

The Company and its subsidiaries recognized lease liabilities related to the rental of real estate properties and equipment in accordance with the assumptions in CPC 06 (R2)/IFRS 16 – Leases. These liabilities were measured considering the present value of future lease payments, discounted using the average rate of 11.09% (11.58% as of December 31, 2024), and the corresponding entry was recorded as right of use in assets. The total impacts measured are presented below:

Company									
	12/31/2023	Remeasurement and new contracts	Payments	Allocation of financial charge	12/31/2024	Remeasurement and new contracts	Payments	Allocation of financial charge	06/30/2025
Real estate	15,107	631	(3,276)	956	13,418	2	(1,397)	435	12,458
Total	15,107	631	(3,276)	956	13,418	2	(1,397)	435	12,458
Current liabilities					1,958				2,008
Non-current liabilities					11,460				10,450
					13,418				12,458

Consolidated									
	12/31/2023	Remeasurement and new contracts	Payments	Allocation of financial charge	12/31/2024	Remeasurement and new contracts	Payments	Allocation of financial charge	06/30/2025
Real estate	28,755	1,143	(6,732)	2,259	25,425	1,196	(4,132)	1,112	23,601
Equipment	541	-	(242)	61	360	-	(120)	20	260
Total	29,296	1,143	(6,974)	2,320	25,785	1,196	(4,252)	1,132	23,861
Current liabilities					6,775				6,968
Non-current liabilities					19,010				16,893
					25,785				23,861

As of June 30, 2025, the aging of the lease liabilities is as follows:

Company								
	≤01 year	01–05 years	>05anos	12/31/2024	≤01 year	01–05 years	>05anos	06/30/2025
Real estate	1,958	9,897	1,563	13,418	2,008	9,377	1,073	12,458
<b>Total</b>	<b>1,958</b>	<b>9,897</b>	<b>1,563</b>	<b>13,418</b>	<b>2,008</b>	<b>9,377</b>	<b>1,073</b>	<b>12,458</b>

Consolidated								
	≤01 year	01–05 years	>05anos	12/31/2024	≤01 year	01–05 years	>05anos	06/30/2025
Real estate	6,571	17,291	1,563	25,425	6,747	15,781	1,073	23,601
Equipment	204	156	-	360	221	39	-	260
<b>Total</b>	<b>6,775</b>	<b>17,447</b>	<b>1,563</b>	<b>25,785</b>	<b>6,968</b>	<b>15,820</b>	<b>1,073</b>	<b>23,861</b>

**Notes to the financial statements****Odontoprev S.A.**
**Notes to the individual and consolidated, condensed interim financial statements**  
**June 30, 2025 and 2024 and December 31, 2024**

(Amounts expressed in thousands of Reais, unless otherwise indicated)

**17. Shareholders' equity****17.1. Capital**

	Company and Consolidated	
	06/30/2025	12/31/2024
Subscribed and paid-in capital (in thousands of reais)	851,017	851,017
Number of common shares, without par value (number of shares)	545,825,286	552,495,663
Article 7 of Bylaws - authorization for the issuance of shares, without amendment to the Bylaws (number of shares)	80,000,000	80,000,000
Closing quotation: ODPV3 - B3 SA Brasil Bolsa Balcão (R\$/share)	11.72	10.86
Equity value (R\$/share)	2.45	2.33

**17.2. Capital reserves****Other capital reserves:** goodwill/negative goodwill in capital transaction.**17.3. Profit reserves**

	Company and Consolidated	
	06/30/2025	12/31/2024
Legal reserve	127,428	127,428
Statutory Reserve of Regulatory Capital	100,000	100,000
Investment and expansion statutory reserve	107,105	183,733
Tax incentive reserve	129	129
First investment reserve	-	81,000
	<b>334,462</b>	<b>492,290</b>

**17.4. Treasury shares**

On a timely manner, the Company carries out Share Repurchase Programs which, in addition to regular payments of interest on own capital and dividends, have the objective of maximizing the generation of value for shareholders.

At a meeting on February 28, 2024, the Board of Directors approved a new Repurchase Program of up to 10 million shares, representing 3.9% of shares outstanding on the market, including within an execution period up to August 29, 2025.

Up to June 30, 2025, the shares repurchased had an average nominal cost of R\$ 11.41 per share and an average price adjusted for dividends of R\$ 10.23, totaling an investment of R\$ 84,460 thousand, with 7,403,600 shares repurchased. On June 30, 2025, the treasury position recorded 732,100 shares, after the cancellation of 6,670,377 shares at the Annual Meeting held on April 01, 2025.



## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 17.5. Resolutions

Company						
Resolution				Payment date	Payment date	
Approval	Type	Date	Dividend per share (R\$)		06/30/2025	12/31/2024
RCA	Interest on own capital	03/27/2024	0.04137	08/21/2024	-	22,779
RCA	Interest on own capital	06/17/2024	0.03953	01/29/2025	-	21,642
RCA	Interest on own capital	09/26/2024	0.03360	04/03/2025	-	18,392
RCA	Interest on own capital	12/17/2024	0.03919	12/10/2025	-	21,423
RCA	Interest on own capital	03/19/2025	0.04536	12/10/2025	24,749	-
RCA	Interest on own capital	06/18/2025	0.04773	12/10/2025	26,017	-
			<b>Interest on own capital</b>		<b>50,766</b>	<b>84,236</b>
RCA	Dividends	05/07/2024	0.13333	12/18/2024	-	73,000
RCA	Dividends	08/06/2024	0.15615	04/03/2025	-	85,478
RCA	Dividends	08/06/2024	0.22567	04/03/2025	-	123,427
RCA	Dividends	05/06/2025	0.21648	12/10/2025	118,000	-
			<b>Interim dividends</b>		<b>118,000</b>	<b>281,905</b>
AUG	Additional dividend proposed	02/26/2025	0.14840	12/10/2025	-	81,000
			<b>Additional dividend</b>		<b>-</b>	<b>81,000</b>
			<b>Total deliberated earnings</b>		<b>168,766</b>	<b>447,141</b>

RCA = Board of Directors' Meeting.

AGO = Ordinary General Meeting.

## 18. Operating segments

The activities of the Company and its subsidiaries are organized in the following business segments:

- (a) Corporate: includes clients over 200 beneficiaries;
- (b) SMALL AND MEDIUM-SIZED ENTERPRISE (SME): clients sized between 3 and 199 beneficiaries;
- (c) Individual: monthly and annual plans sold to individuals; and
- (d) Other: segments with less representation in the Company's total revenues, as follows: (i) dental care service in the Company's dental clinics (Clidec and Boutique Dental); (ii) management and advisory services provided (Odontoprev Serviços and Oprev); (iii) acquisition and distribution of dental care materials for the accredited network (Dental Partner); (iv) software development (Easy), (v) health insurance (Odontored); and (vi) imaging diagnosis (Papaiz).

	Contribution margin - Consolidated									
	CORPORATE		SME		INDIVIDUAL		OTHER		TOTAL	
	Period ended		Period ended		Period ended		Period ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024
Insurance revenue (Premium Allocation Approach - PAA)	634,770	591,356	258,916	236,823	-	-	14,937	22,893	908,623	851,072
Insurance revenue (Building Block Approach - BBA)	-	-	-	-	263,151	254,286	-	-	263,151	254,286
<b>Insurance and reinsurance revenue</b>	<b>634,770</b>	<b>591,356</b>	<b>258,916</b>	<b>236,823</b>	<b>263,151</b>	<b>254,286</b>	<b>14,937</b>	<b>22,893</b>	<b>1,171,774</b>	<b>1,105,358</b>
Sales of goods and services	-	-	-	-	-	-	26,253	26,643	26,253	26,643
Taxes on sales of goods and services	-	-	-	-	-	-	(6,532)	(7,206)	(6,532)	(7,206)
<b>Revenue from sales of goods and services</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>19,721</b>	<b>19,437</b>	<b>19,721</b>	<b>19,437</b>
<b>SALES REVENUE</b>	<b>634,770</b>	<b>591,356</b>	<b>258,916</b>	<b>236,823</b>	<b>263,151</b>	<b>254,286</b>	<b>34,658</b>	<b>42,330</b>	<b>1,191,495</b>	<b>1,124,795</b>
Events occurred	(263,835)	(317,627)	(46,983)	(18,356)	(33,865)	(40,547)	(7,026)	(8,426)	(351,709)	(384,956)
Costs of purchase	(44,342)	(43,105)	(38,309)	(28,575)	(45,928)	(45,856)	(1,977)	(2,914)	(130,556)	(120,450)
Tax expenses	(27,708)	(24,695)	(13,490)	(12,647)	(14,908)	(14,412)	-	-	(56,106)	(51,754)
<b>OPERATING INCOME</b>	<b>298,885</b>	<b>205,929</b>	<b>160,134</b>	<b>177,245</b>	<b>168,450</b>	<b>153,471</b>	<b>25,655</b>	<b>30,990</b>	<b>653,124</b>	<b>567,635</b>
<b>CONTRIBUTION MARGIN</b>	<b>298,885</b>	<b>205,929</b>	<b>160,134</b>	<b>177,245</b>	<b>168,450</b>	<b>153,471</b>	<b>25,655</b>	<b>30,990</b>	<b>653,124</b>	<b>567,635</b>
<b>Sales revenue (%)</b>	<b>54.2</b>	<b>53.5</b>	<b>22.1</b>	<b>21.4</b>	<b>22.5</b>	<b>23.0</b>	<b>3.0</b>	<b>3.8</b>	<b>100.0</b>	<b>100.0</b>
<b>Margin x sales revenue (%)</b>	<b>47.1</b>	<b>34.8</b>	<b>61.8</b>	<b>74.8</b>	<b>64.0</b>	<b>60.4</b>	<b>74.0</b>	<b>73.2</b>	<b>54.8</b>	<b>50.5</b>
<b>Distribution of margin x total/segment (%)</b>	<b>45.8</b>	<b>36.3</b>	<b>24.5</b>	<b>31.2</b>	<b>25.8</b>	<b>27.0</b>	<b>3.9</b>	<b>5.5</b>	<b>100.0</b>	<b>100.0</b>

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Contribution margin - Consolidated									
	CORPORATE		SME		INDIVIDUAL		OTHER		TOTAL	
	Quarter ended		Quarter ended		Quarter ended		Quarter ended		Quarter ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024
Insurance revenue (Premium Allocation Approach - PAA)	319,904	299,720	130,315	118,726	-	-	10,425	9,746	460,644	428,192
Insurance revenue (Building Block Approach - BBA)	-	-	-	-	133,818	132,913	-	-	133,818	132,913
Insurance and reinsurance revenue	319,904	299,720	130,315	118,726	133,818	132,913	10,425	9,746	594,462	561,105
Sales of goods and services	-	-	-	-	-	-	12,516	12,772	12,516	12,772
Taxes on sales of goods and services	-	-	-	-	-	-	(3,283)	(3,583)	(3,283)	(3,583)
Revenue from sales of goods and services	-	-	-	-	-	-	9,233	9,189	9,233	9,189
SALES REVENUE	319,904	299,720	130,315	118,726	133,818	132,913	19,658	18,935	603,695	570,294
Events occurred	(137,119)	(164,183)	(26,583)	(11,349)	(17,711)	(22,158)	(4,776)	(5,563)	(186,189)	(203,253)
Costs of purchase	(22,540)	(19,832)	(23,532)	(14,982)	(25,875)	(24,416)	(1,269)	(1,252)	(73,216)	(60,482)
Tax expenses	(13,474)	(12,400)	(6,600)	(6,441)	(7,474)	(7,389)	-	-	(27,548)	(26,230)
OPERATING INCOME	146,771	103,305	73,600	85,954	82,758	78,950	13,613	12,120	316,742	280,329
CONTRIBUTION MARGIN	146,771	103,305	73,600	85,954	82,758	78,950	13,613	12,120	316,742	280,329
Sales revenue (%)	27.3	27.1	11.1	10.7	11.4	12.0	1.7	1.7	100.0	100.0
Margin x sales revenue (%)	45.9	34.5	56.5	72.4	61.8	59.4	69.2	64.0	52.5	49.2
Distribution of margin x total/segment (%)	46.3	36.9	23.2	30.7	26.1	28.2	4.3	4.3	100.0	100.0

## 19. Sales revenue

	Company				Consolidated			
	Quarter ended		Period ended		Quarter ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024
Considerations attributed to the PAA (Premium Allocation Approach) period	450,219	418,445	893,687	828,179	460,644	428,192	908,623	851,072
Revenues related to BBA (Building Block Approach) contracts	32,832	34,344	64,264	63,605	32,832	34,343	64,264	63,605
Change in the risk adjustment for non-financial risk	1,963	2,013	3,658	3,548	1,963	2,013	3,658	3,548
CSM recognized for services rendered	71,711	72,371	142,038	141,762	71,711	72,371	142,038	141,762
Recovery of acquisition cash flow	27,312	24,186	53,191	45,371	27,312	24,186	53,191	45,371
Insurance and reinsurance revenue	584,037	551,359	1,156,838	1,082,465	594,462	561,105	1,171,774	1,105,358
Sale of goods and services	-	-	-	-	12,516	12,772	26,253	26,643
Taxes on sales of goods and services	-	-	-	-	(3,283)	(3,583)	(6,532)	(7,206)
	584,037	551,359	1,156,838	1,082,465	603,695	570,294	1,191,495	1,124,795

## 20. Insurance expenses

	Company				Consolidated			
	Quarter ended		Period ended		Quarter ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024
Events occurred	(189,978)	(204,005)	(358,240)	(388,717)	(186,189)	(203,253)	(351,709)	(384,956)
Costs of purchase	(71,962)	(60,576)	(128,621)	(117,249)	(73,216)	(60,482)	(130,556)	(120,450)
Tax expenses	(27,549)	(26,230)	(56,107)	(51,754)	(27,548)	(26,230)	(56,106)	(51,754)
Administrative expenses	(91,911)	(84,965)	(173,460)	(165,063)	(92,073)	(84,946)	(173,782)	(164,869)
	<b>(381,400)</b>	<b>(375,776)</b>	<b>(716,428)</b>	<b>(722,783)</b>	<b>(379,026)</b>	<b>(374,911)</b>	<b>(712,153)</b>	<b>(722,029)</b>

## 21. Financial income (loss)

	Company				Consolidated			
	Quarter ended		Period ended		Quarter ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024
Yields from interest earning bank deposits	20,879	26,828	48,292	55,425	21,708	27,648	50,066	57,100
Inflation adjustment on judicial deposits	749	(382)	1,419	179	752	(379)	1,426	192
Inflation adjustment on tax credits <sup>1</sup>	1,227	517	2,302	3,966	1,249	637	2,344	4,086
Interest for late receipt <sup>2</sup>	952	(335)	1,913	1,785	954	(334)	1,916	1,789
Other	1,335	595	2,356	1,246	1,535	1,707	2,697	2,358
Financial revenues	25,142	27,223	56,282	62,601	26,198	29,279	58,449	65,525
Bank fees	(1,166)	(1,265)	(2,362)	(2,501)	(1,220)	(1,286)	(2,437)	(2,543)
Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	(214)	(243)	(435)	(494)	(598)	(602)	(1,132)	(1,220)
Inflation adjustment of provision for judicial contingencies	(2,768)	(529)	(5,251)	(1,614)	(2,839)	(543)	(5,479)	(1,655)
Discounts granted	(334)	(441)	(783)	(677)	(840)	(536)	(1,344)	(772)
Interest accreditation (CPC 50 / IFRS 17)	(10,174)	(9,165)	(20,927)	(17,617)	(10,174)	(9,165)	(20,927)	(17,617)
Other financial expenses	(669)	(763)	(1,706)	(1,387)	(975)	(1,091)	(2,408)	(2,037)
Financial expenses	(15,325)	(12,406)	(31,464)	(24,290)	(16,646)	(13,223)	(33,727)	(25,844)
	9,817	14,817	24,818	38,311	9,552	16,056	24,722	39,681

<sup>1</sup>In 2024, it mainly refers to update of Employer INSS credits, in which Odontoprev (which merged Rede Dental) received a final and unappealable decision in the lawsuit, securing its right to offset social security contributions unduly collected by Rede Dental on payments made to individual dentists between October 2007 to October 2019 (period after acquisition by Odontoprev).

<sup>2</sup>Refers mainly to the recognition of interest on individual/family plans.

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

## 22. Calculation of IRPJ/CSLL

	Company				Consolidated			
	Quarter ended		Period ended		Quarter ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024	06/30/2025	06/30/2024
Effect (CPC 50 / IFRS 17) before IRPJ and CSLL	2,372	11,629	7,889	(1,829)	2,502	11,735	7,271	(1,333)
IRPJ and CSLL calculation basis	206,526	171,238	446,207	392,904	207,602	173,714	449,646	397,655
	<b>208,898</b>	<b>182,867</b>	<b>454,096</b>	<b>391,075</b>	<b>210,104</b>	<b>185,449</b>	<b>456,917</b>	<b>396,322</b>
(x) Current rate (%)	34	34	34	34	34	34	34	34
<b>Estimate of IRPJ and CSLL expenses, according to the current rate</b>	<b>(71,025)</b>	<b>(62,175)</b>	<b>(154,393)</b>	<b>(132,966)</b>	<b>(71,435)</b>	<b>(63,053)</b>	<b>(155,352)</b>	<b>(134,749)</b>
Effect of Corporate Income Tax and Social contribution on permanent/temporary differences:								
Equity in net income of subsidiaries	975	1,323	2,146	3,077	543	572	1,104	1,006
Provision for lawsuits	(488)	(394)	(2,730)	(1,137)	(327)	(364)	(2,392)	(1,141)
Sundry provisions	349	29	1,773	939	338	36	1,758	951
Amortization of goodwill	458	782	915	1,269	550	782	1,101	1,269
Profit sharing	6,491	5,782	4,740	3,908	7,331	6,571	5,351	4,418
Interest on own capital	8,845	7,358	17,260	15,103	8,845	7,358	17,260	15,103
Adjustments - Law 12973/14	3	(10)	2	(23)	3	(4)	(5)	(16)
Tax losses	-	-	-	-	(543)	-	(1,510)	-
Effect (CPC 50 / IFRS 17)	806	3,953	2,682	(622)	850	3,991	2,472	(453)
Insurance Expenses   Acquisition Costs and ILP Program	3,781	1,608	19,600	-	4,094	1,731	19,768	-
Other	(3,145)	(176)	(2,978)	298	(3,107)	(838)	(3,096)	(762)
<b>Current IRPJ and CSLL expense</b>	<b>(52,950)</b>	<b>(41,920)</b>	<b>(110,983)</b>	<b>(110,154)</b>	<b>(52,858)</b>	<b>(43,218)</b>	<b>(113,541)</b>	<b>(114,374)</b>
Deferred IRPJ and CSLL revenue (expense)	(7,380)	(6,964)	(22,396)	(5,011)	(8,579)	(8,267)	(23,463)	(5,715)
Deferred IRPJ and CSLL revenue (CPC 50 / IFRS 17)	(740)	(3,848)	(3,165)	962	(870)	(3,954)	(2,547)	466
<b>Deferred IRPJ and CSLL expense</b>	<b>(8,120)</b>	<b>(10,812)</b>	<b>(25,561)</b>	<b>(4,049)</b>	<b>(9,449)</b>	<b>(12,221)</b>	<b>(26,010)</b>	<b>(5,249)</b>
<b>Total IRPJ and CSLL expense</b>	<b>(61,070)</b>	<b>(52,732)</b>	<b>(136,544)</b>	<b>(114,203)</b>	<b>(62,307)</b>	<b>(55,439)</b>	<b>(139,551)</b>	<b>(119,623)</b>
Effective rate	29.2%	28.8%	30.1%	29.2%	29.7%	29.9%	30.5%	30.2%

## 23. Earnings per share – basic and diluted

	Quarter ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024
<b>Income attributable to Company's shareholders (in thousands of reais)</b>	<b>147,828</b>	<b>130,135</b>	<b>317,552</b>	<b>276,872</b>
<b>Common shares (in thousands)</b>				
Weighted average number of common shares issued (thousands)	545,093	548,087	545,567	550,883
<b>Weighted average number of shares for the basic and diluted earnings per share</b>	<b>545,093</b>	<b>548,087</b>	<b>545,567</b>	<b>550,883</b>
<b>Basic and diluted earnings per share (R\$)</b>	<b>0.27120</b>	<b>0.23743</b>	<b>0.58206</b>	<b>0.50260</b>

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

### June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

#### 24. Related parties

Related party transactions are carried out at values, terms and average rates in line with the ones practiced with third parties (if any), in force on the respective dates.

Operations of the Company with its Subsidiaries, Associated Companies and Key Management Personnel (Note 5)	Classification   Nature	Quarter ended		Period ended		Quarter ended		Period ended	
		06/30/2025		12/31/2024		06/30/2025		06/30/2024	
		Assets	Liabilities	Assets	Liabilities	Revenue	Expense	Revenue	Expense
Dental Partner	Sales of goods and services   Dental materials	-	-	76	-	1,038	-	1,559	-
Dental Partner	Administrative expenses   Dental Assistance	-	-	-	-	-	(1)	-	-
Odontoprev	Administrative expenses   Administrative services	-	-	76	-	(15,930)	-	(33,265)	(18,722)
Odontoprev Serviços	Sales of goods and services   Commercial advisory	622	-	717	-	13,246	-	27,475	-
Odontoprev Serviços	Administrative expenses   Dental Assistance	-	-	-	-	-	(27)	-	(54)
Brasildental	Insurance Expenses   Administrative Services	-	631	-	726	-	(2,024)	-	(5,106)
Odontoprev	Considerations   Dental plans	-	-	-	-	56	-	106	-
Odontoprev	Considerations   Assumed/ceded co-responsibility	4,558	-	4,346	-	13,148	-	25,597	-
Odontoprev	Other operating revenues   Revenues from healthcare plans	9	-	9	-	46	-	101	-
Brasildental	Insurance expenses   Assumed/ceded co-responsibility	-	4,558	-	4,346	-	(13,148)	-	(25,597)
Clidec	Other operating costs   Dental Assistance	-	-	-	-	-	(14)	-	(27)
Clidec	Sales of goods and services   Clinical dental services	-	-	-	-	8,125	-	16,603	-
Boutique Dental	Sales of goods and services   Clinical dental services	-	-	-	-	1,242	-	2,117	-
Papaiz	Sales of goods and services   Radiology services	837	-	-	-	1,887	-	3,529	-
Papaiz	Other operating costs   Dental Assistance	-	-	-	-	-	(12)	-	(22)
Papaiz	Other operating costs   Rent	-	-	-	-	-	(51)	-	(51)
Odontoprev	Known or reported events/claims   Dental services	-	711	-	-	-	(6,469)	-	(11,301)
Odontoprev	Other healthcare expenses   Dental care materials	-	-	-	-	-	(1,038)	-	(1,559)
Clidec	Other operating costs   Dental materials	-	-	-	-	-	-	-	(8)
Boutique Dental	Property revenues   Rent	-	-	-	-	51	-	51	-
Boutique Dental	Other operating costs   Radiological services	-	126	-	-	-	(102)	-	(102)
Easy	Administrative expenses   Dental Assistance	-	-	-	-	-	(2)	-	(3)
Easy	Administrative expenses   Administrative services	-	-	-	-	-	(21)	-	(50)
Odontoprev	Other accounts receivable	5	-	-	-	-	-	-	-
Clidec	Other accounts receivable	1	-	-	-	-	-	-	-
Boutique Dental	Other accounts payable	-	1	-	-	-	-	-	-
Odontoprev Serviços	Other accounts payable	-	5	-	-	-	-	-	-
MaChiron	Intangible asset   System development	2,582	-	2,056	-	-	-	-	-
Key management personnel	Insurance Revenue   Dental Plans	-	-	-	-	2	-	4	-
<b>Total</b>		<b>8,614</b>	<b>6,032</b>	<b>7,204</b>	<b>5,148</b>	<b>38,841</b>	<b>(38,839)</b>	<b>77,142</b>	<b>(77,138)</b>
								<b>39,828</b>	<b>(39,828)</b>
									<b>78,662</b>
									<b>(78,662)</b>

## Notes to the financial statements

Odontoprev S.A.



## Notes to the individual and consolidated, condensed interim financial statements

June 30, 2025 and 2024 and December 31, 2024

(Amounts expressed in thousands of Reais, unless otherwise indicated)

The Company and its Subsidiaries conduct transactions with companies of Bradesco Organization, of which Bradesco Saúde, shareholder of Odontoprev, is part:

Consolidated		Quarter ended		Period ended		Quarter ended		Period ended	
Companies related to Banco Bradesco	Classification   Nature	06/30/2025		12/31/2024		06/30/2025		06/30/2025	
		Assets		Liabilities		Revenue		Expense	
		Assets	Liabilities	Assets	Liabilities	Revenue	Expense	Revenue	Expense
Alelo S.A.	Insurance Expenses   Employee Benefits	-	-	-	33	-	(849)	-	(2,118)
Banco Bradescard S.A.	Insurance Expenses   Acquisition Cost	17	761	29	-	-	(1,526)	-	(3,859)
Banco Bradesco S.A.	Checking account	3,160	-	6,713	-	-	-	-	-
Banco Bradesco S.A.	Interest earning bank deposit	890,829	-	887,225	-	22,334	-	49,633	-
Banco Bradesco S.A.	Insurance Revenue   Dental Plans	10	-	10	-	12,400	-	24,833	-
Banco Bradesco S.A.	Insurance expenses   Travel and accommodation - officers and employees	-	1	-	-	-	(385)	-	(910)
Banco Bradesco S.A.	Financial Expenses   Bookkeeping of shares	-	-	-	-	-	(72)	-	(171)
Banco Bradesco S.A.	Insurance Expenses   Rentals of branches	-	-	-	-	-	(53)	-	(140)
Banco Bradesco S.A.	Financial Expenses   Investment management	-	-	-	-	-	(89)	-	(187)
Banco Bradesco S.A.	Financial expenses   Bank fee	-	-	-	-	-	(921)	-	(1,851)
Banco Bradesco S.A.	Right-of-use and lease liability	887	1,021	937	1,061	-	794	-	(130)
Bradesco Auto-Re Companhia De Seguros	Insurance Expenses   Civil liability Insurance and insurance guarantee	-	-	-	-	-	-	-	(7)
Bradesco S/A Corretora De Títulos E Valores Mobiliários	Insurance Expenses   Acquisition Cost	-	-	-	2,419	-	(3)	-	(6)
Bradesco Capitalização S.A.	Special savings bonds	8,042	-	4,360	-	-	-	-	-
Bradesco Saúde S.A.	Insurance Expenses   Medical Assistance - Employees	-	-	-	-	-	(4,610)	-	(8,995)
Bradesco Saúde S.A.	Dividends and interest on own capital	-	145,194	-	142,994	-	-	-	-
Bradesco Vida e Previdência S.A.	Insurance Expenses   Private pension - employees	-	-	-	-	-	(451)	-	(885)
Bradesco Vida e Previdência S.A.	Insurance Expenses   Life Insurance - Employees	-	-	-	-	-	(109)	-	(172)
Bradescor Corretora de Seguros Ltda.	Insurance Expenses   Acquisition Cost	81	631	74	372	-	(562)	-	(1,170)
Bradeseg Promotora de Vendas S.A.	Insurance Expenses   Acquisition Cost	1,508	5,363	334	4,301	-	(4,388)	-	(10,334)
Braspag -Tecnologia em Pagamento Ltda.	Insurance Expenses   Financial Services	-	-	-	-	-	-	-	152
Bsp Empreendimento Imobiliário D166 Ltda.	Insurance Expenses   Rentals of branches	-	-	-	-	-	(10)	-	(27)
Bsp Empreendimento Imobiliário D166 Ltda.	Right-of-use and lease liability	468	543	514	587	-	481	-	(65)
Bsp Park Estacionamentos E Participações S.A.	Insurance Expenses   Parking	-	-	-	-	-	-	-	(1)
Bsp Empreendimentos Imobiliários R12 Ltda.	Right-of-use and lease liability	287	333	313	357	-	(37)	-	(37)
Bsp Empreendimentos Imobiliários R12 Ltda.	Insurance Expenses   Rentals of branches	-	-	-	-	-	(11)	-	(11)
Mediservice	Other operating revenues   Management Fee	-	-	-	-	74	-	148	-
Santecorp Holding Ltda	Insurance Expenses   Medical/Outpatient Services	-	-	-	-	-	(107)	-	(179)
Santecorp Holding Ltda	Insurance Revenue   Dental Plans	-	-	-	-	4	-	7	-
Stelo S.A.	Financial expenses   Management fee	-	-	-	-	-	(166)	-	(335)
Swiss Re Corporate Solutions Brasil Seguros S.A.	Insurance Expenses   Legal Guarantee Insurance	-	-	-	-	-	(71)	-	(138)
Banco Digio S.A.	Insurance Expenses   Acquisition Cost	1	6	1	5	-	(4)	-	(9)
Fluery CPMA	Insurance Revenue   Dental Plans	-	-	-	-	15	-	29	-
Fluery S.A.	Insurance Revenue   Dental Plans	-	-	-	-	789	-	1,573	-
Instituto de Radiologia de Natal Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	11	-	22	-
Centro de Patologia Clínica Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	3	-	5	-
Saúde Newco Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	1	-	2	-
Metodos Laboratório, Análises Clínicas e Hematologia Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	6	-	12	-
Genesis Análises Genômicas S.A.	Insurance Revenue   Dental Plans	-	-	-	-	16	-	33	-
Instituto Hermes Pardini S.A.	Insurance Revenue   Dental Plans	-	-	-	-	183	-	366	-
Laboratório Padrão S.A.	Insurance Revenue   Dental Plans	-	-	-	-	18	-	37	-
Diagnóstico Por Imagem Sete Lagoas Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	1	-	2	-
Toxicologia Pardini Laboratórios S.A.	Insurance Revenue   Dental Plans	-	-	-	-	4	-	8	-
Laboratório de Patologia Clínica Dr Paulo C. de Azevedo	Insurance Revenue   Dental Plans	-	-	-	-	13	-	30	-
Instituto de Análises Clínicas de Santos	Insurance Revenue   Dental Plans	-	-	-	-	13	-	25	-
Anatomia Patológica Hugo Silviano Branda	Insurance Revenue   Dental Plans	-	-	-	-	-	-	1	-
Haitong Banco de Investimentos do Brasil S.A.	Insurance Revenue   Dental Plans	-	-	-	-	57	-	79	-
Bradescard México, Limited Liability Company	Insurance Expenses   Acquisition Cost	-	500	-	149	-	(3,092)	-	(3,613)
CIP Centro de Infusões Pacaembu Ltda.	Insurance Revenue   Dental Plans	-	-	-	-	5	-	5	-
Key management personnel	Insurance Expenses   Acquisition Cost	5	-	5	-	-	(3)	-	(5)
Key management personnel	Insurance Revenue   Dental Plans	-	-	-	-	1	-	3	-
Key management personnel	Insurance Expenses   Administrative Expenses	-	-	-	-	-	(1,058)	-	(1,822)
Key management personnel	Intangible asset   System development	2,542	-	1,116	-	-	-	-	-
Key management personnel	Accounts payable   Service providers	-	170	-	97	-	-	-	-
Key management personnel	Insurance Expenses   Events occurred	-	-	-	-	-	(1)	-	(2)
Key management personnel	Insurance expenses   Consulting	-	-	-	-	-	(7)	-	(20)
<b>Total</b>		<b>907,837</b>	<b>154,523</b>	<b>901,631</b>	<b>152,375</b>	<b>35,948</b>	<b>(17,310)</b>	<b>76,853</b>	<b>(37,199)</b>
								<b>41,856</b>	<b>(17,141)</b>
									<b>84,104</b>
									<b>(35,470)</b>

The Company contracted a court guarantee insurance related to the tax assessment notices on the stock options whose policies were contracted together with Swiss Re Corporate Solutions Brasil Seguros S.A. (Swiss Re Brasil) which maintains an investment with Bradesco Seguros S.A. (Bradesco Seguros).

The Company and its subsidiaries grant profit sharing to its employees and officers linked to the achievement of operating goals and specific objectives established and approved at the beginning of each year. On June 30, 2025, the amounts of R\$ 9,130 (R\$ 15,876 on June 30, 2024) and R\$ 10,962 (R\$ 18,545 as of June 30, 2024) were appropriated as profit sharing in the Company and in the Consolidated.

In 2019, the Company implemented a long-term incitement program (ILP Program), which establishes the criteria for the payment of cash bonuses, corresponding to salary multiples, to be made by the Company and its subsidiaries to the eligible beneficiaries after the measurement period, provided that the goals and conditions established in the terms are met.

**Notes to the financial statements****Odontoprev S.A.**

**Notes to the individual and consolidated, condensed interim financial statements**

**June 30, 2025 and 2024 and December 31, 2024**

**(Amounts expressed in thousands of Reais, unless otherwise indicated)**

The measurement period corresponds to three years and the payment is conditioned upon the achievement of the corporate performance targets established by the Board of Directors and the service condition.

As of June 30, 2025, the amounts of R\$ 7,527 and R\$ 8,422 in the Company and Consolidated, respectively (R\$ 9,912 and R\$ 10,614 as of June 30, 2024), were appropriated to income (loss) for the period.

The stock options program remains in effect, as approved by the Shareholders' Meeting with the last granting being made in 2016.

The annual fixed remuneration attributed to the members of the Board of Directors and the Tax Council, as well as the fixed and variable remuneration allocated to the Statutory Executive Board, are as follows:

	Quarter ended		Period ended	
	06/30/2025	06/30/2024	06/30/2025	06/30/2024
<b>Statutory Executive Board</b>	<b>15,237</b>	<b>17,575</b>	<b>16,650</b>	<b>19,423</b>
Directors fee	1,166	1,513	2,332	3,071
Benefits	175	214	352	419
Private pension	70	91	140	176
Private pension	4,810	7,252	4,810	7,252
Private pension	9,016	8,505	9,016	8,505
<b>Board of Directors</b>	<b>1,164</b>	<b>1,020</b>	<b>2,328</b>	<b>1,980</b>
Directors fee	1,164	1,020	2,328	1,980
<b>Fiscal Council</b>	<b>130</b>	<b>130</b>	<b>261</b>	<b>261</b>
Directors fee	130	130	261	261
	<b>16,531</b>	<b>18,725</b>	<b>19,239</b>	<b>21,664</b>

The Board of Directors and Tax Council, as well as the Personnel Management Committee, include members who are part of the management of Banco Bradesco S.A. and Bradesco Seguros.

The Company does not sponsor post-employment benefit (except for a supplementary pension plan) or any termination of employment contract.

## **25. Subsequent events**


In a meeting held on August 05, 2025, the Board of Directors approved the distribution of dividends for the second quarter of 2025 in the amount of R\$ 115 million.

# Other information the Company deems to be relevant

SHAREHOLDING POSITION OF THE HOLDERS OF OVER 5% OF THE COMPANY'S SHARES						
Position as of 06/30/2025						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradesco Saúde S.A.	292,213,236	53.54	-	-	292,213,236	53.54
Treasury shares	732,100	0.13	-	-	732,100	0.13
Outstanding shares	252,879,950	46.33	-	-	252,879,950	46.33
<b>Total</b>	<b>545,825,286</b>	<b>100.00</b>	<b>-</b>	<b>-</b>	<b>545,825,286</b>	<b>100.00</b>
BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradesco Saúde S.A. Position as of 06/30/2025						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradesco Gestão de Saúde S.A.	20,870,945	100.00	-	-	20,870,945	100.00
BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradesco Gestão de Saúde S.A. Position as of 06/30/2025						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradseq Participações S.A.	12,251,025,597	100.00	-	-	12,251,025,597	100.00
<b>Total</b>	<b>12,251,025,597</b>	<b>100.00</b>	<b>-</b>	<b>-</b>	<b>12,251,025,597</b>	<b>100.00</b>
BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradseg Participações S.A. Position as of 06/30/2025						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Banco Bradesco S.A.	12,318	100.00	-	-	12,318	100.00
<b>Total</b>	<b>12,318</b>	<b>100.00</b>	<b>-</b>	<b>-</b>	<b>12,318</b>	<b>100.00</b>
*according to the Reference Form of 07/03/2025, available on the RI website of Banco Bradesco.						
BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Banco Bradesco S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Cidade de Deus Cia Cial Participações	2,445,219,983	46.10	1,292,135	0.02	2,446,512,118	23.10
Fundação Bradesco	914,471,634	17.24	3	0.00	914,471,637	8.63
NCF Participações S.A.	451,890,822	8.52	119,774,968	2.26	571,665,790	5.40
Other	1,484,788,342	27.99	5,159,574,141	97.57	6,644,362,483	62.73
Treasury shares	7,500,000	0.14	7,500,000	0.14	15,000,000	0.14
<b>Total</b>	<b>5,303,870,781</b>	<b>100.00</b>	<b>5,288,141,247</b>	<b>100.00</b>	<b>10,592,012,028</b>	<b>100.00</b>
BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Cidade de Deus Cia Cial Participações						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Fundação Bradesco	2,779,096,924	35.44	-	-	2,779,096,924	35.44
Nova Cidade de Deus Participações S.A.	3,758,724,093	47.93	-	-	3,758,724,093	47.93
Other	1,304,138,507	16.63	-	-	1,304,138,507	16.63
<b>Total</b>	<b>7,841,959,524</b>	<b>100.00</b>	<b>-</b>	<b>-</b>	<b>7,841,959,524</b>	<b>100.00</b>
BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: NCF Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Cidade de Deus Cia Cial Participações	1,430,717,378	74.72	-	-	1,430,717,378	39.51
Fundação Bradesco	481,149,175	25.13	1,706,485,482	100.00	2,187,634,657	60.41
Nova Cidade de Deus Participações S.A.	2,864,526	0.15	-	-	2,864,526	0.08
<b>Total</b>	<b>1,914,731,079</b>	<b>100.00</b>	<b>1,706,485,482</b>	<b>100.00</b>	<b>3,621,216,561</b>	<b>100.00</b>
BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Nova Cidade de Deus Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
BBD Participações S.A.	189,425,112	53.70	-	-	189,425,112	26.07
Fundação Bradesco	163,332,621	46.30	373,794,914	100.00	537,127,535	73.93
<b>Total</b>	<b>352,757,733</b>	<b>100.00</b>	<b>373,794,914</b>	<b>100.00</b>	<b>726,552,647</b>	<b>100.00</b>
BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: BBD Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Treasury shares	46,126,598	20.80	9,696,750	4.38	55,823,348	12.59
NCD Participações Ltda	67,114,094	30.27	141,898,399	64.05	209,012,493	47.15
Other	108,504,179	48.93	69,965,077	31.58	178,469,256	40.26
<b>Total</b>	<b>221,744,871</b>	<b>100.00</b>	<b>221,560,226</b>	<b>100.00</b>	<b>443,305,097</b>	<b>100.00</b>
BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: NCD Participações Ltda						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Fundação Bradesco	2,793,303,110	100.00	-	-	2,793,303,110	100.00
<b>Total</b>	<b>2,793,303,110</b>	<b>100.00</b>	<b>-</b>	<b>-</b>	<b>2,793,303,110</b>	<b>100.00</b>

CONSOLIDATED SHAREHOLDING POSITION OF THE CONTROLLING SHAREHOLDERS AND DIRECTORS AND OFFICERS AND SHARES IN CIRCULATION						
Position as of 06/30/2025						
Shareholder	Number of Common Shares (Units)	%	Number of Preferred Shares (Units)	%	Total Number of Shares (Units)	%
Controlling managers	292,213,236	53.54	-	-	292,213,236	53.54
Managers	1,145,659	0.21	-	-	1,145,659	0.21
Treasury shares	732,100	0.13	-	-	732,100	0.13
Other	251,734,291	46.12	-	-	251,734,291	46.12
Total	545,825,286	100.00	-	-	545,825,286	100.00
Outstanding shares	251,734,291	46.12	-	-	251,734,291	46.12
CONSOLIDATED SHAREHOLDING POSITION OF THE CONTROLLING SHAREHOLDERS AND DIRECTORS AND OFFICERS AND SHARES IN CIRCULATION						
Position as of 06/30/2024						
Shareholder	Number of Common Shares (Units)	%	Number of Preferred Shares (Units)	%	Total Number of Shares (Units)	%
Controlling managers	292,213,236	52.89	-	-	292,213,236	52.89
Managers	1,390,659	0.25	-	-	1,390,659	0.25
Treasury shares	5,069,100	0.92	-	-	5,069,100	0.92
Other	253,822,668	45.94	-	-	253,822,668	45.94
Total	552,495,663	100.00	-	-	552,495,663	100.00
Outstanding shares	253,822,668	45.94	-	-	253,822,668	45.93





## Opinions and Statements / Special Review Report - Unqualified

To The Board of Directors and Shareholders of  
Odontoprev S.A.  
Barueri - SP

### Introduction

We have reviewed the individual and consolidated, condensed interim financial information of Odontoprev S.A. ("Company"), contained in the Quarterly Information - ITR Form for the quarter ended June 30, 2025, which comprises the balance sheet as of June 30, 2025 and related statements of income, of comprehensive income for the three and six-month periods then ended, of changes in shareholders' equity and of cash flows for the quarter then ended, including the explanatory notes.

Company's Management is responsible for the preparation of the individual interim financial information in accordance with CPC 21 (R1) and the consolidated, condensed interim financial information in accordance with CPC 21 (R1) and with international standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board - (IASB), as well as for the presentation of this information in a manner consistent with the standards issued by the Brazilian Securities and Exchange Commission, applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on these interim financial information based on our review.

### Scope of the review

Our review was carried out in accordance with the Brazilian and international review standards for interim information (NBC TR 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity and ISRE 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists in asking questions, chiefly to the persons in charge of financial and accounting affairs, and in applying analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion on the interim, individual condensed information

Based on our review, we are not aware of any facts that would lead us to believe that the interim, individual condensed financial information included in the quarterly information referred to above was not prepared, in all material respects, in accordance with CPC 21(R1) applicable to the preparation of Quarterly Information (ITR), and presented in a manner consistent with the standards issued by the Brazilian Securities and Exchange Commission.

### Conclusion on the interim, consolidated and condensed information

Based on our review, we are not aware of any facts that would lead us to believe that the interim consolidated, condensed financial information included in the quarterly information referred to above was not prepared, in all material respects, in accordance with CPC 21 (R1) and IAS 34, applicable to the preparation of Quarterly Information - ITR, and presented in a manner consistent with the standards issued by the Brazilian Securities and Exchange Commission.

### Other issues - Statements of added value

The aforementioned interim quarterly information includes the individual and consolidated statements of added value for the six-month period ended June 30, 2025, prepared under responsibility of Company's Management, and presented as supplementary information for IAS 34 purposes. These statements have been subject to review procedures performed in conjunction with the review of the quarterly information, in order to determine whether they are reconciled with the interim financial information and book records, as applicable, and whether their form and content are in accordance with the criteria defined in Technical Pronouncement CPC 09 – Statement of Added Value. Based on our review, we are not aware of any facts that may lead us to believe that those statements of added value have not been prepared, in all material respects, in accordance with the criteria set forth in this Standard and consistently with respect to the interim, individual and consolidated, condensed financial information taken as a whole.

São Paulo, August 5, 2025.

KPMG Auditores Independentes Ltda.  
CRC 2SP- 014428/O-6

Fernando Antonio Rodrigues Alfredo  
Accountant CRC 1SP252419/O-0

## **Opinions and Statements / Statement of the Executive Officers on the Financial Statements**

We declare, in our capacity as Statutory Directors of Odontoprev S.A., a joint stock company headquartered in the city of Barueri, state of São Paulo, at Alameda Araguaia, 2104, 21º Andar - Alphaville, CNPJ [EIN] 58.119.199/0001-51, pursuant to article 27, §1, item VI of CVM Resolution 80 of March 29, 2022, as amended, which we reviewed, discussed and agreed with the Financial Statements for the second quarter of 2025.

Barueri/SP, August 5, 2025

**Opinions and Statements / Statement of the Directors on Independent Auditor's Report**

We declare, in our capacity as Statutory Directors of Odontoprev S.A., a joint stock company headquartered in the city of Barueri, state of São Paulo, at Alameda Araguaia, 2104, 21º Andar - Alphaville, CNPJ [EIN] 58.119.199/0001-51, pursuant to article 27, para. 1, item V of CVM Resolution 80 of March 29, 2022, as amended, which we reviewed, discussed and agreed with the opinions expressed in the report of the independent auditors of the Company, KPMG Auditores Independentes Ltda., referring to the Company's 2Q25 quarterly earnings.

Barueri/SP, August 5, 2025